News Celebrity Entertainment Tech Gaming Health Sports Travel Miscellaneous

Health (50)

IsoVerge Keto Pills | IsoVerge Ketogenic Blend Reviews

isoverge-ketogenic.wixsite.com
Submitted 11 hour(s) ago by mariyamwooth

Everyone deserves to have an attractive body that makes them feel proud and comfortable. With IsoVerge Keto food supplement, users can achieve a slender physique in just a few days. However, the supplement does not promise overnight results. It is important to use the supplement continuously for 2-3 months to achieve the desired results. To get all the benefits of this nutritional supplement, it is recommended that you take a few tablets daily. The good thing is IsoVerge Keto is easy to follow. Just take the recommended dose as shown on the bottle. Also, remember to drink plenty of water throughout the day to keep yourself hydrated. @ https://isoverge-ketogenic.wixsite.com/isoverge-keto

 

The “In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand B

www.rootsanalysis.com
Submitted 16 hour(s) ago by Alberto Brando

 

To order this detailed 290+ page report, please visit this link

 

Key Inclusions

  • A detailed review of the overall landscape of companies offering in silico drug discovery services for large molecules, including information on year of establishment, company size, location of headquarters, type of business model used (contract service providers (CROs), software / technology providers, consulting service providers and training service providers), number of drug discovery step(s) for which the company offers services involving the use of in silico approaches (target identification, target validation, hit generation, hit-to-lead and lead optimization), type of large molecules(s) handled (antibodies (monoclonal antibodies, bispecific antibodies, polyclonal antibodies, antibody drug conjugates (ADCs), antibody fragments, single domain antibodies, antisense antibodies and others), proteins (fusion proteins, protein fragments, enzymes and hormones), peptides, cell therapies, gene therapies, vectors and nucleic acids), type of in silico approach used (structure-based drug design (SBDD), fragment-based drug design (FBDD), target-based drug design (TBDD), ligand-based drug design (LBDD) and interface-based drug design (IBDD)), type of in silico service(s) offered (virtual screening, molecular docking, molecular modeling, scaffold hopping and 8+ services), and type of clientele served (pharmaceutical / biotechnology companies and academic / research institutes).
  • Insights on contemporary market trends, depicted using four schematic representations, which include [A] a logo landscape of the industry players engaged in this domain, distributed based on the basis of location of their company size (small (1-50 employees), mid-sized (51-200 employees) and large (>200 employees)) and respective headquarters, [B] a tree map representation of in silico service providers, featuring a distribution of stakeholders on the basis of the company size and drug discovery steps, [C] a world map representation, highlighting the key hubs with respect to outsourcing activity within this domain, and [D] an insightful grid analysis, presenting the distribution of companies based on the type of large molecule, in silico approach used and type of clientele.
  • Elaborate profiles of key industry players that offer a wide range of in silico drug discovery services, featuring a brief overview of the company (including details related to year of establishment, company size, location of headquarters and key members of the executive team), funding and investment information (if available), in silico-based service(s) portfolio) and an informed future outlook.
  • A detailed peer group-based benchmarking analysis, comparing the involved players based on several relevant parameters, such as the experience of the company, number of drug discovery step(s), number of in silico service(s) offered, number of large molecule(s) for which the aforementioned services are offered and type of clientele.
  • An insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain on the basis of the strength of their respective service portfolios, taking into consideration the experience of a service provider, number of drug discovery services offered and number of large molecules, for which the aforementioned services are offered.
  • A detailed analysis assessing the current opportunity within in silico drug discovery services market, comparing the number of pipeline products and current market size across different types of large molecules, and the availability and capabilities of affiliated in silico drug discovery service providers.
  • A discussion on the various business strategies that can be adopted by in silico drug discovery service providers in order to maintain a competitive edge in this industry, based on the different types of large molecules handled and the technical expertise of service providers, in terms of capabilities across different steps of drug discovery.
  • An insightful analysis highlighting the cost saving potential associated with the use of in silico approaches in the drug discovery process.
  • A case study comparing the key challenges associated with the discovery and production of large molecules, affiliated product development timelines, and manufacturing protocols, with those of small molecule drugs.
  • Insights from an industry-wide survey, featuring inputs solicited from various experts who are directly / indirectly involved in providing in silico services for discovery of large molecule drugs.
  • A discussion on the upcoming computational approaches (such as artificial intelligence and cloud computing) that are being adopted for drug discovery purposes and are likely to impact early stage research over the coming years.
  • A case study highlighting several non-computational methods / technologies, which are considered to be of significant importance to the overall drug discovery process.

 

 

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

 

  • Key Drug Discovery Steps
  • Target Identification
  • Target Validation
  • Hit Generation
  • Hit-to-Lead
  • Lead Optimization

 

  • Type of Large Molecule
  • Antibodies
  • Proteins
  • Peptides
  • Nucleic Acids
  • Vectors

 

  • Company Size
  • Small
  • Mid-sized
  • Large

 

  • Target therapeutic Area
  • Autoimmune Disorders
  • Blood Disorders
  • Cardiovascular Disorders
  • Gastrointestinal and Digestive Disorders
  • Hormonal Disorders
  • Human Immunodeficiency Virus (HIV) / Acquired Immunodeficiency Syndrome (AIDS)
  • Infectious Diseases
  • Metabolic Disorders
  • Mental Disorders
  • Musculoskeletal Disorders
  • Neurological Disorders
  • Oncological Disorders
  • Respiratory Disorders
  • Skin Disorders
  • Urogenital Disorders
  • Others

 

  • Type of Sponsor
  • Industry Players
  • Non-Industry Players

 

  • Key Geographical Regions
  • North America
  • Europe
  • Asia-Pacific

 

The report includes detailed transcripts of discussions held with the following experts:

 

To request sample pages, please visit this link

 

Key Questions Answered

  • Who are the leading in silico service providers for discovery of different types of large molecule drugs?
  • What are the key challenges associated with the discovery of large molecule drugs?
  • What is the likely cost saving opportunity associated with the use of in silico tools?
  • What are the key computational approaches being used by in silico service providers for drug discovery operations?
  • What are the popular business strategies being used by in silico drug discovery service providers?
  • How is the current and future market opportunity likely to be distributed across key market segments?

 

You may also be interested in the following titles:

  1. DNA-Encoded Libraries: Platforms and Services Market
  2. Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030
  3. Companion Diagnostics Services Market, 2020-2030

 

Contact Us

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

Over 90 firms are actively involved in providing in silico services for drug discovery of different types of biologics; of these, over 30 players claim to have the capabilities to offer services for all steps of discovery

www.rootsanalysis.com
Submitted 16 hour(s) ago by Alberto Brando

 

Presently, in silico tools / approaches are available for the identification, selection and optimization of pharmacological leads. in fact, the predictive power of such solutions has been demonstrated to enable researchers to bypass the traditional experimental screening of billions of molecules against hundreds of biological targets, thereby, allowing significant reductions in the investment of both time and resources.

 

To order this 290+ page report, which features 120+ figures and 135+ tables, please visit this link

 

The USD 124 million (by 2030) financial opportunity within the in silico drug discovery market for large molecules has been analyzed across the following segments:

  • Key Drug Discovery Steps
  • Target Identification
  • Target Validation
  • Hit Generation
  • Hit-to-Lead
  • Lead Optimization

 

  • Type of Large Molecule
  • Antibodies
  • Proteins
  • Peptides
  • Nucleic Acids
  • Vectors

 

  • Company Size
  • Small
  • Mid-sized
  • Large

 

  • Target therapeutic Area
  • Autoimmune Disorders
  • Blood Disorders
  • Cardiovascular Disorders
  • Gastrointestinal and Digestive Disorders
  • Hormonal Disorders
  • Human Immunodeficiency Virus (HIV) / Acquired Immunodeficiency Syndrome (AIDS)
  • Infectious Diseases
  • Metabolic Disorders
  • Mental Disorders
  • Musculoskeletal Disorders
  • Neurological Disorders
  • Oncological Disorders
  • Respiratory Disorders
  • Skin Disorders
  • Urogenital Disorders
  • Others

 

  • Type of Sponsor
  • Industry Players
  • Non-Industry Players

 

  • Key Geographical Regions
  • North America
  • Europe
  • Asia-Pacific

 

The In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules, 2020-2030, report features the following companies, which we identified to be key players in this domain:

  • Abzena
  • BioDuro
  • BioNTech
  • ChemPartner
  • Creative Biostructure
  • GenScript
  • LakePharma
  • Sundia MediTech
  • Sygnature Discovery
  • Viva Biotech

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction

  3. Market Landscape

  4. Key Insights

  5. Company Profiles

  6. Company Competitiveness Analysis

  7. Key Opportunity Areas

  8. Emerging Business Models and Strategies

  9. Case study: comparison of drug discovery processes of small molecules and large molecules

  10. Survey insights

  11. Cost saving analysis

  12. Market Forecast

  13. In silico tools and upcoming trends in drug discovery

 

  1. Executive Insights

 

  1. Appendix 1: Tabulated Data

 

  1. Appendix 2: List of Companies and Organizations

 

  1. Appendix 3: Non-Computational Methods for Drug Discovery

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

In silico drug discovery services market is likely to be worth USD 124 million by 2030, growing at an annualized rate of 15.6%, claims Roots Analysis

www.rootsanalysis.com
Submitted 16 hour(s) ago by Alberto Brando

 

Roots Analysis has done a detailed study on “In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery / Multi-Target Drug Design, Interface Based Drug Discovery, Approaches)” covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 290+ page report, which features 120+ figures and 135+ tables, please visit this link

 

Key Market Insights

  • Over 90 firms are actively involved in providing in silico services for drug discovery of different types of biologics; of these, over 30 players claim to have the capabilities to offer services for all steps of discovery
  • Majority of the companies offer structure-based drug design focused on early stage drug discovery of a range of large molecules, including antibodies, proteins and peptides
  • Featuring the presence of small-mid sized firms, the in silico service provider landscape is well-distributed across various regions; these players have adopted various business models to cater to the evolving needs of the clients
  • Several players involved in this domain are steadily expanding their capabilities in order to enhance their respective in silico-based service portfolios and maintain a competitive edge in this industry
  • The integration of novel computational techniques, such as artificial intelligence and cloud-based platforms, with in silico approaches is likely to revolutionize the overall drug discovery process
  • Service providers are adopting various business strategies in order to continue providing significant cost saving advantages, along with expediting discovery timelines and improving product success
  • Driven by the growing demand for effective therapeutics and increase in drug discovery efforts of various biologics across a wide range of therapeutic areas, the market is expected to witness sustained growth in future
  • In the long-term, the projected opportunity is anticipated to be well distributed across various geographies, type of sponsors and sizes of in silico service providers

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html

 

Table of Contents

 

  1. PREFACE

1.1.       Scope of the Report

1.2.       Research Methodology

1.3.       Chapter Outlines

 

  1. EXECUTIVE SUMMARY

 

  1. INTRODUCTION

3.1.       Chapter Overview

3.2.       Drug Discovery and Development Timelines

3.3.       Overview of In Silico Drug Discovery Tools

3.3.1.    Historical Evolution of the In Silico Approach

3.3.2.    Comparison of Traditional Drug Discovery Approaches and In Silico / Computer Aided Methods

3.3.3.    In Silico / Computed Aided Approaches for Drug Design and Development

 

3.4.       Applications of In Silico Tools in the Drug Discovery Process

3.4.1.    Target Identification

3.4.1.1. Chemoinformatics-based Tools

3.4.1.2. Network-based Drug Discovery

3.4.1.3. Computational Platforms and Interaction Repositories

 

3.4.2.    Target Validation

 

3.4.3.    Hit Generation

3.4.3.1. High-Throughput Screening

3.4.3.2. Fragment Based Screening

3.4.3.3. Virtual Screening

 

3.4.4.    Hit-to-Lead

3.4.4.1. Pharmacodynamics and Pharmacokinetics Modeling

3.4.4.2. Other Novel Approaches

 

3.4.5.    Lead Optimization

3.4.5.1. Pharmacophore Modeling

3.4.5.2. Docking

3.4.5.3. Structure Activity Relationships (SAR) / Quantitative Structure Activity Relationship (QSAR)

3.4.5.4. Molecular Modeling

 

3.5.       Advantages of using In Silico Tools for Drug Discovery Operations

3.6.       Challenges Associated with Conducting In Silico Drug Discovery Operations In-house

3.7.       Anticipated Rise in Outsourcing In Silico Drug Discovery Operations

3.8.       Concluding Remarks

 

  1. MARKET LANDSCAPE

4.1.       Chapter Overview

4.2.       In Silico Drug Discovery Services for Large Molecules: List of Industry Players

4.2.1.    Analysis by Year of Establishment

4.2.2.    Analysis by Company Size

4.2.3.    Analysis by Location of Headquarters

4.2.4.    Analysis by Company Size and Location of Headquarters

4.2.5.    Analysis by Type of Business Model

4.2.6.    Analysis by Drug Discovery Steps

4.2.7.    Analysis by Type of Large Molecule

4.2.7.1. Analysis by Type of Antibody

4.2.7.2. Analysis by Type of Protein

4.2.8.    Analysis by Type of In Silico Approach Used

4.2.9.    Analysis by Types of In Silico Services Offered

4.2.10.  Analysis by Type of Clientele

 

4.3.       In Silico Drug Discovery Services: List of Software / Technologies

 

  1. KEY INSIGHTS

5.1.       Chapter Overview

5.2.       Logo Landscape: Analysis by Company Size and Location of Headquarters

5.3.       Tree Map Representation: Analysis by Company Size and Drug Discovery Steps

5.4.       World Map Representation: Regional Analysis of Outsourcing Activity

5.5.       Grid Representation: Analysis by Type of Large Molecule, In Silico Approach Used and  Type of Clientele

 

  1. COMPANY PROFILES

6.1.       Chapter Overview

6.2.       Key In Silico Service Providers Based in North America

6.2.1.    BioDuro

6.2.1.1. Company Overview

6.2.1.2. Funding and Investment Information

6.2.1.3. In Silico-based Service Portfolio

6.2.1.4. Recent Developments and Future Outlook

6.2.1.5. Peer Group Benchmark Comparison

 

6.2.2.    Creative Biostructure

6.2.2.1. Company Overview      

6.2.2.2. Funding and Investment Information

6.2.2.3. In Silico-based Service Portfolio

6.2.2.4. Recent Developments and Future Outlook

6.2.2.5. Peer Group Benchmark Comparison

 

6.2.3.    GenScript

6.2.3.1. Company Overview

6.2.3.2. Funding and Investment Information

6.2.3.3. In Silico-based Service Portfolio

6.2.3.4. Recent Developments and Future Outlook

6.2.3.5. Peer Group Benchmark Comparison

 

6.2.4.    LakePharma

6.2.4.1. Company Overview

6.2.4.2. Funding and Investment Information

6.2.4.3. In Silico-based Service Portfolio

6.2.4.4. Recent Developments and Future Outlook

6.2.4.5. Peer Group Benchmark Comparison

 

6.3.       Leading Players Based in Europe

6.3.1.    Abzena

6.3.1.1. Company Overview

6.3.1.2. Funding and Investment Information

6.3.1.3. In Silico-based Service Portfolio

6.3.1.4. Recent Developments and Future Outlook

6.3.1.5. Peer Group Benchmark Comparison

 

6.3.2.    BioNTech

6.3.2.1. Company Overview

6.3.2.2. Funding and Investment Information      

6.3.2.3. Recent Developments and Future Outlook

6.3.2.4. Peer Group Benchmark Comparison

 

6.3.3.    Sygnature Discovery

6.3.3.1. Company Overview

6.3.3.2. Funding and Investment Information

6.3.3.3. In Silico-based Service Portfolio

6.3.3.4. Recent Developments and Future Outlook

6.3.3.5. Peer Group Benchmark Comparison

 

6.4.       Leading Players Based in Asia-Pacific

6.4.1.    ChemPartner

6.4.1.1. Company Overview

6.4.1.2. In Silico-based Service Portfolio

6.4.1.3. Recent Developments and Future Outlook

6.4.1.4. Peer Group Benchmark Comparison

 

6.4.2.    Sundia MediTech

6.4.2.1. Company Overview

6.4.2.2. Funding and Investment Information

6.4.2.3. In Silico-based Service Portfolio

6.4.2.4. Recent Development and Future Outlook

6.4.2.5. Peer Group Benchmark Comparison

                       

6.4.3.    Viva Biotech

6.4.3.1. Company Overview

6.4.3.2. Funding and Investment Information

6.4.3.3. In Silico-based Service Portfolio

6.4.3.4. Recent Development and Future Outlook

6.4.3.5. Peer Group Benchmark Comparison

 

  1. COMPANY COMPETITIVENESS ANALYSIS

7.1.       Chapter Overview

7.2.       Key Parameters

7.3.       Methodology

7.4.       Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in North America

7.5.       Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in Europe

7.6.       Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in Asia-Pacific and Rest of the World

 

  1. KEY OPPORTUNITY AREAS

8.1.       Chapter Overview

8.2.       Key Assumptions and Parameters

8.3.       Methodology

8.4.       Antibodies

8.4.1.    Developer Landscape

8.4.1.1. Number of Pipeline Molecules

8.4.1.2. Affiliated Market Size and Growth Rate

8.4.2.    In Silico Service Providers for Antibodies: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size

 

8.5.       Peptides

8.5.1.    Developer Landscape

8.5.1.1. Number of Pipeline Molecules

8.5.1.2. Affiliated Market Size and Growth Rate

8.5.2.    In Silico Service Providers for Peptides: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size

 

8.6.       Proteins

8.6.1.    Developer Landscape

8.6.1.1. Number of Pipeline Molecules

8.6.1.2. Affiliated Market Size and Growth Rate

8.6.2.    In Silico Service Providers for Proteins: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size

 

8.7.       Other Advanced Therapies

8.7.1     Developer Landscape

8.7.1.1  Number of Pipeline Molecules

8.7.1.2  Affiliated Market Size and Growth Rate

8.7.2.    In Silico Service Providers for Vectors: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size

 

  1. EMERGING BUSINESS MODELS AND STRATEGIES

9.1.       Chapter Overview

9.2.       Key Assumptions and Methodology

9.3.       In Silico Service Providers: Analysis by Number of Large Molecules and Drug Discovery Steps Covered

9.3.1.    Strategies for Short Term Success

9.3.2.    Strategies for Long Term Success

9.4.       Concluding Remarks

 

  1. CASE STUDY: COMPARISON OF DRUG DISCOVERY PROCESSES OF SMALL MOLECULES AND LARGE MOLECULES

10.1.     Chapter Overview

10.2.     Small Molecule and Large Molecule Drugs / Therapies

10.2.1.  Comparison of Key Specifications

10.2.2.  Comparison of Manufacturing Processes

10.2.3.  Comparison of Drug Discovery Processes

10.3.     Approaches to Improve Discovery Process of Large Molecules

 

  1. SURVEY INSIGHTS

11.1.     Chapter Overview

11.2.     Overview of Respondents

11.2.1. Designation of Respondents

 

11.3.     Survey Insights

11.3.1. Drug Discovery Steps

11.3.2. Type of Molecules Handled

11.3.3. In Silico Drug Design Focused Service Portfolio

11.3.4.  Likely Adoption of In Silico Tools for Large Molecules Drug Discovery

11.3.5. Current Market Opportunity

11.3.6. Likely Growth Rate

11.3.7.  Cost Saving Potential of the In Silico Approach

 

  1. COST SAVING ANALYSIS

12.1.     Chapter Overview

12.2.     Key Assumptions

12.3.     Methodology

12.4.     Overall Cost Saving Potential of In Silico Tools in Large Molecule Drug Discovery, 2020-2030

12.5.     Concluding Remarks

 

  1. MARKET FORECAST

13.1.     Chapter Overview

13.2.     Forecast Methodology and Key Assumptions

 

13.3.     Overall In Silico Drug Discovery Services Market for Large Molecules, 2020-2030

 

13.3.1.  In Silico Drug Discovery Services Market for Large Molecules: Distribution by Drug Discovery Steps, 2020-2030

13.3.1.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Target Identification, 2020-2030

13.3.1.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Target Validation, 2020- 2030 

13.3.1.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Hit Generation, 2020-2030

13.3.1.4. In Silico Drug Discovery Services Market for Large Molecules: Share of Hit-to-Lead, 2020-2030

13.3.1.5. In Silico Drug Discovery Services Market for Large Molecules: Share of Lead Optimization, 2020-2030

 

13.3.2.  In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Large Molecule, 2020-2030

13.3.2.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Antibodies, 2020-2030

13.3.2.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Proteins, 2020-2030

13.3.2.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Peptides, 2020-2030

13.3.2.4. In Silico Drug Discovery Services Market for Large Molecules: Share of Nucleic Acids, 2020-     2030

13.3.2.5. In Silico Drug Discovery Services Market for Large Molecules: Share of Vectors, 2020-2030

 

13.3.3.  In Silico Drug Discovery Services Market for Large Molecules: Distribution by Company Size, 2020-2030

13.3.3.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Small Companies, 2020-2030

13.3.3.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Mid-sized Companies,    2020-2030

13.3.3.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Large Companies, 2020-2030

 

13.3.4.  In Silico Drug Discovery Services Market for Large Molecules: Distribution by Therapeutic Area, 2020-2030

13.3.4.1.In Silico Drug Discovery Services Market for Large Molecules: Share of Autoimmune Disorders, 2020-2030

13.3.4.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Blood Disorders, 2020-2030

13.3.4.3.In Silico Drug Discovery Services Market for Large Molecules: Share of Cardiovascular Disorders, 2020-2030

13.3.4.4.In Silico Drug Discovery Services Market for Large Molecules: Share of Gastrointestinal and    Digestive Disorders, 2020-2030

13.3.4.5. In Silico Drug Discovery Services Market for Large Molecules: Share of Hormonal Disorders, 2020-2030

13.3.4.6. In Silico Drug Discovery Services Market for Large Molecules: Share of Human Immunodeficiency Virus (HIV) / Acquired Immunodeficiency Syndrome (AIDS), 2020-2030

13.3.4.7. In Silico Drug Discovery Services Market for Large Molecules: Share of Infectious Diseases, 2020-2030

13.3.4.8. In Silico Drug Discovery Services Market for Large Molecules: Share of  Metabolic Disorders, 2020-2030

13.3.4.9.In Silico Drug Discovery Services Market for Large Molecules: Share of Mental Disorders, 2020-2030

13.3.4.10.In Silico Drug Discovery Services Market for Large Molecules: Share of Musculoskeletal Disorders, 2020-2030

13.3.4.11.In Silico Drug Discovery Services Market for Large Molecules: Share of Neurological Disorders, 2020-2030

13.3.4.12.In Silico Drug Discovery Services Market for Large Molecules: Share of Oncological Disorders 2020-2030

13.3.4.13.In Silico Drug Discovery Services Market for Large Molecules: Share of Respiratory Disorders, 2020-2030

13.3.4.13.In Silico Drug Discovery Services Market for Large Molecules: Share of Skin Disorders, 2020-2030

13.3.4.14.In Silico Drug Discovery Services Market for Large Molecules: Share of Urogenital Disorders, 2020-2030

13.3.4.15.In Silico Drug Discovery Services Market for Large Molecules: Share of Others, 2020-2030        

 

13.3.5.  In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Sponsor, 2020-2030

13.3.5.1.In Silico Drug Discovery Services Market for Large Molecules: Share of Industry Players, 2020-2030

13.3.5.2.In Silico Drug Discovery Services Market for Large Molecules: Share of Non-Industry Players, 2020-2030

 

13.3.6.  In Silico Drug Discovery Services Market for Large Molecules: Distribution by Key Geographical Regions, 2020-2030

13.3.6.1.In Silico Drug Discovery Services Market for Large Molecules: Share of North America, 2020-2030

13.3.6.1.1.In Silico Drug Discovery Services Market for Large Molecules: Share of US, 2020-2030

13.3.6.1.2.In Silico Drug Discovery Services Market for Large Molecules: Share of Canada, 2020-2030

 

13.3.6.2.In Silico Drug Discovery Services Market for Large Molecules: Share in Europe, 2020-2030

13.3.6.2.1.In Silico Drug Discovery Services Market for Large Molecules: Share in Germany, 2020-2030

13.3.6.2.2.In Silico Drug Discovery Services Market for Large Molecules: Share in France, 2020-2030

13.3.6.2.3.In Silico Drug Discovery Services Market for Large Molecules: Share in the UK, 2020-2030

13.3.6.2.4.In Silico Drug Discovery Services Market for Large Molecules: Share in Italy, 2020-2030

13.3.6.2.5.In Silico Drug Discovery Services Market for Large Molecules: Share in Spain, 2020-2030

13.3.6.2.6.In Silico Drug Discovery Services Market for Large Molecules: Share in Rest of Europe, 2020-2030

13.3.6.3.In Silico Drug Discovery Services Market for Large Molecules: Share in Asia-Pacific and Rest of the World, 2020-2030

13.3.6.3.1.In Silico Drug Discovery Services Market for Large Molecules: Share in China, 2020-2030

13.3.6.3.2.In Silico Drug Discovery Services Market for Large Molecules: Share in India, 2020-2030

13.3.6.3.3.In Silico Drug Discovery Services Market for Large Molecules: Share in Japan, 2020-2030

 

  1. IN SILICO TOOLS AND UPCOMING TRENDS IN DRUG DISCOVERY

14.1.     Chapter Overview

14.2.     Owing to Potential Cost and Time-related Benefits, Outsourcing of Drug Discovery Operations is Expected to Increase in the Future

14.3.     Technological Advancements are Likely to Revolutionize the Current Drug Discovery Processes

14.3.1.  Integration of Artificial Intelligence in the Drug Discovery Process is Expected to Improve the Overall Efficiency and Productivity

14.3.2.  Increased Adoption of Cloud Based Technology Platforms is Anticipated to Enhance the Scalability and Flexibility of the Drug Discovery Process

14.3.3.  Rising Interest in Use of Force Fields for  In Silico Drug Discovery

14.4.     Concluding Remarks

 

  1. EXECUTIVE INSIGHTS

15.1.     Chapter Overview

15.2.     ProSciens

15.2.1. Company Snapshot

15.2.2. Interview Transcript: Edelmiro Moman, Founder and Chief Executive Officer

 

15.3.     Conifer Point Pharmaceuticals

15.3.1. Company Snapshot

15.3.2.  Interview Transcript: John L Kulp, Chief Executive Officer and Chief Technical Officer

 

15.4.     Evotec

15.4.1.  Company Snapshot

15.4.2. Interview Transcript: Mark Whittaker, Senior Vice President, Drug Discovery

 

15.5.     Candidum

15.5.1. Company Snapshot

15.5.2. Interview Transcript: Sven Benson, Founder

 

  1. APPENDIX I: TABULATED DATA

 

  1. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

 

  1. APPENDIX III: NON-COMPUTATIONAL METHODS FOR DRUG DISCOVERY

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

In silico drug discovery services market is likely to be worth USD 124 million by 2030, growing at an annualized rate of 15.6%, claims Roots Analysis

www.rootsanalysis.com
Submitted 16 hour(s) ago by Alberto Brando

 

Excessive capital requirement and myriad of other complexities associated with the discovery of biologics have prompted drug developers to adopt in silico tools / techniques to expedite the discovery timelines

 

Roots Analysis is pleased to announce the publication of its recent study, titled, “In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery / Multi-Target Drug Design, Interface Based Drug Discovery, Approaches).”

 

The  report features an extensive study on the current landscape and the likely future potential of the companies offering services for the discovery of large molecule drugs based on the use of in silico tools and techniques. The study features an in-depth analysis, highlighting the capabilities of various industry stakeholders. In addition to other elements, the report includes:

  • A detailed assessment of the current market landscape of companies offering in silico drug discovery services for large molecules. 
  • Elaborate profiles of key industry players that offer a wide range of in silico drug discovery services (shortlisted on the basis of the company size).
  • A detailed peer group-based benchmarking analysis, comparing the involved players based on several relevant parameters related to company and services.
  • An insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain.
  • A detailed analysis assessing the current opportunity within in silico drug discovery services market.
  • A discussion on the various business strategies that can be adopted by in silico drug discovery service providers in order to maintain a competitive edge in this industry.
  • An insightful analysis highlighting the cost saving potential associated with the use of in silico approaches in the drug discovery process.
  • A case study comparing the key challenges associated with the discovery and production of large molecules.
  • Insights from an industry-wide survey, featuring inputs solicited from various experts in this domain.
  • A discussion on the upcoming computational approaches that are being adopted for drug discovery purposes.
  • A case study highlighting several non-computational methods / technologies used in drug discovery process.
  • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
  • Key Drug Discovery Steps
  • Target Identification
  • Target Validation
  • Hit Generation
  • Hit-to-Lead
  • Lead Optimization

 

  • Type of Large Molecule
  • Antibodies
  • Proteins
  • Peptides
  • Nucleic Acids
  • Vectors

 

  • Company Size
  • Small
  • Mid-sized
  • Large

 

  • Target therapeutic Area
  • Autoimmune Disorders
  • Blood Disorders
  • Cardiovascular Disorders
  • Gastrointestinal and Digestive Disorders
  • Hormonal Disorders
  • Human Immunodeficiency Virus (HIV) / Acquired Immunodeficiency Syndrome (AIDS)
  • Infectious Diseases
  • Metabolic Disorders
  • Mental Disorders
  • Musculoskeletal Disorders
  • Neurological Disorders
  • Oncological Disorders
  • Respiratory Disorders
  • Skin Disorders
  • Urogenital Disorders
  • Others

 

  • Type of Sponsor
  • Industry Players
  • Non-Industry Players

 

  • Key Geographical Regions
  • North America
  • Europe
  • Asia-Pacific

 

  • Transcripts of interviews held with the following senior level representatives of stakeholder companies
  • John L Kulp (Chief Executive Officer and Chief Technical Officer, Conifer Point Pharmaceuticals)
  • Sven Benson (Founder, candidum)
  • Mark Whittaker (Senior Vice President, Evotec)
  • Edelmiro Moman (Scientific Consultant and Teacher, ProSciens)

 

Key companies covered in the report

  • Abzena
  • BioDuro
  • BioNTech
  • ChemPartner
  • Creative Biostructure
  • GenScript
  • LakePharma
  • Sundia MediTech
  • Sygnature Discovery
  • Viva Biotech

 

For more information please click on the following link:

https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html

 

Other Recent Offerings

  1. DNA-Encoded Libraries: Platforms and Services Market
  2. Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030
  3. Companion Diagnostics Services Market, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

In silico drug discovery services market is likely to be worth USD 124 million by 2030, growing at an annualized rate of 15.6%, claims Roots Analysis

www.rootsanalysis.com
Submitted 16 hour(s) ago by Alberto Brando

 

Owing to their cost and time saving potential, in silico tools are widely used in modern pharmacological research; several companies have developed novel tools, which are specifically designed to accelerate and augment the drug discovery process.

 

 

Roots Analysis has announced the addition of “In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery / Multi-Target Drug Design, Interface Based Drug Discovery, Approaches)” report to its list of offerings.

 

Presently, in silico tools / approaches are available for the identification, selection and optimization of pharmacological leads. in fact, the predictive power of such solutions has been demonstrated to enable researchers to bypass the traditional experimental screening of billions of molecules against hundreds of biological targets, thereby, allowing significant reductions in the investment of both time and resources.

 

To order this 290+ page report, which features 120+ figures and 130+ tables, please visit this link

 

Key Market Insights

 

Over 90 players currently claim to provide in silico drug discovery services for biologics

More than 70% of these companies are small and mid-sized firms. Further, close to 60% of the CROs engaged in this domain, claim to provide services to both pharmaceutical companies and academic institutes. It is worth mentioning that about 30% of players presently offer end-to-end drug discovery services

 

Over 150 software solutions are currently available for use in drug discovery

Around 90 companies are currently providing software tools, web applications and other technology platforms for drug discovery. Examples of popular softwares include (in alphabetical order) FORECASTER SUITE, MOPAC2016™, PKPlus™, REAL Space Navigator, SaaS Platform and VolSurf+.

 

Nearly 80% of in silico drug discovery service providers are based in the developed geographies

This can be attributed to the relatively high adoption of the in silico approach by players based in Europe and North America. On the other hand, there are companies that are using this approach for drug discovery operations, in emerging regions, such as India and China, as well.

 

Around 40% of the companies claim to specialize in antibodies, proteins and peptides

Within the antibodies segment, nearly 60% of in silico service offerings are focused on the discovery of monoclonal antibodies. This is followed by companies providing services for antibody fragments (43%), bispecific antibodies (34%) and polyclonal antibodies (26%).

 

Using in silico solutions / tools is estimated to save ~35% of the overall drug discovery cost

By 2030, we anticipate net, annual cost savings of over USD 23 billion to be brought about by the adoption of in silico tools in large molecule drug discovery processes. The computation approach also enables researchers to expedite the overall process, thereby, saving a significant amount of time, as well.

 

North America and Europe are anticipated to capture over 75% of the market share by 2030

Within North America, US is anticipated to hold the 90% of the market share. It is worth mentioning that the market in Asia-Pacific region is anticipated to grow at a relatively faster rate (16.1%).

 

To request a sample copy / brochure of this report, please visit this link       

 

Key Questions Answered

  • Who are the leading in silico service providers for discovery of different types of large molecule drugs?
  • What are the key challenges associated with the discovery of large molecule drugs?
  • What is the likely cost saving opportunity associated with the use of in silico tools?
  • What are the key computational approaches being used by in silico service providers for drug discovery operations?
  • What are the popular business strategies being used by in silico drug discovery service providers?
  • How is the current and future market opportunity likely to be distributed across key market segments?

 

The USD 124 million (by 2030) financial opportunity within the in silico drug discovery market for large molecules has been analyzed across the following segments:

  • Key Drug Discovery Steps
  • Target Identification
  • Target Validation
  • Hit Generation
  • Hit-to-Lead
  • Lead Optimization

 

  • Type of Large Molecule
  • Antibodies
  • Proteins
  • Peptides
  • Nucleic Acids
  • Vectors

 

  • Company Size
  • Small
  • Mid-sized
  • Large

 

  • Target therapeutic Area
  • Autoimmune Disorders
  • Blood Disorders
  • Cardiovascular Disorders
  • Gastrointestinal and Digestive Disorders
  • Hormonal Disorders
  • Human Immunodeficiency Virus (HIV) / Acquired Immunodeficiency Syndrome (AIDS)
  • Infectious Diseases
  • Metabolic Disorders
  • Mental Disorders
  • Musculoskeletal Disorders
  • Neurological Disorders
  • Oncological Disorders
  • Respiratory Disorders
  • Skin Disorders
  • Urogenital Disorders
  • Others

 

  • Type of Sponsor
  • Industry Players
  • Non-Industry Players

 

  • Key Geographical Regions
  • North America
  • Europe
  • Asia-Pacific

 

The report features inputs from eminent industry stakeholders, according to whom the in silico approaches significantly simplifies the drug discovery process, offering better screening accuracy, as well as enabling innovators to reduce wet-lab efforts. The report includes detailed transcripts of discussions held with the following experts:

 

The research covers brief profiles of several companies (including those listed below); each profile features an overview of the company, financial information (if available), in silico-based service(s) portfolio and an informed future outlook.

  • Abzena
  • BioDuro
  • BioNTech
  • ChemPartner
  • Creative Biostructure
  • GenScript
  • LakePharma
  • Sundia MediTech
  • Sygnature Discovery
  • Viva Biotech

 

For additional details, please visit 

https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html or email sales@rootsanalysis.com

 

You may also be interested in the following titles:

  1. DNA-Encoded Libraries: Platforms and Services Market
  2. Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030
  3. Companion Diagnostics Services Market, 2020-2030

 

 

Contact:

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

 

The “Global Handheld Ultrasound Imaging Devices Market, 2020-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of such compact diagnostic devices, over the next decade. The report

www.rootsanalysis.com
Submitted 16 hour(s) ago by Alberto Brando

 

To order this detailed 235+ page report, please visit this link

 

Key Inclusions

  • An overview of the current market landscape of the handheld ultrasound imaging devices, providing information on the status of development, application area (abdomen, cardiac, gynecological, pulmonary, urological scanning and others), weight of device, type of transducer array (convex / curved, linear, micro-convex, transvaginal, phased and others), transducer frequency, mode of imaging (brightness, color doppler, motion, power doppler, pulsed wave, tissue harmonic and others), field of view, scanning depth, type of software (smartphone application and customized software application), connectivity provision (universal serial bus (USB), cellular / WiFi and bluetooth), data management feature(s) (internal, external, and cloud / remote monitoring), battery backup and cost of device. In addition, it presents details of the device developers, highlighting year of establishment, company size, type of business model used (B2B and B2C), target market (domestic and domestic and international) and location of headquarters. Further, it highlights the key initiatives taken by the various device developers to tackle the on-going global pandemic of COVID-19.

 

  • An in-depth analysis of the contemporary market trends, presented using four schematic representations, including [A] a bubble analysis comparing the leading players engaged in the development of handheld ultrasound imaging devices, based on the parameters, such as application area, mode of imaging, number of devices and company size, [B] a grid representation illustrating the distribution of scanners based on application area, type of transducer array and type of software, [C] an insightful heat map representation, highlighting the distribution of devices on the basis of application area and mode of imaging, and [D] a tree map representation of the handheld ultrasound imaging devices, distributed on the basis of mode of imaging and connectivity provision.

 

  • Elaborate profiles of mid-sized / large companies that are engaged in the development of handheld ultrasound imaging scanners. Each company profile features a brief overview of the company (with information on year of establishment, number of employees, location of headquarters and key members of the executive team), details of their respective product portfolio, recent developments and an informed future outlook.

 

  • A detailed brand positioning analysis of key industry players, highlighting the current perceptions regarding their proprietary brands by taking into consideration several relevant aspects, such as strength of product portfolio, type of software, mode of imaging, connectivity provisions, geographical presence / reach and supplier power of each company.

 

  • An analysis of the partnerships that have been inked by stakeholders in the domain, during the time period 2010-2020 (till April), covering licensing agreements, acquisitions and mergers, research and development agreements, product distribution agreements and other relevant types of deals.

 

  • An insightful analysis highlighting cost saving potential associated with the use of handheld ultrasound imaging devices, based on information from close to 50 countries, taking into consideration various parameters, such as total number of radiologists, annual salary, number of ultrasound scans performed and increase in efficiency by adoption of these handheld ultrasound imaging devices.

 

  • An informed estimate of the global demand for handheld ultrasound imaging devices for the period 2020-2030, taking into account the impact of COVID-19, historical sales of these devices, and annual revenues (generated by sales of these devices) of prominent device manufacturers.

 

  • A review of the product distribution strategies adopted by different device-developers, demand and market attractiveness for handheld ultrasound imaging devices across different types of end-users, including ambulatory surgical centers, diagnostic imaging centers, hospitals, maternity clinics, specialty clinics, and other end-users.
  • An insightful discussion on the impact of COVID-19 on the overall handheld ultrasound imaging devices market, along with the key lessons learnt from big pharma players in 2008 recession.

 

  • An informative analysis of contemporary Google Trends in the time period between 2015 and 2020 (till April) and insights from the recent news articles related to handheld ultrasound imaging devices, indicating the increasing popularity of this domain.

 

 

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

 

  • Application Area
  • Cardiac Scanning
  • Emergency Medicines
  • Gynecological / Obstetrics Scanning
  • Musculoskeletal Scanning
  • Pulmonary Scanning
  • Urological Scanning
  • Vascular Surgery
  • Other Application Areas

 

  • Type of Transducer Array
  • Curved
  • Endocavity
  • Linear
  • Phased
  • Other Scanners

 

  • Type of Software
  • Smartphone Applications
  • Customized Software

 

  • End-Users
  • Ambulatory Surgical Centers
  • Diagnostic Imaging Centers
  • Hospitals
  • Maternity Clinics
  • Specialty Clinics
  • Other End-Users

 

  • Key Geographical Regions 
  • North America
  • Europe
  • Asia-Pacific and the Rest of the World

 

The report includes detailed transcripts of discussions held with the following experts:

  • Stefan Maas (Chief Executive Officer, SomaView)
  • Anais Concepcion (Director of Content and Campaign Management, EchoNous)
  • Zhengzheng Zhu (Oversea Business Development, PeakSonic)

 

To request sample pages, please visit this link

 

Key Questions Answered

  • Who are the leading developers of handheld ultrasound imaging devices?
  • What are the key application areas for handheld ultrasound imaging scanners?
  • What is the potential usability of handheld ultrasound scanners devices for lung scanning in COVID-19 patients?
  • Which partnership models are commonly adopted by stakeholders in this industry?
  • What is the annual global demand for handheld ultrasound imaging devices?
  • What is the impact of COVID-19 on the demand for handheld ultrasound imaging devices?
  • What is the likely cost saving potential associated with the use of handheld ultrasound imaging devices?
  • What are the key factors influencing the adoption of handheld ultrasound imaging scanners, among different end-users?
  • How is the current and future opportunity likely to be distributed across key market segments?

 

You may also be interested in the following titles:

  1. Large Volume Wearable Injectors Market (5th Edition), 2020-2030
  2. Companion Diagnostics Market (2nd Edition), 2019-2030
  3. Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers

 

Contact Us

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

The global handheld ultrasound imaging devices market is projected to be over USD 1.1 billion by 2030, growing at a CAGR of over 11%, claims Roots Analysis

www.rootsanalysis.com
Submitted 17 hour(s) ago by Alberto Brando

 

Roots Analysis has done a detailed study on “Global Handheld Ultrasound Imaging Devices Market, 2020-2030” covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 235+ page report, which features 95+ figures and 110+ tables, please visit this link

 

Key Market Insights

  • Several players are currently engaged in the development / manufacturing of point-of-care handheld ultrasound scanners that offer a variety of imaging modes to produce high-quality diagnosis images.
  • Around 100 handheld ultrasound imaging devices, incorporating different transducer arrays and advanced software, are being actively used by physicians to scan different body parts.
  • Companies engaged in the development of handheld ultrasound imaging devices are spread across the globe; further, a number of start-ups have taken initiatives to offer novel scanners.
  • Stakeholders have established strong brand positions in different geographies; in future, such companies with competitive edge are anticipated to contribute the most to the overall revenue generation potential.
  • The growing interest in this field is reflected by the increased partnerships, involving both international and indigenous stakeholders, across different geographical marketplaces.
  • Owing to the ease of handling, better image visualization and remote data transmission features, these devices can significantly enhance a radiologists’ efficiency, demonstrating the potential to save the overall healthcare cost.
  • Future growth of the market is likely to be driven by increased demand for these devices; novel transducers and advanced software-based scanners offer lucrative market opportunities.
  • The opportunity is anticipated to be well-distributed across different application areas, end-users and key geographical regions.

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/handheld-imaging-devices/319.html

 

Table of Contents

 

  1. PREFACE

1.1.       Scope of the Report

1.2.       Research Methodology

1.3.       Chapter Outlines

 

  1. EXECUTIVE SUMMARY

 

  1. INTRODUCTION

3.1.       Chapter Overview

3.2.       Introduction to Ultrasound Imaging

3.3.       Historical Evolution of Ultrasound Imaging

3.4.       Challenges with Conventional Ultrasound Imaging Devices

 

3.5.       Introduction to Portable Ultrasound Imaging Devices

3.5.1.    Device Classification

3.5.1.1. Movable Ultrasound Imaging Devices

3.5.1.2. Handheld Ultrasound Imaging Devices

 

3.5.2.    Key Application Areas

3.5.3.    Regulatory Guidelines

3.5.4.    Key Advantages and Roadblocks

 

3.6.       Prevalent Trends Related to Handheld Ultrasound Imaging Devices

3.6.1.    Emerging Focus Areas

3.6.2.    Key Historical Trends

3.6.3.    Geographical Distribution of Activity

 

  1. MARKET LANDSCAPE

4.1.       Chapter Overview

4.2.       Handheld Ultrasound Imaging Devices: Overall Market Landscape

4.2.1.    Analysis by Status of Development

4.2.2.    Analysis by Application Area

4.2.3.    Analysis by Weight of Device

4.2.4.    Analysis by Type of Transducer Array

4.2.5.    Analysis by Transducer Frequency

4.2.6.    Analysis by Mode of Imaging

4.2.7.    Analysis by Scanning Depth

4.2.8.    Analysis by Type of Software

4.2.9.    Analysis by Connectivity Provisions

4.2.10.  Analysis by Data Management Feature(s)

4.2.11.  Analysis by Battery Backup

4.2.12.  Analysis by Cost of Device

 

4.3.       Handheld Ultrasound Imaging Devices: Additional Information

4.4.       Handheld Ultrasound Imaging Devices: Information on Affiliated Technologies

4.5.       Handheld Ultrasound Imaging Devices: List of Manufacturers

4.5.1.    Analysis by Year of Establishment

4.5.2.    Analysis by Company Size

4.5.3.    Analysis by Types of Business Model Used

4.5.4.    Analysis by Target Market

4.5.5.    Analysis by Location of Headquarters

4.5.6.    Leading Manufacturers: Analysis by Number of Products

 

4.6.       Handheld Ultrasound Imaging Devices: Product Competitiveness Analysis

4.7.       Leading Manufacturers: 4D Bubble Analysis based on Application area, Mode                              of Imaging, Number of Devices and Company Size

4.8.       Grid Representation: Analysis by Application Area, Type of Transducer Array                               and Type of Software

4.9.       Heat Map Representation: Analysis by Application Area and Mode of                                           Imaging

4.10.     Tree Map Representation: Analysis by Mode of Imaging and Connectivity                                    Provision

4.11.     World Map Representation: Regional Activity

4.12.     Handheld Scanners with Potential for Use during the COVID-19 Pandemic

 

  1. COMPANY PROFILES

5.1.       Chapter Overview

5.2.       Butterfly Network

5.2.1.    Company Overview

5.2.2.    Product Portfolio: Handheld Ultrasound Imaging Devices

5.2.3.    Recent Developments and Future Outlook

 

5.3.       Clarius Mobile Health

5.3.1.    Company Overview

5.3.2.    Product Portfolio: Handheld Ultrasound Imaging Devices

5.3.3.    Recent Developments and Future Outlook

 

5.4.       EchoNous

5.4.1.    Company Overview

5.4.2.    Product Portfolio: Handheld Ultrasound Imaging Devices

5.4.3.    Recent Developments and Future Outlook

 

5.5.       Fujifilm

5.5.1.    Company Overview

5.5.2.    Product Portfolio: Handheld Ultrasound Imaging Devices

5.5.3.    Recent Developments and Future Outlook

 

5.6.       GE Healthcare

5.6.1.    Company Overview

5.6.2.    Product Portfolio: Handheld Ultrasound Imaging Devices

5.6.3.    Recent Developments and Future Outlook

 

5.7.       Philips

5.7.1.    Company Overview

5.7.2.    Product Portfolio: Handheld Ultrasound Imaging Devices

5.7.3.    Recent Developments and Future Outlooks

 

5.8.       WuHan Youkey Bio-Medical Electronics

5.8.1.    Company Overview

5.8.2.    Product Portfolio: Handheld Ultrasound Imaging Devices

5.8.3.    Recent Developments and Future Outlook

 

  1. BRAND POSITIONING ANALYSIS OF KEY PLAYERS

6.1.       Chapter Overview

6.2.       Scope and Methodology

6.3.       Brand Positioning Matrix: Butterfly Network

6.4.       Brand Positioning Matrix: Clarius Mobile Health

6.5.       Brand Positioning Matrix: EchoNous

6.6.       Brand Positioning Matrix: Fujifilm

6.7.       Brand Positioning Matrix: GE Healthcare

6.8.       Brand Positioning Matrix: Philips

6.9.       Brand Positioning Matrix: WuHan Youkey Bio-Medical Electronics

 

  1. PARTNERSHIPS AND COLLABORATIONS

7.1.       Chapter Overview

7.2.       Partnership Models

7.3.       Handheld Ultrasound Imaging Devices: List of Partnerships and Collaborations

7.3.1.    Analysis by Year of Partnership

7.3.2.    Analysis by Type of Partnership

7.3.3.    Analysis by Year and Type of Partnership

7.3.4.    Analysis by Type of Partner

7.3.5.    Analysis by Focus Area

7.3.6.    Most Active Players: Analysis by Number of Partnerships

7.3.7.    Regional Analysis

7.3.8.    Intercontinental and Intracontinental Agreements

 

  1. COST SAVING ANALYSIS

8.1.       Chapter Overview

8.2.       Key Assumptions

8.3.       Methodology

8.4.       Key Parameters Influencing the Cost of Handheld Ultrasound Imaging Devices

8.5.       Overall Cost Saving Potential of Handheld Ultrasound Imaging Devices, 2020-2030

 

8.6.       Cost Saving Potential of Handheld Ultrasound Imaging Devices: Analysis by Geography

8.6.1.    Cost Saving Potential of Handheld Ultrasound Imaging Devices in North America, 2020-               2030

8.6.2.    Cost Saving Potential of Handheld Ultrasound Imaging Devices in Europe, 2020-2030

8.6.3.    Cost Saving Potential of Handheld Ultrasound Imaging Devices in Asia-Pacific and Rest               of the World, 2020-2030

 

8.7.       Cost Saving Potential of Handheld Ultrasound Imaging Devices: Analysis by Economic                Strength

8.7.1.    Cost Saving Potential of Handheld Ultrasound Imaging Devices in High Income                            Countries, 2020-2030

8.7.2.    Cost Saving Potential of Handheld Ultrasound Imaging Devices in Upper Middle Income Countries, 2020-2030

8.7.3.    Cost Saving Potential of Handheld Ultrasound Imaging Devices in Lower Middle Income               Countries, 2020-2030

8.8.       Concluding Remarks: Cost Saving Scenarios

 

  1. DEMAND ANALYSIS

9.1.       Chapter Overview

9.2.       Methodology

9.3.       Impact of COVID-19 Pandemic on Global Demand for Handheld Ultrasound Imaging                    Devices

9.4.       Overall Global Demand for Handheld Ultrasound Imaging Devices, 2020-2030

9.5.       Global Demand for Handheld Ultrasound Imaging Devices: Analysis by Key Industry                    Players

9.6.       Global Demand for Handheld Ultrasound Imaging Devices: Analysis by End-Users

 

  1. MARKET FORECAST

10.1.     Chapter Overview

10.2.     Forecast Methodology and Key Assumptions

10.3.     Impact of COVID-19 Pandemic on Handheld Ultrasound Imaging Devices                                    Market

 

10.4.     Overall Handheld Ultrasound Imaging Devices Market, 2020-2030

10.4.1.  Handheld Ultrasound Imaging Devices Market: Distribution by Application Area

10.4.1.1. Handheld Ultrasound Imaging Devices Market for Cardiac Scanning, 2020-2030

10.4.1.2. Handheld Ultrasound Imaging Devices Market for Emergency Medicines, 2020-2030

10.4.1.3. Handheld Ultrasound Imaging Devices Market for Gynecological / Obstetrics Scanning,                2020-2030

10.4.1.4. Handheld Ultrasound Imaging Devices Market for Musculoskeletal Scanning, 2020-2030

10.4.1.5. Handheld Ultrasound Imaging Devices Market for Pulmonary Scanning, 2020-2030

10.4.1.6. Handheld Ultrasound Imaging Devices Market for Urological Scanning, 2020-2030

10.4.1.7. Handheld Ultrasound Imaging Devices Market for Vascular Surgery, 2020-2030

10.4.1.8. Handheld Ultrasound Imaging Devices Market for Other Application Areas, 2020-2030

 

10.4.2.  Handheld Ultrasound Imaging Devices Market: Distribution by Type of Transducer Array

10.4.2.1. Handheld Ultrasound Imaging Devices Market for Curved Array-based Scanners, 2020-                2030

10.4.2.2. Handheld Ultrasound Imaging Devices Market for Endocavity Array-based Scanners,                   2020-2030

10.4.2.3. Handheld Ultrasound Imaging Devices Market for Linear Array-based Scanners, 2020-                 2030

10.4.2.4. Handheld Ultrasound Imaging Devices Market for Phased Array-based Scanners, 2020-               2030

10.4.2.5. Handheld Ultrasound Imaging Devices Market for Other Scanners, 2020-2030

 

10.4.3.  Handheld Ultrasound Imaging Devices Market: Distribution by Type of Software

10.4.3.1. Handheld Ultrasound Imaging Devices Market for Smartphone Application-based                         Scanners, 2020-2030

10.4.3.2. Handheld Ultrasound Imaging Devices Market for Customized Software-based                             Scanners, 2020-2030

 

10.4.4.  Handheld Ultrasound Imaging Devices Market: Distribution by End-Users

10.4.4.1. Handheld Ultrasound Imaging Devices Market for Ambulatory Surgical Centers, 2020-2030

10.4.4.2. Handheld Ultrasound Imaging Devices Market for Diagnostic Imaging Center, 2020-2030

10.4.4.3. Handheld Ultrasound Imaging Devices Market for Hospitals, 2020-2030

10.4.4.4. Handheld Ultrasound Imaging Devices Market for Maternity Clinics, 2020-2030

10.4.4.4. Handheld Ultrasound Imaging Devices Market for Specialty Clinics, 2020-                                    2030

10.4.4.4. Handheld Ultrasound Imaging Devices Market for Other End-Users, 2020-2030

 

10.5.5.  Handheld Ultrasound Imaging Devices Market: Distribution by Key Geographical                          Regions

10.5.5.1. Handheld Ultrasound Imaging Devices Market in North America, 2020-2030

10.5.5.2. Handheld Ultrasound Imaging Devices Market in Europe, 2020-2030

10.5.5.3. Handheld Ultrasound Imaging Devices Market in Asia-Pacific and Rest of the World,                    2020-2030

 

10.6.     Concluding Remarks

 

  1. END-USER SPECIFIC OPPORTUNITY ANALYSIS

11.1.     Chapter Overview

11.2.     Methodology

11.3.     Distribution Strategies Adopted by Device Developers

 

11.4.     Demand for Handheld Ultrasound Imaging Devices

11.4.1.  End-User Demand Analysis: Ambulatory Surgical Centers, 2020-2030

11.4.2.  End-User Demand Analysis: Diagnostic Imaging Centers, 2020-2030

11.4.3.  End-User Demand Analysis: Hospitals, 2020-2030

11.4.4.  End-User Demand Analysis: Maternity Clinics, 2020-2030

11.4.5.  End-User Demand Analysis: Specialty Clinics, 2020-2030

11.4.6.  End-User Demand Analysis: Other End-Users, 2020-2030

 

11.5.     Market Attractiveness Analysis

11.5.1.  End-User Market Attractiveness: Ambulatory Surgical Centers, 2020-2030

11.5.2.  End-User Market Attractiveness: Diagnostic Imaging Centers, 2020-2030

11.5.3.  End-User Market Attractiveness: Hospitals, 2020-2030

11.5.4.  End-User Market Attractiveness: Maternity Clinics, 2020-2030

11.5.5.  End-User Market Attractiveness: Specialty Clinics, 2020-2030

11.5.6.  End-User Market Attractiveness: Other End-Users, 2020-2030

 

  1. CASE STUDY: IMPACT OF CORONAVIRUS OUTBREAK

12.1.     Chapter Overview

12.2.     Impact of Coronavirus Pandemic

12.2.1.  Short Term Impact

12.2.2.  Long Term Impact

12.3.     Future Strategies and Action Plans

 

  1. CONCLUSION

13.1.     Chapter Overview

13.2.     Key Takeaways

 

  1. EXECUTIVE INSIGHTS

14.1.     Chapter Overview

 

14.2.     SomaView

14.2.1.  Company Snapshot

14.2.2.  Interview Transcript: Stefan Mass, Chief Executive Officer

 

14.3.     EchoNous

14.3.1.  Company Snapshot

14.3.2.  Interview Transcript: Anais Concepcion, Director of Content and Digital    Campaigns

 

14.4.     PeakSonic

14.4.1.  Company Snapshot

14.4.2.  Interview Transcript: Zhengzheng Zhu, International Business Development

 

  1. APPENDIX 1: TABULATED DATA

 

  1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

The global handheld ultrasound imaging devices market is projected to be over USD 1.1 billion by 2030, growing at a CAGR of over 11%, claims Roots Analysis

www.rootsanalysis.com
Submitted 17 hour(s) ago by Alberto Brando

 

Roots Analysis has done a detailed study on “Global Handheld Ultrasound Imaging Devices Market, 2020-2030” covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 235+ page report, which features 95+ figures and 110+ tables, please visit this link

 

Key Market Insights

  • Several players are currently engaged in the development / manufacturing of point-of-care handheld ultrasound scanners that offer a variety of imaging modes to produce high-quality diagnosis images.
  • Around 100 handheld ultrasound imaging devices, incorporating different transducer arrays and advanced software, are being actively used by physicians to scan different body parts.
  • Companies engaged in the development of handheld ultrasound imaging devices are spread across the globe; further, a number of start-ups have taken initiatives to offer novel scanners.
  • Stakeholders have established strong brand positions in different geographies; in future, such companies with competitive edge are anticipated to contribute the most to the overall revenue generation potential.
  • The growing interest in this field is reflected by the increased partnerships, involving both international and indigenous stakeholders, across different geographical marketplaces.
  • Owing to the ease of handling, better image visualization and remote data transmission features, these devices can significantly enhance a radiologists’ efficiency, demonstrating the potential to save the overall healthcare cost.
  • Future growth of the market is likely to be driven by increased demand for these devices; novel transducers and advanced software-based scanners offer lucrative market opportunities.
  • The opportunity is anticipated to be well-distributed across different application areas, end-users and key geographical regions.

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/handheld-imaging-devices/319.html

 

Table of Contents

 

  1. PREFACE

1.1.       Scope of the Report

1.2.       Research Methodology

1.3.       Chapter Outlines

 

  1. EXECUTIVE SUMMARY

 

  1. INTRODUCTION

3.1.       Chapter Overview

3.2.       Introduction to Ultrasound Imaging

3.3.       Historical Evolution of Ultrasound Imaging

3.4.       Challenges with Conventional Ultrasound Imaging Devices

 

3.5.       Introduction to Portable Ultrasound Imaging Devices

3.5.1.    Device Classification

3.5.1.1. Movable Ultrasound Imaging Devices

3.5.1.2. Handheld Ultrasound Imaging Devices

 

3.5.2.    Key Application Areas

3.5.3.    Regulatory Guidelines

3.5.4.    Key Advantages and Roadblocks

 

3.6.       Prevalent Trends Related to Handheld Ultrasound Imaging Devices

3.6.1.    Emerging Focus Areas

3.6.2.    Key Historical Trends

3.6.3.    Geographical Distribution of Activity

 

  1. MARKET LANDSCAPE

4.1.       Chapter Overview

4.2.       Handheld Ultrasound Imaging Devices: Overall Market Landscape

4.2.1.    Analysis by Status of Development

4.2.2.    Analysis by Application Area

4.2.3.    Analysis by Weight of Device

4.2.4.    Analysis by Type of Transducer Array

4.2.5.    Analysis by Transducer Frequency

4.2.6.    Analysis by Mode of Imaging

4.2.7.    Analysis by Scanning Depth

4.2.8.    Analysis by Type of Software

4.2.9.    Analysis by Connectivity Provisions

4.2.10.  Analysis by Data Management Feature(s)

4.2.11.  Analysis by Battery Backup

4.2.12.  Analysis by Cost of Device

 

4.3.       Handheld Ultrasound Imaging Devices: Additional Information

4.4.       Handheld Ultrasound Imaging Devices: Information on Affiliated Technologies

4.5.       Handheld Ultrasound Imaging Devices: List of Manufacturers

4.5.1.    Analysis by Year of Establishment

4.5.2.    Analysis by Company Size

4.5.3.    Analysis by Types of Business Model Used

4.5.4.    Analysis by Target Market

4.5.5.    Analysis by Location of Headquarters

4.5.6.    Leading Manufacturers: Analysis by Number of Products

 

4.6.       Handheld Ultrasound Imaging Devices: Product Competitiveness Analysis

4.7.       Leading Manufacturers: 4D Bubble Analysis based on Application area, Mode                              of Imaging, Number of Devices and Company Size

4.8.       Grid Representation: Analysis by Application Area, Type of Transducer Array                               and Type of Software

4.9.       Heat Map Representation: Analysis by Application Area and Mode of                                           Imaging

4.10.     Tree Map Representation: Analysis by Mode of Imaging and Connectivity                                    Provision

4.11.     World Map Representation: Regional Activity

4.12.     Handheld Scanners with Potential for Use during the COVID-19 Pandemic

 

  1. COMPANY PROFILES

5.1.       Chapter Overview

5.2.       Butterfly Network

5.2.1.    Company Overview

5.2.2.    Product Portfolio: Handheld Ultrasound Imaging Devices

5.2.3.    Recent Developments and Future Outlook

 

5.3.       Clarius Mobile Health

5.3.1.    Company Overview

5.3.2.    Product Portfolio: Handheld Ultrasound Imaging Devices

5.3.3.    Recent Developments and Future Outlook

 

5.4.       EchoNous

5.4.1.    Company Overview

5.4.2.    Product Portfolio: Handheld Ultrasound Imaging Devices

5.4.3.    Recent Developments and Future Outlook

 

5.5.       Fujifilm

5.5.1.    Company Overview

5.5.2.    Product Portfolio: Handheld Ultrasound Imaging Devices

5.5.3.    Recent Developments and Future Outlook

 

5.6.       GE Healthcare

5.6.1.    Company Overview

5.6.2.    Product Portfolio: Handheld Ultrasound Imaging Devices

5.6.3.    Recent Developments and Future Outlook

 

5.7.       Philips

5.7.1.    Company Overview

5.7.2.    Product Portfolio: Handheld Ultrasound Imaging Devices

5.7.3.    Recent Developments and Future Outlooks

 

5.8.       WuHan Youkey Bio-Medical Electronics

5.8.1.    Company Overview

5.8.2.    Product Portfolio: Handheld Ultrasound Imaging Devices

5.8.3.    Recent Developments and Future Outlook

 

  1. BRAND POSITIONING ANALYSIS OF KEY PLAYERS

6.1.       Chapter Overview

6.2.       Scope and Methodology

6.3.       Brand Positioning Matrix: Butterfly Network

6.4.       Brand Positioning Matrix: Clarius Mobile Health

6.5.       Brand Positioning Matrix: EchoNous

6.6.       Brand Positioning Matrix: Fujifilm

6.7.       Brand Positioning Matrix: GE Healthcare

6.8.       Brand Positioning Matrix: Philips

6.9.       Brand Positioning Matrix: WuHan Youkey Bio-Medical Electronics

 

  1. PARTNERSHIPS AND COLLABORATIONS

7.1.       Chapter Overview

7.2.       Partnership Models

7.3.       Handheld Ultrasound Imaging Devices: List of Partnerships and Collaborations

7.3.1.    Analysis by Year of Partnership

7.3.2.    Analysis by Type of Partnership

7.3.3.    Analysis by Year and Type of Partnership

7.3.4.    Analysis by Type of Partner

7.3.5.    Analysis by Focus Area

7.3.6.    Most Active Players: Analysis by Number of Partnerships

7.3.7.    Regional Analysis

7.3.8.    Intercontinental and Intracontinental Agreements

 

  1. COST SAVING ANALYSIS

8.1.       Chapter Overview

8.2.       Key Assumptions

8.3.       Methodology

8.4.       Key Parameters Influencing the Cost of Handheld Ultrasound Imaging Devices

8.5.       Overall Cost Saving Potential of Handheld Ultrasound Imaging Devices, 2020-2030

 

8.6.       Cost Saving Potential of Handheld Ultrasound Imaging Devices: Analysis by Geography

8.6.1.    Cost Saving Potential of Handheld Ultrasound Imaging Devices in North America, 2020-               2030

8.6.2.    Cost Saving Potential of Handheld Ultrasound Imaging Devices in Europe, 2020-2030

8.6.3.    Cost Saving Potential of Handheld Ultrasound Imaging Devices in Asia-Pacific and Rest               of the World, 2020-2030

 

8.7.       Cost Saving Potential of Handheld Ultrasound Imaging Devices: Analysis by Economic                Strength

8.7.1.    Cost Saving Potential of Handheld Ultrasound Imaging Devices in High Income                            Countries, 2020-2030

8.7.2.    Cost Saving Potential of Handheld Ultrasound Imaging Devices in Upper Middle Income Countries, 2020-2030

8.7.3.    Cost Saving Potential of Handheld Ultrasound Imaging Devices in Lower Middle Income               Countries, 2020-2030

8.8.       Concluding Remarks: Cost Saving Scenarios

 

  1. DEMAND ANALYSIS

9.1.       Chapter Overview

9.2.       Methodology

9.3.       Impact of COVID-19 Pandemic on Global Demand for Handheld Ultrasound Imaging                    Devices

9.4.       Overall Global Demand for Handheld Ultrasound Imaging Devices, 2020-2030

9.5.       Global Demand for Handheld Ultrasound Imaging Devices: Analysis by Key Industry                    Players

9.6.       Global Demand for Handheld Ultrasound Imaging Devices: Analysis by End-Users

 

  1. MARKET FORECAST

10.1.     Chapter Overview

10.2.     Forecast Methodology and Key Assumptions

10.3.     Impact of COVID-19 Pandemic on Handheld Ultrasound Imaging Devices                                    Market

 

10.4.     Overall Handheld Ultrasound Imaging Devices Market, 2020-2030

10.4.1.  Handheld Ultrasound Imaging Devices Market: Distribution by Application Area

10.4.1.1. Handheld Ultrasound Imaging Devices Market for Cardiac Scanning, 2020-2030

10.4.1.2. Handheld Ultrasound Imaging Devices Market for Emergency Medicines, 2020-2030

10.4.1.3. Handheld Ultrasound Imaging Devices Market for Gynecological / Obstetrics Scanning,                2020-2030

10.4.1.4. Handheld Ultrasound Imaging Devices Market for Musculoskeletal Scanning, 2020-2030

10.4.1.5. Handheld Ultrasound Imaging Devices Market for Pulmonary Scanning, 2020-2030

10.4.1.6. Handheld Ultrasound Imaging Devices Market for Urological Scanning, 2020-2030

10.4.1.7. Handheld Ultrasound Imaging Devices Market for Vascular Surgery, 2020-2030

10.4.1.8. Handheld Ultrasound Imaging Devices Market for Other Application Areas, 2020-2030

 

10.4.2.  Handheld Ultrasound Imaging Devices Market: Distribution by Type of Transducer Array

10.4.2.1. Handheld Ultrasound Imaging Devices Market for Curved Array-based Scanners, 2020-                2030

10.4.2.2. Handheld Ultrasound Imaging Devices Market for Endocavity Array-based Scanners,                   2020-2030

10.4.2.3. Handheld Ultrasound Imaging Devices Market for Linear Array-based Scanners, 2020-                 2030

10.4.2.4. Handheld Ultrasound Imaging Devices Market for Phased Array-based Scanners, 2020-               2030

10.4.2.5. Handheld Ultrasound Imaging Devices Market for Other Scanners, 2020-2030

 

10.4.3.  Handheld Ultrasound Imaging Devices Market: Distribution by Type of Software

10.4.3.1. Handheld Ultrasound Imaging Devices Market for Smartphone Application-based                         Scanners, 2020-2030

10.4.3.2. Handheld Ultrasound Imaging Devices Market for Customized Software-based                             Scanners, 2020-2030

 

10.4.4.  Handheld Ultrasound Imaging Devices Market: Distribution by End-Users

10.4.4.1. Handheld Ultrasound Imaging Devices Market for Ambulatory Surgical Centers, 2020-2030

10.4.4.2. Handheld Ultrasound Imaging Devices Market for Diagnostic Imaging Center, 2020-2030

10.4.4.3. Handheld Ultrasound Imaging Devices Market for Hospitals, 2020-2030

10.4.4.4. Handheld Ultrasound Imaging Devices Market for Maternity Clinics, 2020-2030

10.4.4.4. Handheld Ultrasound Imaging Devices Market for Specialty Clinics, 2020-                                    2030

10.4.4.4. Handheld Ultrasound Imaging Devices Market for Other End-Users, 2020-2030

 

10.5.5.  Handheld Ultrasound Imaging Devices Market: Distribution by Key Geographical                          Regions

10.5.5.1. Handheld Ultrasound Imaging Devices Market in North America, 2020-2030

10.5.5.2. Handheld Ultrasound Imaging Devices Market in Europe, 2020-2030

10.5.5.3. Handheld Ultrasound Imaging Devices Market in Asia-Pacific and Rest of the World,                    2020-2030

 

10.6.     Concluding Remarks

 

  1. END-USER SPECIFIC OPPORTUNITY ANALYSIS

11.1.     Chapter Overview

11.2.     Methodology

11.3.     Distribution Strategies Adopted by Device Developers

 

11.4.     Demand for Handheld Ultrasound Imaging Devices

11.4.1.  End-User Demand Analysis: Ambulatory Surgical Centers, 2020-2030

11.4.2.  End-User Demand Analysis: Diagnostic Imaging Centers, 2020-2030

11.4.3.  End-User Demand Analysis: Hospitals, 2020-2030

11.4.4.  End-User Demand Analysis: Maternity Clinics, 2020-2030

11.4.5.  End-User Demand Analysis: Specialty Clinics, 2020-2030

11.4.6.  End-User Demand Analysis: Other End-Users, 2020-2030

 

11.5.     Market Attractiveness Analysis

11.5.1.  End-User Market Attractiveness: Ambulatory Surgical Centers, 2020-2030

11.5.2.  End-User Market Attractiveness: Diagnostic Imaging Centers, 2020-2030

11.5.3.  End-User Market Attractiveness: Hospitals, 2020-2030

11.5.4.  End-User Market Attractiveness: Maternity Clinics, 2020-2030

11.5.5.  End-User Market Attractiveness: Specialty Clinics, 2020-2030

11.5.6.  End-User Market Attractiveness: Other End-Users, 2020-2030

 

  1. CASE STUDY: IMPACT OF CORONAVIRUS OUTBREAK

12.1.     Chapter Overview

12.2.     Impact of Coronavirus Pandemic

12.2.1.  Short Term Impact

12.2.2.  Long Term Impact

12.3.     Future Strategies and Action Plans

 

  1. CONCLUSION

13.1.     Chapter Overview

13.2.     Key Takeaways

 

  1. EXECUTIVE INSIGHTS

14.1.     Chapter Overview

 

14.2.     SomaView

14.2.1.  Company Snapshot

14.2.2.  Interview Transcript: Stefan Mass, Chief Executive Officer

 

14.3.     EchoNous

14.3.1.  Company Snapshot

14.3.2.  Interview Transcript: Anais Concepcion, Director of Content and Digital    Campaigns

 

14.4.     PeakSonic

14.4.1.  Company Snapshot

14.4.2.  Interview Transcript: Zhengzheng Zhu, International Business Development

 

  1. APPENDIX 1: TABULATED DATA

 

  1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

The global handheld ultrasound imaging devices market is projected to be over USD 1.1 billion by 2030, growing at a CAGR of 11%, claims Roots Analysis

www.rootsanalysis.com
Submitted 18 hour(s) ago by Alberto Brando

Advances in the field of disease diagnostics have led to a substantial increase in the development of point-of-care medical imaging devices; handheld ultrasound scanners have emerged as a novel solution to cater to the unmet need in this domain. In fact, the demand for handheld ultrasound devices is on a surge amidst the COVID-19 pandemic. These portable, pocket-friendly, point-of-care devices have revolutionized the treatment of COVID-19 patients by provide remote access to doctors and ensures safety of the staff.

 

Roots Analysis is pleased to announce the publication of its recent study, titled, “Global Handheld Ultrasound Imaging Devices Market, 2020-2030”.

 

The  report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of such compact diagnostic devices, over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape of companies engaged in the development / manufacturing of handheld ultrasound imaging devices
  • Elaborate profiles of key industry players that offer a several handheld ultrasound imaging scanners (shortlisted on the basis of the product portfolio).
  • A detailed brand positioning analysis of key industry players, highlighting the current perceptions regarding their proprietary brands by taking into consideration several relevant aspects.
  • An insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain.
  • A comprehensive product competitiveness analysis to evaluate prominent scanners based on several product specific parameters.
  • An analysis of the partnerships that have been inked by stakeholders in the domain, during the time period 2010-2020.
  • An insightful analysis highlighting the cost saving potential associated with the use of handheld ultrasound imaging devices, based on information from close to 50 countries.
  • An informed estimate of the global demand for handheld ultrasound imaging devices for the period 2020-2030.
  • A review of the end-user specific product distribution strategies adopted by different device developers along with demand and market attractiveness for handheld ultrasound imaging devices.
  • An insightful discussion on the impact of COVID-19 on the overall handheld ultrasound imaging devices market, along with the key lessons learnt from big pharma players in 2008 recession.
  • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
  • Application Area
  • Cardiac Scanning
  • Emergency Medicines
  • Gynecological / Obstetrics Scanning
  • Musculoskeletal Scanning
  • Pulmonary Scanning
  • Urological Scanning
  • Vascular Surgery
  • Other Application Areas

 

  • Type of Transducer Array
  • Curved
  • Endocavity
  • Linear
  • Phased
  • Other Scanners

 

  • Type of Software
  • Smartphone Applications
  • Customized Software

 

  • End-Users
  • Ambulatory Surgical Centers
  • Diagnostic Imaging Centers
  • Hospitals
  • Maternity Clinics
  • Specialty Clinics
  • Other End-Users

 

  • Key Geographical Regions
  • North America
  • Europe
  • Asia-Pacific and Rest of the World

 

  • Transcripts of interviews held with the following senior level representatives of stakeholder companies
  • Stefan Maas (Chief Executive Officer, SomaView)
  • Anais Concepcion (Director of Content and Campaign Management, EchoNous)
  • Zhengzheng Zhu (Oversea Business Development, PeakSonic)

 

Key companies covered in the report

  • Aidmax Medical
  • Beijing Konted Medical Technology
  • Biim Ultrasound
  • BreastIT
  • Butterfly Network
  • CJ Medical
  • Clarius Mobile Health
  • EchoNous
  • Fujifilm
  • GE Healthcare
  • Guangzhou Top Medical Equipment
  • Healcerion
  • Interson Medical Instruments
  • Philips
  • Somax Systems
  • VINNO
  • WuHan Youkey Bio-Medical Electronics
  • Yor Labs

 

For more information please click on the following link:

https://www.rootsanalysis.com/reports/view_document/handheld-imaging-devices/319.html

 

Other Recent Offerings

  1. Large Volume Wearable Injectors Market (5th Edition), 2020-2030
  2. Companion Diagnostics Market (2nd Edition), 2019-2030
  3. Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com                   

 

The global handheld ultrasound imaging devices market is projected to be over USD 1.1 billion by 2030, growing at a CAGR of 11%, claims Roots Analysis

www.rootsanalysis.com
Submitted 19 hour(s) ago by Alberto Brando

 

The increasing medical diagnostic imaging burden has compelled industry players to develop advanced handheld ultrasound scanners that will enable physicians to accurately visualize all major organ systems for diagnostic purposes

 

Roots Analysis has announced the addition of “Global Handheld Ultrasound Imaging Devices Market, 2020-2030” report to its list of offerings.

 

According to industry experts, handheld ultrasound imaging devices are being adopted at a faster pace by different end-users owing to their higher efficiency and wider applicability. Further, these devices have proven to be useful in quarantining patients demonstrating symptoms of pleural wall thickening and lung congestion, a characteristic of pneumonia, as well as observed in patients suffering from the novel coronavirus (COVID-19).

 

To order this 235+ page report, which features 95+ figures and 110+ tables, please visit this link

 

Key Market Insights

 

Nearly 100 handheld ultrasound imaging devices are presently available / under development

Close to 85% of the aforementioned scanners use linear and curved / convex transducer arrays. Further, to offer variations in image visualization, about 46% of these devices support more than two modes of imaging, including brightness mode (B-mode), color doppler, motion mode (M-mode), pulsed wave, power doppler and tissue harmonic mode.

 

70% of scanners are based on smartphone applications

Handheld devices using abovementioned type of software are primarily being used for gynecology / obstetrics (32%), urological (21%) and abdomen (12%) scanning.  It is worth mentioning that customized software-based scanners are preferred in emergency medicines and hospital operating rooms, owing to their ease of handling .

 

Partnership activity has grown at an annualized rate of nearly 43%, between 2016 and 2019

Majority of the collaborations signed in this domain were reported to be distribution and supply agreements (over 30%). In addition, key value drivers in majority of the agreements were expansion of market reach and incorporation of advanced features in devices.

 

Demand for handheld ultrasound scanners is anticipated to grow at a CAGR of 12.1%, between 2020 and 2030

Presently, over 80,000 units of handheld ultrasound scanners are estimated to be used for diagnostic imaging purpose by physicians. In fact, scanners offered by Butterfly Network, Clarius Mobile Health, Fujifilm, GE Healthcare, Siemens Healthineers and Philips are estimated to cater to more than 80% of the current demand for such devices.

 

Handheld ultrasound scanners are estimated to enhance radiologists’ efficiency by ~10%

Owing to their light-weight, portability and advanced imaging features, these devices allow radiologists to perform more number of scans (as compared to conventional stationary devices) in a single day. In fact, by 2030, we anticipate net annual cost savings of over USD 30 billion to be brought about by the adoption of handheld ultrasound scanners.

 

By 2030, North America and Europe are anticipated to capture over 70% of the market opportunity

The market in European regions is anticipated to grow at a relatively faster rate (12.2%). In terms of end-users, by 2030, hospitals are likely to represent the largest share of the market, followed by ambulatory surgical centers (25%) and specialty clinics (16%).

 

To request a sample copy / brochure of this report, please visit this link

 

Key Questions Answered

  • Who are the leading developers of handheld ultrasound imaging devices?
  • What are the key application areas for handheld ultrasound imaging scanners?
  • What is the potential usability of handheld ultrasound scanners devices for lung scanning in COVID-19 patients?
  • Which partnership models are commonly adopted by stakeholders in this industry?
  • What is the annual global demand for handheld ultrasound imaging devices?
  • What is the impact of COVID-19 on the demand for handheld ultrasound imaging devices?
  • What is the likely cost saving potential associated with the use of handheld ultrasound imaging devices?
  • What are the key factors influencing the adoption of handheld ultrasound imaging scanners, among different end-users?
  • How is the current and future opportunity likely to be distributed across key market segments?

 

The USD 1.1 billion (by 2030) financial opportunity within the handheld ultrasound imaging devices market has been analyzed across the following segments:

  • Application Area
  • Cardiac Scanning
  • Emergency Medicines
  • Gynecological / Obstetrics Scanning
  • Musculoskeletal Scanning
  • Pulmonary Scanning
  • Urological Scanning
  • Vascular Surgery
  • Other Application Areas

 

  • Type of Transducer Array
  • Curved
  • Endocavity
  • Linear
  • Phased
  • Other Scanners

 

  • Type of Software
  • Smartphone Applications
  • Customized Software

 

  • End-Users
  • Ambulatory Surgical Centers
  • Diagnostic Imaging Centers
  • Hospitals
  • Maternity Clinics
  • Specialty Clinics
  • Other End-Users

 

  • Key Geographical Regions 
  • North America
  • Europe
  • Asia-Pacific and the Rest of the World 

The report features inputs from eminent industry stakeholders, according to whom handheld ultrasound imaging devices are likely to offer lucrative market opportunities for players working in this domain. The report includes detailed transcripts of the discussions held with following industry experts:

  • Stefan Maas (Chief Executive Officer, SomaView)
  • Anais Concepcion (Director of Content and Campaign Management, EchoNous)
  • Zhengzheng Zhu (Oversea Business Development, PeakSonic)

 

The research covers brief profiles of key players engaged in the development of handheld ultrasonic diagnostic imaging devices; other popular industry players featured in the report include:

  • Aidmax Medical
  • Beijing Konted Medical Technology
  • Biim Ultrasound
  • BreastIT
  • CJ Medical
  • Guangzhou Top Medical Equipment
  • Healcerion
  • Interson Medical Instruments
  • Somax Systems
  • VINNO
  • WuHan Youkey Bio-Medical Electronics
  • Yor Labs

 

For additional details, please visit

https://www.rootsanalysis.com/reports/view_document/handheld-imaging-devices/319.html

 

You may also be interested in the following titles:

  1. Large Volume Wearable Injectors Market (5th Edition), 2020-2030
  2. Companion Diagnostics Market (2nd Edition), 2019-2030
  3. Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers

 

Contact:

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Gaurav.Chaudhary@rootsanalysis.com

Bill Maher CBD Oil: Reviews, Maher CBD Farms |Is Bill Maher CBD Scam|?

supplements4fitness.com
Submitted 1 day(s) ago by ansgninge

One Bill Maher CBD Oil of in recent times we can again placed on makeup, fashion our hair, get dressed up, and go out for an evening at the theater, soaking in all the glorious laughter and chatter of being in a room full of people, not afraid of what might be transmitted. One day once more, we are able to have fun a special event at an upscale eating place, surrounded a bit too carefully with the aid of different diners - however we may not mind. One of in recent times we will host dinner events and wrap our hands round and hold tight each and everyone who enters our residence.

 

https://supplements4fitness.com/bill-maher-cbd-oil/

 

https://bilmahercbdoil.wixsite.com/my-site

Keto Wave Pills Reviews - Updates 2021 - Shocking Revelation || Price And Sale!!

apnews.com
Submitted 1 day(s) ago by oneketobmx

Keto Wave Pills Reviews overall undertakings to relax up the fat that has been set neighboring the touchy zones like the thigh, chest, and stomach. This traditional obsession everything considered longings the person to improve the speed of ketosis which will assist you with improving the thin and fit body. The general blood course of the body will in like way be improved coming about to shaking the pill with the body liquid. The mixes will assist you with eliminating a wide assortment of things from the body. As Keto Wave Pills Avis handles your body, it will make the antibodies there which will assist you with battling against the formation of fat cells. There will be no more transmission of fat cells. It in like way permits your body to control the yearning all together not to encounter more restricted needing inclinations. The fat consumed during the Keto Wave Pills Avis system will be supplanted by tirelessness and confirmation rather than carbs. This strong strategy will permit you to recognize life unhindered and with satisfaction. Click here to get Keto Wave Pills for the most discounted price: https://apnews.com/press-release/newmediawire/lifestyle-nutrition-health-dietary-supplements-diet-and-exercise-c339c1cec83d7273eac2c95d7c115bf8

    One Shot Keto [LATEST UPDATE 2021] – Side Effects, Price - Where To Buy?

    www.prnewswire.com
    Submitted 1 day(s) ago by oneketobmx

    Extra fat is helpful for none. It doesn't look engaging besides. You will be left with afflictions like thyroid, weight, and diabetes in case you are strong. Getting more fit is definitely not a troublesome endeavor any more as it shows up. One-Shot keto will help you all through the journey to your weight decrease. One Shot Keto is the best improvement that will help you with getting more slender. This improvement shields your body from making plenitude fat. It will similarly smother your hankering and assistants in the ketosis cycle. Resulting to consuming this upgrade, your yearning will be diminished that will help your body extended the ketosis cycle. One-shot keto will over the long haul increase your steadiness and moreover will help your processing. One she keto won't simply help you in weight decrease and besides will execute the peril of afflictions associated with heaviness. Visit Official Website To Order One Shot Keto: https://www.prnewswire.com/news-releases/one-shot-keto-latest-diet-pill-for-usa--canada-customers-301191805.html

    Trust Modalert Tablets to unleash the real potential of your brain


    Submitted 1 day(s) ago by ymedz1234

    Cognition could be thought as the procedure for receiving advice out of the mind within the brain and processing on exactly the same to extract information out of the subconscious mind. This procedure involves several stages including logical reasoning, understanding and decision. Since the brain is the chair of most skills therefore the normal exercise of their brain through puzzles, insignificant mathematical and games quiz might improve cognitive capability. Emotional exercises have to be supplemented with physical exercise.

     

    Standard writing and reading are able to continue to keep the mind on the job. Combining different intellectual and societal groups and blending with all the proper men and women may aid an individual to master a couple of matters in life and proceed ahead. Seeing inspirational tapes or playing inspirational addresses may improve cognitive functioning. Further, an individual needs to possess a balanced diet full of minerals and vitamins. An individual can supplement their diet with fruits and vegetables, since they contain important nutritional elements which enhance the operation of the mind. Cardiovascular nutritional supplements like Modalert increase energy, enhance cognitive performance and enhance learning capacity and enhance attention.

     

    Anybody can benefit with the suitable usage of buy modalert online UK -- a weary practitioner, a busy pub street dealer or even a worried outside university-student. Modalert Tablets give you an all pure boost that may keep an individual awake and attentive for upto 12 hours without a crash. It's a greater stimulant than caffeine to staying awake and careful for lengthy hours. Modalert assists folks in different walks of lifestyles and also in various careers to elevate their operation pub. It promotes concentration degrees, improves mental awakeness and instills confidence in visitors to shoot better decisions. Students with great cognitive skills have a fantastic position to succeed in academic pursuits. Modalert is exceptionally popular with accountants who want just a tiny bit of attention and mental endurance to be certain all their characters are not correct. This tablet computer advances the emotional skill and endurance of attorneys that need to assert for lengthy hours at the court. It helps computer developers to discover logical solutions to issues and errors inside the code also may invent the ideal program for his or her clientele. An individual ought to choose the opinion of a doctor beforehand and really should modalert 200 uk next day delivery on the web from a trusted pharmacy in the UK .

      Improve Sleep Wake Rhythm With Ambien Sleeping Pills


      Submitted 1 day(s) ago by ymedz1234

      A number of biological functions have been determined by the circadian rhythm of the human anatomy. Circadian disruptions can ravage the metabolic functions of the human body and cause severe health conditions. In such circumstances, a solid sleep becomes influenced the most, which frequently increase the severity of pre existing health problems. Inadequate or disrupted sleep is often in charge of inducing additional health complications, too. In these situations, an individual must find the greatest remedy to palliate the complications and treat the disease.

      Types Of Circadian Rhythm Sleep Disorders

      There are 3 significant kinds of circadian rhythm sleep disorders, especially a shift-work disorder, a complex or delayed sleep phase disease, also non-24 sleep-wake disease. Under such health conditions, individuals fail to acquire a solid sleep due to disturbances in the circadian rhythms, especially a result of the non uniform work schedule, travelling in 1 time zone into another, and extreme climatic conditions. Circadian rhythm sleep disorders disturb the sleeping routine unnaturally and ravage the neuro logical functions too.

      Techniques Of Treatment

      Circadian rhythm sleep problems may be treated efficiently by following a sleep regime. However, certain medications can also help fight the illness. In these cases, an individual may take where can i buy ambien sleeping pills tartrate 10 mg tablets, including Ambien sleeping pills, to excite the regulation of the circadian rhythms. This drug helps enhance neural activities and cause quality slumbers. Besides the, taking Zolpidem tartrate tablets one can support the noise sleep to the recommended duration in the odd hours of their afternoon also. Individuals will get this medicine at a fair price or cheap Ambien pills from a few of these reputable drug providers to acquire outstanding relief. But some health measures should be followed closely before using the medication.

      Preventive Measures

      Zolpidem tartrate medicines help fight the complications of circadian rhythm sleep problems and improve the high quality of sleep. Certain precautions must be taken together with the medicines, which include:- Individuals suffering from chronic heart diseases, kidney diseases, and liver diseases should use Ambien sleeping pills only on the recommendation of a professional doctor. Even though alcohol is a relaxant, it should be avoided through the usage of all Ambien sleeping pills for sale. Circadian rhythm sleep disorders have been treated well together with drugs. Practising swimming may also help modulate the sleep-wake cycle. Whatever the case, one must avoid the overdose of the medicine to prevent additional health problems.

        Improve Sleep Posture and Attain Sound Sleep With Zopiclone Online UK


        Submitted 1 day(s) ago by ymedz1234

        The regulation of the sleep-wake cycle depends widely on the kind of sleeping places. It can help induce a solid sleep and also retain it for an extended duration as well. Sleeping spots include the body position over the bed to get to sleep. These sleeping places help regulate the digestive tract and also relax the brain as well. Choosing an inappropriate sleeping posture can cause disturbances in the circadian rhythm of the human body. Sleeping in an uncomfortable position can boost the number of frequent awakenings and it frequently contributes to chronic problems with sleep. Even though a sleep problem is treated effortlessly with sleeping aid medications. An individual can find Zopiclone pills to modulate the sleep-wake cycle and also reach a sound sleep. These cyclopyrrolone medicines help assuage the darkening of the nervous system and boost caliber slumbers. Besides sleeping tablets, one must elect for the very best sleeping spots to locate comfort within their pregnancy.

        Best Sleeping Positions To Induce A Deep-sleep And Retain It For Long

        Fetal Position

        A large number of individuals throughout the world select side sleep because it is the best suited position to reach a solid sleep. Approx 41 percent of the people decide to maneuver in this manner, curled upon the sides with one knee bent. This is called fetal position and more women than men choose this sleeping posture onto their bed. This could be definitely the most used sleeping posture and helps regulate the circulation of the blood in your system. Snorers can opt to this position to ease the complications and develop a profound sleep. However, an individual can also buy Zopiclone tablets to palliate apnea-related troubles.

        On Your Back

        As per a poll, just 8 percent of those men and women on earth choose to sleep on their back. This implies that it is promptly maybe not a favorite sleeping position, nevertheless the healthiest option for acquiring a sound sleep. This sleeping position reduces pressure on those areas, where one can experience pain, and help promote excellent slumbers. Besides this, one can buy zopiclone online paypal to fight the complications of inadequate sleep and revel in salubrious sleep hours.

        About Your Body Negative

        This is the sleeping position, where your torso and legs are relatively in a direct line. This sleeping position helps mitigate back pain ailments. Around 15 percent of the folks decide to sleep on the sides. This posture could help attenuate the apnea-related problems. These are some of the healthier sleeping positions to obtain a sound sleep. These places also aid in treating certain sleep disorders. But, one can buy genuine zopiclone online UK to palliate sleep-related maladies. These are very effective sleep aid drugs and aid Refrain from such health

        The ‘‘Microbial Contract Biomanufacturing Market, 2020-2030’’ report features an extensive study of the current market landscape and future opportunities associated with the microbial contract biomanufacturing market. The study also features a detailed an

        www.rootsanalysis.com
        Submitted 1 day(s) ago by Alberto Brando

         

        To order this detailed 320+ page report, please visit this link

         

        Key Inclusions

        • A detailed review of the current landscape of companies offering contract manufacturing services for biologics, using microbial expression systems, along with information on their year of establishment, company size, location of headquarters, number and location of their production facilities, scale of operation (preclinical, clinical and commercial), type of biologic(s) manufactured (peptides / proteins, antibodies, vaccines, biosimilars, oligonucleotides, plasmid DNA and others), type of microbial expression system(s) used (bacterial, yeast and others), type of fermenter(s) employed (single-use fermenters, stainless steel fermenters and others), type of manufacturing service(s) offered (cell banking, process development and characterization, analytical method development and testing, quality assurance and control, scale-up, downstream processing and regulatory support), and regulatory accreditations / certifications received (if any).
        • A region-wise, company competitiveness analysis, highlighting key players engaged in microbial based contract manufacturing based on their experience (considering the year of establishment of the firm) and expertise (taking into account their service portfolio, number of different types of biologics manufactured and number of distinct expression system(s) used).
        • An analysis of the various partnerships signed within this domain, with a focus on microbial contract biomanufacturing, since 2016, based on several relevant parameters, such as year of partnership, type of partnership model adopted, scale of operation, type of biologic, focus area, therapeutic area, most active players (in terms of number of partnerships signed), and geography. Further, it features a detailed analysis of the various mergers and acquisitions that were carried out in this domain, highlighting the trend in terms of number of players acquired between 2016-2020 (till May), along with the geographical distribution of this activity.
        • An elaborate analysis of the various expansion initiatives undertaken by contract manufacturers using microbial expression systems in order to augment their capabilities, over the period 2016-2020 (till May), taking into consideration several relevant parameters, such as year of expansion, type of expansion (capability expansion, capacity expansion, facility expansion and new facility), scale of operation of manufacturing facility, type of biologic and location of manufacturing facility.
        • A review of the varied microbial based manufacturing initiatives undertaken by big pharma players (shortlisted from the top 20 pharmaceutical companies as of 2019), highlighting trends across various parameters, such as number of initiatives, year of initiative and type of initiative.
        • A detailed proprietary 2×2 representation that was developed to assess the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.
        • Elaborate profiles of key players that offer contract biomanufacturing services using microbial expression systems across different geographies, namely North America, Europe and Asia Pacific. Each profile features a brief overview of the company, information related to its service portfolio, manufacturing capabilities and facilities, recent developments and an informed future outlook.
        • A discussion on industry affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the evolution of this field. It also includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on industry dynamics.
        • A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
        • An insightful discussion on the impact of COVID-19 outbreak on the overall microbial contract biomanufacturing market, and the key initiatives undertaken by CMOs to combat the challenges posed due to ongoing situation.

         

        The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

        • Type of Product
        • API
        • FDF

         

        • Type of Biologic
        • Proteins
        • Enzymes
        • Growth Hormones
        • Antibody based Drugs
        • Others (plasmid DNA, probiotics, microbiome-based biologics)

         

        • Type of Microbial Expression System
        • Bacteria
        • Yeast
        • Others (Algae and fungi)

         

        • Scale of Operation
        • Commercial
        • Preclinical / Clinical

         

        • Type of End User
        • Small Companies
        • Mid-sized Companies
        • Large / Very Large Companies

         

        • Key Geographical Regions
        • North America
        • Europe
        • Asia Pacific
        • Middle East and North Africa
        • Latin America

         

        To request sample pages, please visit this link

         

        Key Questions Answered

        • Who are the leading CMOs with expertise in production of microbial biologics?
        • What are the preferred microbial expression systems used in biologic development and manufacturing?
        • What are the key microbial fermentation technology platforms?
        • Who could be the potential partners for the microbial CMOs?
        • What kind of partnership models are commonly adopted by stakeholders engaged in this domain?
        • What type of expansion initiatives are being carried out by CMOs in this domain?
        • What initiatives are being undertaken by big pharma players in this domain?
        • What are the key factors influencing the make (manufacture in-house) versus buy (outsource) decision related to microbial fermentation?
        • What are the key trends within the microbial contract biomanufacturing market?
        • How is the current and future market opportunity likely to be distributed across key market segments?

         

        You may also be interested in the following titles:

        1. Drug Repurposing Service Providers Market, 2020 – 2030
        2. Antibody Discovery Services and Platforms Market (3rd Edition), 2020-2030
        3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020 - 2030

         

        Contact Us

        Gaurav Chaudhary

        +1 (415) 800 3415

        gaurav.chaudhary@rootsanalysis.com

        Over 115 companies, across the world, claim to offer a variety of product development, manufacturing and support services, for various types of biologics that are manufactured / expressed in microbial systems, claims Roots Analysis

        www.rootsanalysis.com
        Submitted 1 day(s) ago by Alberto Brando

         

        Despite mammalian cell cultures being the preferred manufacturing approach for biologics, recent advances in microbial fermentation have enabled the development of versatile biomanufacturing systems, which are both robust and cost friendly. Presently, a number of service provider companies claim to offer end-to-end solutions, ranging from product development to commercial production, for microbial biologics. Given the obvious advantages of outsourcing, drug developers are likely to continue relying on contract service providers for various aspects of their respective microbial biologic development programs.

         

        To order this 320+ page report, which features 150+ figures and 150+ tables, please visit this link

         

        The USD 9.3 billion (by 2030) financial opportunity within the microbial biomanufacturing market has been analyzed across the following segments:

        • Type of Product
        • API
        • FDF

         

        • Type of Biologic
        • Proteins
        • Enzymes
        • Growth Hormones
        • Antibody based Drugs
        • Others (plasmid DNA, probiotics, microbiome-based biologics)

         

        • Type of Microbial Expression System
        • Bacteria
        • Yeast
        • Others (Algae and fungi)

         

        • Scale of Operation
        • Commercial
        • Preclinical / Clinical

         

        • Type of End User
        • Small Companies
        • Mid-sized Companies
        • Large / Very Large Companies

         

        • Key Geographical Regions
        • North America
        • Europe
        • Asia Pacific
        • Middle East and North Africa
        • Latin America

         

        The Microbial Contract Biomanufacturing Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:

        • AGC Biologics
        • Aldevron
        • BioVectra
        • EirGenix
        • Etinpro
        • Eurogentec
        • Northway Biotechpharma
        • Ology Bioservices
        • Porton Biopharma
        • Stelis Biopharma

         

        Table of Contents

         

        1. Preface

          2. Executive Summary

        2. Introduction

        3. Market Landscape

        4. Company Competitiveness Analysis

         

        1. Company Profiles

        2.  Recent Partnerships

        3. Recent Expansions

        4. Microbial fermentation technology platforms

        5. Assessment of Relative Competition and Growth

        6. Make versus Buy Decision Making Framework

         

        1. Big Pharma Initiatives in Microbial Biomanufacturing

         

        1. Case study: comparison of small molecule and large

         

        1. Market Sizing and Opportunity Analysis

        2. Impact of covid-19 pandemic on microbial contract biomanufacturing market

         

        1. Swot Analysis

         

        1. Conclusion Appendix 3: List of Companies and Organizations
        2. Interview Transcripts

         

        1. Appendix 1: Tabulated Data

         

        1. Appendix 2: List of Companies and Organizations

         

        To purchase a copy, please visit https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html

         

        Contact Details

        Gaurav Chaudhary

        +1 (415) 800 3415

        gaurav.chaudhary@rootsanalysis.com 

        The microbial contract biomanufacturing market is projected grow at an annualized rate of 8.7%, till 2030

        www.rootsanalysis.com
        Submitted 1 day(s) ago by Alberto Brando

         

        Roots Analysis has done a detailed study on Microbial Contract Biomanufacturing Market, 2020-2030, covering key aspects of the industry and identifying potential future growth opportunities.

         

        To order this 320+ page report, which features 150+ figures and 150+ tables, please visit this link

         

        Key Market Insights

        • Over 115 companies, across the world, claim to offer a variety of product development, manufacturing and support services, for various types of biologics that are manufactured / expressed in microbial systems
        • Majority of the players have the necessary infrastructure / capability to produce different biologics, primarily proteins, at all scales using bacterial / yeast expression vectors
        • The market features the presence of several well-established players across the globe; the US, the UK and Germany emerged as current hubs for production of biologics using microbial strains
        • Several service providers, involved in this domain, are steadily expanding their capabilities in order to enhance their respective service portfolio and maintain a competitive edge in the industry
        • The growth trend of outsourcing microbial manufacturing operations is evident from the rise in recent partnership activity, as well as expansion initiatives undertaken by CMOs to meet the growing demand for novel biologics
        • Big pharma players have also made significant investments in this domain through establishment of new facilities, entering into strategic collaborations and undertaking financial investments
        • Future growth of the market is likely to be driven by increased adoption of novel biologics that are produced via microbial systems; we expect the service-based revenues to grow at a CAGR of over 8%
        • In the long term, the projected opportunity for contract biomanufacturing is anticipated to be distributed across contract service providers of different sizes, scales of manufacturing and key geographical regions

         

        For more information, please visit https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html

         

        Table of Contents

         

        1. PREFACE

        1.1.       Scope of the Report

        1.2.       Research Methodology

        1.3.       Chapter Outlines                     

         

        1. EXECUTIVE SUMMARY

         

        1. INTRODUCTION

        3.1        Chapter Overview

        3.2.       Overview of Biopharmaceuticals

         

        3.3.       Expression Systems Used for Biopharmaceutical Production

        3.3.1.    Microbial Expression Systems

        3.3.1.1. Bacterial Expression Systems

        3.3.1.2. Fungal Expression Systems

        3.3.1.3. Yeast Expression Systems                   

        3.3.2.    Mammalian versus Microbial Expression Systems

         

        3.4.       Microbial Manufacturing Process

        3.4.1.    Cell Banking

        3.4.2.    Upstream Processing

        3.4.3.    Fermentation

        3.4.4.    Downstream Processing

         

        3.5.       Overview of Contract Manufacturing

        3.6.       Need for Outsourcing Microbial Biomanufacturing Operations

        3.7.       Commonly Outsourced Microbial Biomanufacturing Operations

        3.8.       Advantages and Risks Associated with Outsourcing Microbial Biomanufacturing                                        Operations

        3.9.       Key Considerations while Selecting a CMO Partner

        3.10.     Concluding Remarks     

         

         

        1. MARKET LANDSCAPE

        4.1.       Chapter Overview

        4.2.       Microbial Contract Biomanufacturing Market: Overall Market Landscape

        4.2.1.    Analysis by Year of Establishment

        4.2.2.    Analysis by Company Size

        4.2.3.    Analysis by Location of Headquarters

        4.2.4.    Analysis by Location of Manufacturing Facility

        4.2.5.    Analysis by Scale of Operation

        4.2.6.    Analysis by Type of Biologic

        4.2.7.    Analysis by Type of Expression System Used

        4.2.8.    Analysis by Type of Fermenter

        4.2.9.    Analysis by Type of Service(s) Offered

        4.2.10.  Analysis by Regulatory Accreditations / Certifications

        4.3.       Regional Analysis

        4.3.1.    Analysis by North America

        4.3.2.    Analysis by Europe

        4.3.3.    Analysis by Asia Pacific

        4.3.4.    Analysis by Middle East and North Africa

         

        1. COMPANY COMPETITIVENESS ANALYSIS

        5.1.       Chapter Overview

        5.2.       Assumptions and Key Parameters

        5.3.       Methodology

        5.4.       Competitiveness Analysis

        5.4.1.    Competitiveness Analysis: Companies in North America

        5.4.2.    Competitiveness Analysis: Companies in Europe

        5.4.3.    Competitiveness Analysis: Companies in Asia Pacific    

         

        1. COMPANY PROFILES

        6.1.       Chapter Overview

        6.2.       Microbial Contract Biomanufacturers based in North America

        6.2.1.    AGC Biologics

        6.2.1.1. Company Overview

        6.2.1.2. Service Portfolio

        6.2.1.3. Manufacturing Capabilities and Facilities

        6.2.1.4. Recent Developments and Future Outlook

                   

        6.2.2.    Aldevron

        6.2.2.1. Company Overview

        6.2.2.2. Service Portfolio

        6.2.2.3. Manufacturing Capabilities and Facilities

        6.2.2.4. Recent Developments and Future Outlook

        6.2.3.    BioVectra

        6.2.3.1. Company Overview

        6.2.3.2. Service Portfolio

        6.2.3.3. Manufacturing Capabilities and Facilities

        6.2.3.4. Recent Developments and Future Outlook

         

        6.2.4.    Ology Bioservices

        6.2.4.1. Company Overview

        6.2.4.2. Service Portfolio

        6.2.4.3. Manufacturing Capabilities and Facilities

        6.2.4.4. Recent Developments and Future Outlook

         

        6.3.       Microbial Contract Biomanufacturers Based in Europe

        6.3.1.    Eurogentec

        6.3.1.1. Company Overview

        6.3.1.2. Service Portfolio

        6.3.1.3. Manufacturing Capabilities and Facilities

        6.3.1.4. Recent Developments and Future Outlook

         

        6.3.2.    Northway Biotechpharma

        6.3.2.1. Company Overview

        6.3.2.2. Service Portfolio

        6.3.2.3. Manufacturing Capabilities and Facilities

        6.3.2.4. Recent Developments and Future Outlook

         

        6.3.3.    Porton Biopharma

        6.3.3.1. Company Overview

        6.3.3.2. Service Portfolio

        6.3.3.3. Manufacturing Capabilities and Facilities

        6.3.3.4. Recent Developments and Future Outlook

                   

        6.4.       Microbial Contract Biomanufacturers Based in Asia Pacific

        6.4.1.    EirGenix

        6.4.1.1. Company Overview

        6.4.1.2. Service Portfolio

        6.4.1.3. Manufacturing Capabilities and Facilities

        6.4.1.4. Recent Developments and Future Outlook

         

        6.4.2.    Etinpro

        6.4.2.1. Company Overview

        6.4.2.2. Service Portfolio

        6.4.2.3. Manufacturing Capabilities and Facilities

        6.4.2.4. Recent Developments and Future Outlook

         

        6.4.3.    Stelis Biopharma

        6.4.3.1. Company Overview

        6.4.3.2. Service Portfolio

        6.4.3.3. Manufacturing Capabilities and Facilities

        6.4.3.4. Recent Developments and Future Outlook

         

        1. RECENT PARTNERSHIPS

        7.1.       Chapter Overview

        7.2.       Partnership Models

        7.3.       Microbial Contract Biomanufacturers: Recent Partnerships

        7.3.1.    Analysis by Year of Partnerships

        7.3.2.    Analysis by Type of Partnership Model

        7.3.3.    Analysis by Scale of Operation

        7.3.4.    Analysis by Type of Biologic

        7.3.5.    Analysis by Focus Area

        7.3.6.    Analysis by Target Therapeutic Area

         

        7.3.7.    Analysis by Region

        7.3.7.1. Country-Wise Distribution

        7.3.7.2. Intercontinental and Intracontinental Agreements

         

        7.3.8.    Most Active Players: Analysis by Number of Partnerships

         

        7.4.       Microbial Contract Biomanufacturers: Mergers and Acquisitions

        7.4.1.    Analysis by Year of Merger / Acquisition

        7.4.2.    Analysis by Type of Acquisition 

        7.4.3.    Regional Analysis 

        7.4.3.1. Continent-wise Distribution 

        7.4.3.2. Country-wise Distribution 

        7.4.3.3. Intercontinental and Intracontinental Deals 

          

        7.4.4.    Most Active Players: Analysis by Number of Acquisitions

        7.4.5.    Analysis by Key Value Drivers  

        7.4.5.1. Analysis by Year of Acquisition and Key Value Drivers

         

        1. RECENT EXPANSIONS

        8.1.       Chapter Overview

        8.2.       Microbial Contract Biomanufacturers: Recent Expansions

        8.2.1.    Analysis by Year of Expansion

        8.2.2.    Analysis by Type of Expansion

        8.2.3.    Analysis by Scale of Operation

        8.2.4.    Analysis by Type of Biologic

        8.3.       Geographical Analysis

        8.3.1.    Continent-wise Distribution                   

         

        1. MICROBIAL FERMENTATION TECHNOLOGY PLATFORMS

        9.1.       Chapter Overview

        9.2.       Technology Platforms Commonly Used for Microbial Fermentation

        9.3.       Upcoming Platforms-General Technologies

         

        1. ATTRACTIVENESS COMPETITION MATRIX

        10.1.     Chapter Overview

        10.2.     AC Matrix: An Overview

        10.2.1.  Strong Business Segment

        10.2.2.  Average Business Segment

        10.2.3.  Weak Business Segment

        10.3.     AC Matrix: Analytical Methodology

        10.4.     AC Matrix: Analyzing the Data for North America

        10.5.     AC Matrix: Analyzing the Data for Europe

        10.6.     AC Matrix: Analyzing the Data for Asia Pacific and Middle East

         

        1. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

        11.1.     Chapter Overview

        11.2.     Assumptions and Parameter Definitions

        11.2.1.  Scenario 1

        11.2.2.  Scenario 2

        11.2.3.  Scenario 3

        11.2.4.  Scenario 4

        11.3.     Concluding Remarks

                                                                               

        1. BIG PHARMA INITITATIVES IN MICROBIAL BIOMANUFACTURING

        12.1.     Chapter Overview

        12.2.     List of Microbial Biopharmaceutical Manufacturing Initiatives of Big Pharma Players

        12.2.1.  Analysis by Number of Initiatives

        12.2.2.  Analysis by Year of Initiative

        12.2.3.  Analysis by Company and Year of Initiative

        12.2.4.  Analysis by Purpose of Initiative

        12.2.5.  Analysis by Company and Purpose of Initiative

        12.2.6.  Analysis by Type of Initiative

        12.2.7.  Analysis by Scale of Operation

        12.2.8.  Analysis by Type of Drug Molecule

        12.2.9.  Analysis by Type of Microbial Expression System Used              

        12.2.10. Geographical Analysis by Investment Made

         

        12.3.     Competitive Benchmarking of Big Pharmaceutical Players

        12.3.1. Big Pharma Summary

         

        1. CASE STUDY: COMPARISON OF SMALL MOLECULE AND LARGE MOLECULE DRUGS / THERAPIES

        13.1.     Chapter Overview

        13.2.     Small Molecule and Large Molecule Drugs / Therapies    

        13.2.1. Comparison of Key Characteristics

        13.2.2. Comparison of Microbial Manufacturing Process

        13.2.2.1. Microbial Contract Manufacturers Providing Services for Small Molecules

        13.2.3. Comparison of Key Manufacturing-related Challenges

                                                       

        1. MARKET SIZING AND OPPORTUNITY ANALYSIS

        14.1.     Chapter Overview

        14.2.     Key Assumptions and Forecast Methodology

        14.3.     Overall Microbial Contract Biomanufacturing Market, 2020-2030

        14.3.1.  Microbial Contract Biomanufacturing Market for APIs, 2020-2030

        14.3.2.  Microbial Contract Biomanufacturing Market for FDFs, 2020-2030           

         

        14.4.     Microbial Contract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by Type of Biologic

        14.5.     Microbial Contract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by Type of Microbial Expression System Used

        14.6.     Microbial Contract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by Scale of Operation

        14.7.     Microbial Contract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by Type of           End User

         

        14.8.      Microbial Contract Biomanufacturing Market, 2020, 2025, 2030: Distribution by Key Geographical Regions          

        14.8.1.   Microbial Contract Biomanufacturing Market in North America, 2020-2030

        14.8.1.1. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Proteins

        14.8.1.2. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Enzymes

        14.8.1.3. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Growth   Hormones

        14.8.1.4. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Antibody-based Drugs

        14.8.1.5. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Other Biologics

        14.8.1.6. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Bacterial Cell-based Expression Systems

        14.8.1.7. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Yeast Cell-based Expression Systems

        14.8.1.8. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Other Microbial Cell-based Expression Systems

        14.8.1.9. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Commercial Operations

        14.8.1.10. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Operations

        14.8.1.11. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Small Companies

        14.8.1.12. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Mid-sized Companies

        14.8.1.13. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies

         

        14.8.2.    Microbial Contract Biomanufacturing Market in Europe, 2020-2030

        14.8.2.1. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Proteins

        14.8.2.2. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Enzymes

        14.8.2.3. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Growth Hormones

        14.8.2.4. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Antibody-based Drugs

        14.8.2.5. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Other Biologics

        14.8.2.6. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Bacterial Cell-based Expression Systems

        14.8.2.7. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Yeast Cell-based Expression Systems

        14.8.2.8. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Other Microbial Cell-based Expression Systems

        14.8.2.9. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Commercial Operations

        14.8.2.10. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Operations

        14.8.2.11. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Small Companies

        14.8.2.12. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Mid-sized    Companies

        14.8.2.13. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies

         

        14.8.3.  Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030

        14.8.3.1. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Proteins

        14.8.3.2. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Enzymes

        14.8.3.3. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Growth Hormones

        14.8.3.4. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Antibody- based Drugs

        14.8.3.5. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Other Biologics

        14.8.3.6. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Bacterial Cell-based Expression Systems

        14.8.3.7. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Yeast Cell-based Expression Systems

        14.8.3.8. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Other Microbial Cell-based Expression Systems

        14.8.3.9. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Commercial Operations

        14.8.3.10. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Preclinical / Clinical Operations

        14.8.3.11. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Small Companies

        14.8.3.12. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Mid-sized Companies

        14.8.3.13. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Large / Very Large Companies

         

        14.8.4.  Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030

        14.8.4.1. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Proteins

        14.8.4.2. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030:            Share of Enzymes

        14.8.4.3. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030:            Share of Growth Hormones

        14.8.4.4. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030:            Share of Antibody-based Drugs

        14.8.4.5. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030:            Share of Other Biologics

        14.8.4.6. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030:            Share of Bacterial Cell-based Expression Systems

        14.8.4.7. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Yeast Cell-based Expression Systems

        14.8.4.8. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Other Microbial Cell-based Expression Systems

        14.8.4.9. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Commercial Operations

        14.8.4.10. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Preclinical / Clinical Operations

        14.8.4.11. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030:          Share of Small Companies

        14.8.4.12. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030:          Share of Mid-sized Companies

        14.8.4.13. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030:          Share of Large / Very Large Companies

         

        14.8.5.  Microbial Contract Biomanufacturing Market in Latin America, 2020-2030

         

        1. IMPACT OF COVID-19 PANDEMIC ON MICROBIAL CONTRACT BIOMANUFACTURING MARKET

        15.1.     Chapter Overview

        15.2.     Current Options and Recuperative Initiatives of Key Players

        15.2.1.  KBI Biopharma

        15.2.2.  Lonza

        15.2.3.  Porton Pharma Solutions

        15.2.4.  Wacker Biotech

        15.2.5.  Wuxi AppTec

        15.3.     Impact on Microbial Contract Biomanufacturing Market Opportunity

        15.4.     Recuperative Strategies for CMO Businesses

        15.4.1.  Strategies for Implementation in the Short / Mid Term

        15.4.2.  Strategies for Implementation in the Long Term

         

        1. SWOT ANALYSIS

        16.1.     Chapter Overview

        16.2.     Strengths

        16.3.     Weaknesses

        16.4.     Opportunities

        16.5.     Threats

        16.6.     Comparison of SWOT Factors

         

        1. CONCLUDING REMARKS

        17.1.     Chapter Overview

         

        1. INTERVIEW TRANSCRIPTS

        18.1.     Chapter Overview

        18.2.     Meteoric Biopharmaceuticals

        18.2.1.  Company Snapshot

        18.2.2.  Interview Transcript: Gaurav Kaushik, Managing Director and Chief Executive Officer (Q4 2019)

         

        18.3.     List Biological Laboratories

        18.3.1.  Company Snapshot

        18.3.2.  Interview Transcript: Debbie Pinkston, Vice President, Sales and Business Development (Q3 2019)

         

        18.4.     OLON

        18.4.1.  Company Snapshot

        18.4.2.  Interview Transcript: Andrea Conforto, Sales and Marketing-Bioservices Director)

        18.5.     Luina Bio

        18.5.1.  Company Snapshot

        18.5.2.  Interview Transcript: Max Rossetto, General Manager-Business Development

         

        18.6.     WACKER Biotech

        18.6.1.  Company Snapshot

        18.6.2.  Interview Transcript: Rob van Dijk, Business Development Manager (Q4 2019)

         

        1. APPENDIX 1: TABULATED DATA

         

        1. APPENDIX 2: LIST OF COMPANIES AND ORGANISTIONS

         

         

        Contact Details

        Gaurav Chaudhary

        +1 (415) 800 3415

        gaurav.chaudhary@rootsanalysis.com

        The microbial contract biomanufacturing market is estimated to be worth USD 9.3 billion in 2030, predicts Roots Analysis

        www.rootsanalysis.com
        Submitted 1 day(s) ago by Alberto Brando

         

        Benefits offered by microbial biomanufacturing, such as low production costs and faster development timelines, have led many innovators to adopt these platforms for next generation biologics, offering lucrative opportunities for CMOs / CDMOs

         

        Roots Analysis is pleased to announce the publication of its recent study, titled, “Microbial Contract Biomanufacturing Market, 2020-2030.”

         

        The report features an extensive study of the current market landscape and future opportunities associated with the microbial contract biomanufacturing market. It features a detailed analysis of key drivers and trends related to this evolving domain. In addition to other elements, the study includes:

        • A detailed review of the current landscape of companies offering contract manufacturing services.
        • Elaborate profiles of key players that specialize in offering services for contract biomanufacturing.
        • A competitiveness analysis, highlighting key players engaged in microbial based contract manufacturing, featuring insightful pictorial summaries and representations.
        • An analysis of the partnerships and expansions that have been established in this domain, in the recent past.
        • A competitiveness analysis, highlighting key players engaged in microbial based contract manufacturing, featuring insightful pictorial summaries and representations.
        • A detailed proprietary 2×2 representation to assess the current market scenario
        • An analysis of the initiatives of big biopharma players engaged in this domain.
        • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
        • Type of Product
        • API
        • FDF

         

        • Type of Biologic
        • Proteins
        • Enzymes
        • Growth Hormones
        • Antibody based Drugs
        • Others (plasmid DNA, probiotics, microbiome-based biologics)

         

        • Type of Microbial Expression System
        • Bacteria
        • Yeast
        • Others (Algae and fungi)

         

        • Scale of Operation
        • Commercial
        • Preclinical / Clinical

         

        • Type of End User
        • Small Companies
        • Mid-sized Companies
        • Large / Very Large Companies

         

        • Key Geographical Regions
        • North America
        • Europe
        • Asia Pacific
        • Middle East and North Africa
        • Latin America

         

        Transcripts of interviews held with the following senior level representatives of stakeholder companies

         

         

        Key companies covered in the report

        • AGC Biologics
        • Aldevron
        • BioVectra
        • EirGenix
        • Etinpro
        • Eurogentec
        • Northway Biotechpharma
        • Ology Bioservices
        • Porton Biopharma
        • Stelis Biopharma

         

        For additional details, please visit 

        https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html or email sales@rootsanalysis.com

         

        You may also be interested in the following titles:

        1. Drug Repurposing Service Providers Market, 2020 – 2030
        2. Antibody Discovery Services and Platforms Market (3rd Edition), 2020-2030
        3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020 - 2030

         

        Contact:

        Gaurav Chaudhary

        +1 (415) 800 3415

        +44 (122) 391 1091

        Gaurav.Chaudhary@rootsanalysis.com

        The microbial contract biomanufacturing market is projected to be worth USD 9.3 billion by 2030, growing at a CAGR of 8.7%, claims Roots Analysis

        www.rootsanalysis.com
        Submitted 1 day(s) ago by Alberto Brando

         

        The growing pipeline of biologics that can be produced in microbial systems, such as antibody fragments and plasmid-based therapies, is anticipated to offer lucrative opportunities to service providers serving this niche, but growing market segment

         

         

        London

         

        Roots Analysis has announced the addition of the “Microbial Contract Biomanufacturing Market, 2020-2030” report to its list of offerings.

         

        Despite mammalian cell cultures being the preferred manufacturing approach for biologics, recent advances in microbial fermentation have enabled the development of versatile biomanufacturing systems, which are both robust and cost friendly. Presently, a number of service provider companies claim to offer end-to-end solutions, ranging from product development to commercial production, for microbial biologics. Given the obvious advantages of outsourcing, drug developers are likely to continue relying on contract service providers for various aspects of their respective microbial biologic development programs.

         

        To order this 320+ page report, which features 150+ figures and 150+ tables, please visit this link

         

        Key Market Insights

         

        Over 115 CMOs claim to offer manufacturing services for microbial biologics

        The microbial contract biomanufacturing market is highly fragmented, featuring a mix of small, mid-sized, large and very large players. It is worth mentioning that more than 50% of CMOs mentioned in the report, have the necessary capabilities to manufacture biologics across all scales of operation (preclinical, clinical and commercial).

         

        Presently, more than 70% of service providers use bacterial expression systems

        Recently, a number of microbial biologics manufacturers are shifting to yeast-based production systems. It is also worth highlighting that close to 30% of CMOs, identified in this research, claim to have the required capabilities to manufacture biologics using both bacterial and yeast-based systems.

         

        Europe is currently regarded as a key manufacturing hub for microbial biologics

        There are more than 150 manufacturing facilities, with microbial fermentation capabilities, worldwide; of these, 43% are in Europe, followed by North America (31%). On the other hand, prominent regions in the Asia Pacific and Middle East, where microbial biologics are manufactured, include (in decreasing order of number of resident manufacturing facilities) China, India, Japan, Australia and Israel.

         

        Several partnerships were established in this domain, during the period 2016-2020

        Majority of the deals recorded in the report, were established in 2019. Further, a large number (~25%) of the partnerships were observed to be focused on the production of microbial biologics; this is followed by process development and manufacturing agreements (20%).

         

        Further, multiple expansion initiatives were undertaken by CMOs, since 2016

        More than 30% of expansion projects over the last few years were focused on the establishment of new facilities, followed by those involving the expansion of existing manufacturing facilities (28%). Further, 50% of the expansion initiatives mentioned in the report, were in undertaken by stakeholder companies in Europe, followed North America (39%).

         

        Big pharma players have also been active in this upcoming field

        Around 60% of the initiatives undertaken by big pharma were reported in the period 2016-2020. Of these, 57% involved the establishment of strategic partnerships with other industry stakeholders. It is worth highlighting that, in terms of type of biologic, close to 49% of these initiatives were focused on recombinant proteins.

         

        North America and Europe are anticipated to capture over 80% share (in terms of service revenues) of the market, by 2030

        At present, more than 60% of the total revenues are generated from commercialized microbial biologics, and this trend is unlikely to change significantly in short to mid-term. Further, it is worth mentioning that the contract biomanufacturing market for microbial biologics in the Middle East and North Africa is anticipated to grow at a relatively faster rate (10.3%), followed by Asia Pacific (9%).

         

        To request a sample copy / brochure of this report, please visit this link

         

         

        Key Questions Answered

        • Who are the leading CMOs engaged in the production of microbial biologics?
        • What are the preferred microbial systems for the development and manufacturing of biologics?
        • Which are the key microbial fermentation technology platforms currently available in the market?
        • What kind of partnership models are commonly adopted by stakeholders in this industry?
        • What are the various initiatives undertaken by the big pharma players engaged in this domain?
        • What are the key factors influencing the make (manufacture in-house) versus buy (outsource) decision related to the production of microbial biologics?
        • What are the key trends within the microbial contract biomanufacturing market?
        • How is the current and future market opportunity likely to be distributed across key market segments?

         

        The USD 9.3 billion (by 2030) financial opportunity within the microbial contract biomanufacturing market has been analyzed across the following segments:

        • Type of Product
        • API
        • FDF

         

        • Type of Biologic
        • Proteins
        • Enzymes
        • Growth Hormones
        • Antibody based Drugs
        • Others (plasmid DNA, probiotics, microbiome-based biologics)

         

        • Type of Microbial Expression System
        • Bacteria
        • Yeast
        • Others (Algae and fungi)

         

        • Scale of Operation
        • Commercial
        • Preclinical / Clinical

         

        • Type of End User
        • Small Companies
        • Mid-sized Companies
        • Large / Very Large Companies

         

        • Key Geographical Regions
        • North America
        • Europe
        • Asia Pacific
        • Middle East and North Africa
        • Latin America

         

        The report features inputs from eminent industry stakeholders, according to whom, currently, over 50% operations related to both API and FDF manufacturing of microbial biologics are outsourced to third party service providers. The report includes detailed transcripts of discussions held with the following experts:

         

        The research covers profiles of key players (listed below); each profile features an overview of the company, information related to its microbial manufacturing focused service portfolio, production facilities and capabilities, and an informed future outlook.

        • AGC Biologics
        • Aldevron
        • BioVectra
        • EirGenix
        • Etinpro
        • Eurogentec
        • Northway Biotechpharma
        • Ology Bioservices
        • Porton Biopharma
        • Stelis Biopharma

         

        For additional details, please visit 

        https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html or email sales@rootsanalysis.com

         

        You may also be interested in the following titles:

        1. Drug Repurposing Service Providers Market, 2020 – 2030
        2. Antibody Discovery Services and Platforms Market (3rd Edition), 2020-2030
        3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020 - 2030

         

        Contact:

        Gaurav Chaudhary

        +1 (415) 800 3415

        +44 (122) 391 1091

        Gaurav.Chaudhary@rootsanalysis.com 

        The “In Vitro ADME Testing Services Market, 2019-2030” report features an extensive study on the current landscape and the likely future potential of the companies offering in vitro ADME testing services.

        www.rootsanalysis.com
        Submitted 1 day(s) ago by Alberto Brando

         

        To order this detailed 280+ page report, please visit this link

         

        Key Inclusions

        • A detailed assessment of the current market landscape, featuring a comprehensive list of over 90 CROs that offer in vitro ADME testing services, and analyses based on a number of parameters, such as year of establishment, headquarter location(s), company size, type of additional service(s) offered (in vivo ADME, in silico ADME and toxicology testing), range of assays offered within in vitro ADME service portfolio (blood to plasma ratio, Caco-2 permeability, cytochrome (CYP) enzyme induction / inhibition, metabolic stability, plasma protein binding, reaction phenotyping and others), type of molecule(s) (biologics and small molecules), and type of clientele (pharmaceutical / biotechnology companies and academic / research institutes).
        • A schematic logo landscape of in vitro ADME service providers, highlighting their geographical distribution (on the basis of location of headquarters) and company size (small-sized (1-50 employees), mid-sized (51-200 employees), large (201-1,000 employees), and very large (>1,000 employees)).
        • A discussion on the various outsourcing business models adopted in this domain, along with a list of key considerations that need to be taken into account by industry stakeholders while selecting a CRO partner.
        • Elaborate profiles of popular in vitro ADME testing service providers, featuring a brief overview of the company, its financial information (if available), information on in vitro ADME service(s) capabilities, and a comprehensive future outlook.
        • A comprehensive benchmark analysis, highlighting the key focus areas of small, mid-sized and large companies, comparing their existing capabilities within and beyond their respective peer groups, and thereby, providing a means for stakeholders to identify ways to gain a competitive edge in the industry.
        • A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2005-2018, along with the geographical distribution of this activity. The analysis also features an ownership change matrix, providing a summary of the involvement of private and public sector entities in this domain.
        • A detailed discussion on the various regulatory guidelines related to in vitro ADME testing, which have been laid down by major international / regional regulatory bodies (namely European Medicine Agency (EMA), US Food and Drug Administration (USFDA), Ministry of Health, Labor and Welfare (MHLW), International Council for Harmonisation (ICH) of Technical Requirements for Pharmaceuticals for Human Use, the Organization for Economic Co-operation and Development (OECD), and World Health Organization (WHO)).

         

         

        The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

         

        • Type of Molecule
        • Small Molecules
        • Biologics

         

        • Type of Service
        • Absorption Testing
        • Distribution Testing
        • Metabolism and Elimination Testing

         

        • Type of Assay
        • Caco-2 Permeability Assay
        • PAMPA Permeability Assay
        • MDCK Permeability Assay
        • Protein Binding Assay
        • Blood Brain Barrier Assay
        • Blood to Plasma Ratio
        • Stability / Clearance Assay
        • Enzyme Induction Assay
        • Enzyme Inhibition Assay
        • Metabolite Profiling and Screening / Identification Assay
        • Metabolite Production Assay
        • Reaction Phenotyping Assay
        • Transporter Interactions Assay

         

        • Target Therapeutic Area
        • Blood Disorders
        • Cardiovascular Disorders
        • Gastrointestinal and Digestive Disorders
        • Hormonal Disorders
        • Infectious Diseases
        • Immunological Disorders
        • Metabolic Disorders
        • Mental Disorders
        • Neurological Disorders
        • Oncological Disorders
        • Respiratory Disorders
        • Skin Disorders
        • Urogenital Disorders
        • Others

         

        • Type of Sponsor
        • Industry Players
        • Non-Industry Players

         

        • Key Geographical Regions
        • North America
        • Europe
        • Asia-Pacific and Rest of the World

         

        The report includes detailed transcripts of discussions held with the following experts:

        • Dan Close (Chief Scientific Officer, 490 Bio Tech)
        • Sridhar Iyer (Director and Global Head, Business Development, JRF Global) and Sarang Gorte (Assistant Manager, Business Development, JRF Global)

         

        To request sample pages, please visit this link

         

        Key Questions Answered

        • Who are the leading CROs offering in vitro ADME testing services?
        • What are the key services being offered by in vitro ADME testing service providers?
        • What is the trend of mergers and acquisitions in this domain?
        • How is the current and future market opportunity likely to be distributed across key market segments?
        • What are the anticipated future trends related to in vitro ADME testing services market?

         

        You may also be interested in the following titles:

        1. In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules, 2020-2030
        2. AR / VR based Healthcare Digital Marketing Service Providers Market, 2020-2030
        3. Bioavailability Enhancement Technologies and Services Market, 2020-2030

         

        Contact Us

        Gaurav Chaudhary

        +1 (415) 800 3415

        gaurav.chaudhary@rootsanalysis.com

        Over 90 firms are actively involved in providing in vitro ADME testing services; of these, over 30 players claim to provide end-to-end services

        www.rootsanalysis.com
        Submitted 1 day(s) ago by Alberto Brando

         

        ADME studies are considered to be critical in establishing the safety and efficacy of drug candidates. Currently, there are a number of contract research organizations (CROs) that claim to have the necessary capabilities to offer in vitro ADME services. Over time, such service providers have grown to become an indispensable part of the pharmaceutical / biopharmaceutical market.

         

        To order this 280+ page report, which features 135+ figures and 120+ tables, please visit this  link

        The USD 2.2 billion (by 2030) financial opportunity within the vitro ADME testing services market has been analyzed across the following segments:

         

        • Type of Molecule
        • Small Molecules
        • Biologics

         

        • Type of Service
        • Absorption Testing
        • Distribution Testing
        • Metabolism and Elimination Testing

         

        • Type of Assay
        • Caco-2 Permeability Assay
        • PAMPA Permeability Assay
        • MDCK Permeability Assay
        • Protein Binding Assay
        • Blood Brain Barrier Assay
        • Blood to Plasma Ratio
        • Stability / Clearance Assay
        • Enzyme Induction Assay
        • Enzyme Inhibition Assay
        • Metabolite Profiling and Screening / Identification Assay
        • Metabolite Production Assay
        • Reaction Phenotyping Assay
        • Transporter Interactions Assay

         

        • Target Therapeutic Area
        • Blood Disorders
        • Cardiovascular Disorders
        • Gastrointestinal and Digestive Disorders
        • Hormonal Disorders
        • Infectious Diseases
        • Immunological Disorders
        • Metabolic Disorders
        • Mental Disorders
        • Neurological Disorders
        • Oncological Disorders
        • Respiratory Disorders
        • Skin Disorders
        • Urogenital Disorders
        • Others

         

        • Type of Sponsor
        • Industry Players
        • Non-Industry Players

         

        • Key Geographical Regions
        • North America
        • Europe
        • Asia-Pacific and Rest of the World

         

        The In Vitro ADME Testing Services Market, 2019-2030, report features the following companies, which we identified to be key players in this domain:

        • Albany Molecular Research (AMRI)
        • Charles River Laboratories
        • Pharmaceutical Product Development (PPD)
        • RTI International
        • Eurofins Scientific
        • Evotec
        • Galapagos
        • Tecan Group
        • GVK Biosciences
        • Pharmaron
        • Sai Life Sciences
        • Shanghai Medicilon
        • WuXi AppTec

         

        Table of Contents

         

        1. Preface

          2. Executive Summary

        2. Introduction

        3. Guide to Outsourcing

        4. Market Landscape

        5. Company Profiles

        6. Benchmark Analysis

        7. Mergers and Acquisitions

        8. Regulatory Recommendations and Guidelines

        9. Market Forecast

        10. Conclusion

         

        1. Executive Insights

         

        1. Appendix 1: Tabulated Data

         

        1. Appendix 2: List of Companies and Organizations

         

        To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/in-vitro-adme-testing-services-market-2019-2030/239.html

         

        Contact Details-

        Gaurav Chaudhary

        +1 (415) 800 3415

        gaurav.chaudhary@rootsanalysis.com

         

        In vitro ADME testing services market is likely to be worth USD 2.2 billion by 2030, growing at an annualized rate of ~9.8%

        www.rootsanalysis.com
        Submitted 1 day(s) ago by Alberto Brando

         

        Roots Analysis has done a detailed study on ““In Vitro ADME Testing Services Market, 2019-2030” covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

         

        To order this 280+ page report, which features 135+ figures and 120+ tables, please visit this link

         

        Key Market Insights

        • Over 90 firms are actively involved in providing vitro ADME testing services; of these, over 30 players claim to have the capabilities to offer end-to-end services
        • Majority of the companies offer assays for drug metabolism and elimination testing for both small molecule and biologic drugs; followed by companies offering assays for absorption and distribution testing
        • Featuring the presence of small-mid sized firms, the in vitro ADME testing service provider landscape is well-distributed across various regions; these players have adopted various business models to cater to the evolving needs of the clients
        • Several players involved in this domain are steadily expanding their capabilities in order to enhance their respective in the in vitro ADME testing service portfolios and maintain a competitive edge in this industry
        • Various mergers and acquisitions have taken place from 2005-2018 between industry stakeholders in this domain, for addition of capabilities (primarily related to drug metabolism and pharmacokinetics testing) and geographical expansion / consolidation
        • Driven by the increasing demand for effective pharmacological interventions across a wide range of therapeutic areas, the market is expected to witness sustained growth in future
        • In the long-term, the projected opportunity is anticipated to be well distributed across various geographies, type of sponsors and type of services / assays

         

        For more information, please visit https://www.rootsanalysis.com/reports/view_document/in-vitro-adme-testing-services-market-2019-2030/239.html  

         

        Table of Contents

         

        1. PREFACE

        1.1.       Scope of the Report

        1.2.       Research Methodology

        1.3.       Chapter Outlines

         

        1. EXECUTIVE SUMMARY

         

        1. INTRODUCTION

        3.1.       Chapter Overview

        3.2.       The Drug Discovery and Development Process

        3.3.       Introduction to Absorption, Distribution, Metabolism and Excretion (ADME) Testing

        3.3.1.    Absorption

        3.3.2.    Distribution

        3.3.3.    Metabolism

        3.3.4.    Excretion

         

        3.4.       Importance of ADME Studies in Early Stage Research

        3.5.       Types of ADME Studies in Discovery and Preclinical Development

        3.6.       Types of Assays Used in ADME Testing

         

        3.7.       Types of ADME Testing Studies

        3.7.1.    In Vitro ADME Testing Studies

        3.7.2.    In Silico ADME Testing Studies

        3.7.3.    In Vivo ADME Testing Studies

         

        3.8.       Key Drivers for ADME Testing Studies

        3.9.       Concluding Remarks

         

        1. GUDE TO OUTSOURCING

        4.1.       Chapter Overview

        4.2.       Outsourcing ADME Testing Services

        4.3.       Guiding Models for Outsourcing

        4.3.1.    Transactional Outsourcing Model

        4.3.2.    Performance-based Outsourcing Model

        4.3.3.    Outcomes-based Outsourcing Model

        4.3.4.    Phase-dependent Outsourcing Model

         

        4.4.       Selecting a Contract Research Organization (CRO) Partner

        4.4.1.    Key Considerations

         

        4.5.       Role of CROs in Drug Development

        4.5.1.    Discovery and Preclinical Research

        4.5.2.    Early Clinical Research

        4.5.3.    Late Stage Clinical Research

         

        4.6.       Benefits of Outsourcing ADME Testing Services

        4.7.       Risks and Challenges Associated with Outsourcing ADME Testing Services

        4.8.       Concluding Remarks

         

        1. MARKET LANDSCAPE

        5.1.       Chapter Overview

        5.1.       Chapter Overview

        5.2.       In Vitro ADME Testing Services: List of Industry Players

        5.2.1.    Analysis by Year of Establishment

        5.2.2.    Analysis by Geographical Location

        5.2.3.    Analysis by Company Size

        5.2.4.    Analysis by Type of Service Offering

        5.2.5.    Analysis by Type of In Vitro ADME Assays

        5.2.6.    Analysis by Type of Molecule

        5.2.7.    Analysis by Type of Clientele

        5.2.8.    Logo Landscape: Distribution by Company Size and Location of Headquarters

         

        5.3.       In Silico ADME Testing Services: List of Industry Players

         

        1. COMPANY PROFILES

        6.1.       Chapter Overview

        6.2.       Key Players based in North America

        6.2.1.    Albany Molecular Research (AMRI)

        6.2.1.1. Company Snapshot

        6.2.1.2. Financial Information

        6.2.1.3. ADME Testing Specific Service Portfolio

        6.2.1.4. Recent Developments and Future Outlook

         

        6.2.2.    Charles River Laboratories

        6.2.2.1. Company Snapshot

        6.2.2.2. Financial Information

        6.2.2.3. ADME Testing Specific Service Portfolio

        6.2.2.4. Recent Developments and Future Outlook

         

        6.2.3.    Pharmaceutical Product Development (PPD)

        6.2.3.1. Company Snapshot

        6.2.3.2. ADME Testing Specific Service Portfolio

        6.2.3.3. Recent Developments and Future Outlook

         

        6.2.4.    RTI International

        6.2.4.1. Company Snapshot

        6.2.4.2. Financial Information

        6.2.4.3. ADME Testing Specific Service Portfolio

        6.2.4.4. Recent Developments and Future Outlook

         

        6.3.       Key Players based in Europe

        6.3.1.    Eurofins Scientific

        6.3.1.1. Company Snapshot

        6.3.1.2. Financial Information

        6.3.1.3. ADME Testing Specific Service Portfolio

        6.3.1.4. Recent Developments and Future Outlook

         

        6.3.2.    Evotec

        6.3.2.1. Company Snapshot

        6.3.2.2. Financial Information

        6.3.2.3. ADME Testing Specific Service Portfolio

        6.3.2.4. Recent Developments and Future Outlook

         

        6.3.3.    Galapagos

        6.3.3.1. Company Snapshot

        6.3.3.2. Financial Information

        6.3.3.3. ADME Testing Specific Service Portfolio

        6.3.3.4. Recent Developments and Future Outlook

         

        6.3.4.    Tecan Group

        6.3.4.1. Company Snapshot

        6.3.4.2. Financial Information

        6.3.4.3. ADME Testing Specific Service Portfolio

        6.3.4.4. Recent Developments and Future Outlook

         

        6.4.       Key Players based in Asia-Pacific

        6.4.1.    GVK Biosciences

        6.4.1.1. Company Snapshot

        6.4.1.2. ADME Testing Specific Service Portfolio

        6.4.1.3. Recent Developments and Future Outlook

         

        6.4.2.    Pharmaron

        6.4.2.1. Company Snapshot

        6.4.2.2. ADME Testing Specific Service Portfolio

        6.4.2.3. Recent Developments and Future Outlook

         

        6.4.3.    Sai Life Sciences

        6.4.3.1. Company Snapshot

        6.4.3.2. ADME Testing Specific Service Portfolio

        6.4.3.3. Recent Developments and Future Outlook

         

        6.4.4.    Shanghai Medicilon

        6.4.4.1. Company Snapshot

        6.4.4.2. ADME Testing Specific Service Portfolio

        6.4.4.3. Recent Developments and Future Outlook

         

        6.4.5.    Syngene International

        6.4.5.1. Company Snapshot

        6.4.5.2. Financial Information

        6.4.5.3. ADME Testing Specific Service Portfolio

        6.4.5.4. Recent Developments and Future Outlook

         

        6.4.6.    WuXi AppTec

        6.4.6.1. Company Snapshot

        6.4.6.2. Financial Information

        6.4.6.3. ADME Testing Specific Service Portfolio

        6.4.6.4. Recent Developments and Future Outlook

         

        1. BENCHMARK ANALYSIS

        7.1.       Chapter Overview

        7.2.       Benchmark Analysis: Methodology

        7.3.       Benchmark Analysis: Peer Groups

        7.3.1.    Peer Group I

        7.3.2.    Peer Group II

        7.3.3.    Peer Group III

        7.3.4.    Peer Group IV

        7.3.5.    Peer Group V

        7.3.6.    Peer Group VI

        7.3.7.    Peer Group VII

        7.3.8.    Peer Group VIII

         

        7.4.       Concluding Remarks

         

        1. MERGERS AND ACQUISITIONS

        8.1.       Chapter Overview

        8.2.       In Vitro ADME Testing Services: Mergers and Acquisitions

        8.2.1.    Cumulative Year-wise Trend

        8.2.2.    Geographical Activity

        8.2.3.    Ownership Change Matrix

        8.2.4.    Most Active Players: Analysis by Number of Acquisitions

        8.2.5.    Key Value Drivers

        8.2.6.    Key Acquisitions: Deal Multiples

         

        1. REGULATORY RECOMMENDATIONS AND GUIDELINES

        9.1.       Chapter Overview

        9.2.       Regulatory Guidelines Issued by International Regulatory Agencies

        9.2.1.    The International Council for Harmonisation (ICH) of Technical Requirements for Pharmaceuticals for Human Use

        9.2.2.    World Health Organization (WHO)

        9.2.3.    Organisation for Economic Co-operation and Development (OECD)

         

        9.3.       Regulatory Guidelines Issued by Regional Regulatory Agencies

        9.3.1.    United States Food and Drug Administration (USFDA), US

        9.3.2.    European Medicine Agency (EMA), Europe

        9.3.3.    Ministry of Health, Labour and Welfare (MHLW), Japan

         

        9.4.       In Vitro ADME Testing Service Providers: Information on Regulatory Approval

         

        1. MARKET FORECAST

        10.1.     Chapter Overview

        10.2.     Forecast Methodology and Key Assumptions

        10.3.     Overall In Vitro ADME Testing Services Market, 2019-2030

         

        10.4.     In Vitro ADME Testing Services Market: Distribution by Regions, 2019-2030

        10.4.1.  In Vitro ADME Testing Services Market in North America, 2019-2030

        10.4.1.1. In Vitro ADME Testing Services Market in the US, 2019-2030

        10.4.1.2. In Vitro ADME Testing Services Market in Canada, 2019-2030

         

        10.4.2.  In Vitro ADME Testing Services Market in Europe, 2019-2030

        10.4.2.1. In Vitro ADME Testing Services Market in Germany, 2019-2030

        10.4.2.2. In Vitro ADME Testing Services Market in France, 2019-2030

        10.4.2.3. In Vitro ADME Testing Services Market in the UK, 2019-2030

        10.4.2.4. In Vitro ADME Testing Services Market in Italy, 2019-2030

        10.4.2.5. In Vitro ADME Testing Services Market in Spain, 2019-2030

        10.4.2.6. In Vitro ADME Testing Services Market in Rest of Europe, 2019-2030

         

        10.4.3.  In Vitro ADME Testing Services Market in Asia-Pacific and Rest of the World, 2019-2030

        10.4.3.1. In Vitro ADME Testing Services Market in Japan, 2019-2030

        10.4.3.2. In Vitro ADME Testing Services Market in China, 2018-2028

        10.4.3.3. In Vitro ADME Testing Services Market in India, 2019-2030

        10.4.3.4. In Vitro ADME Testing Services Market in Rest of the World, 2019-2030

         

        10.5.     In Vitro ADME Testing Services Market: Distribution by Type of Services, 2019-2030

        10.5.1.  In Vitro ADME Testing Services Market for Absorption Testing, 2019-2030

        10.5.2.  In Vitro ADME Testing Services Market for Distribution Testing, 2019-2030

        10.5.3.  In Vitro ADME Testing Services Market for Metabolism and Elimination Testing, 2019-2030

         

        10.6.     In Vitro ADME Testing Services Market: Distribution by Type of Assays, 2019-2030

        10.6.1.  In Vitro ADME Testing Services Market for Caco-2 Permeability Assay, 2019-2030

        10.6.2.  In Vitro ADME Testing Services Market for PAMPA Permeability Assay, 2019-2030

        10.6.3.  In Vitro ADME Testing Services Market for MDCK Permeability Assay, 2019-2030

        10.6.4.  In Vitro ADME Testing Services Market for Protein Binding Assay, 2019-2030

        10.6.5.  In Vitro ADME Testing Services Market for Blood Brain Barrier Assay, 2019-2030

        10.6.6.  In Vitro ADME Testing Services Market for Assays for Studying Blood to Plasma Ratio, 2019-2030

        10.6.7.  In Vitro ADME Testing Services Market for Metabolic Stability / Clearance Assay, 2019-2030

        10.6.8.  In Vitro ADME Testing Services Market for Enzyme Induction Assay, 2019-2030

        10.6.9.  In Vitro ADME Testing Services Market for Enzyme Inhibition Assay, 2019-2030

        10.6.10. In Vitro ADME Testing Services Market for Metabolite Profiling and Screening / Identification Assay, 2019-2030

        10.6.11. In Vitro ADME Testing Services Market for Metabolite Production Assay, 2019-2030

        10.6.12. In Vitro ADME Testing Services Market for Reaction Phenotyping Assay, 2019-2030

        10.6.13. In Vitro ADME Testing Services Market for Transporter Interactions Assay, 2019-2030

         

        10.7.     In Vitro ADME Testing Services Market: Distribution by Type of Molecules, 2019-2030

        10.7.1.  In Vitro ADME Testing Services Market for Small Molecules, 2019-2030

        10.7.2.  In Vitro ADME Testing Services Market for Biologics, 2019-2030

         

        10.8.     In Vitro ADME Testing Services Market: Distribution by Therapeutic Areas, 2019-2030

        10.8.1.  In Vitro ADME Testing Services Market for Blood Disorders, 2019-2030

        10.8.2.  In Vitro ADME Testing Services Market for Cardiovascular Disorders, 2019-2030

        10.8.3.  In Vitro ADME Testing Services Market for Gastrointestinal and Digestive Disorders, 2019-2030

        10.8.4.  In Vitro ADME Testing Services Market for Hormonal Disorders, 2019-2030

        10.8.5.  In Vitro ADME Testing Services Market for Infectious Diseases, 2019-2030

        10.8.6.  In Vitro ADME Testing Services Market for Immunological Disorders, 2019-2030

        10.8.7.  In Vitro ADME Testing Services Market for Mental Disorders, 2019-2030

        10.8.8.  In Vitro ADME Testing Services Market for Metabolic Disorders, 2019-2030

        10.8.9.  In Vitro ADME Testing Services Market for Neurological Disorders, 2019-2030

        10.8.10. In Vitro ADME Testing Services Market for Cancers, 2019-2030

        10.8.11. In Vitro ADME Testing Services Market for Respiratory Disorders, 2019-2030

        10.8.12. In Vitro ADME Testing Services Market for Skin Disorders, 2019-2030

        10.8.13. In Vitro ADME Testing Services Market for Urogenital Disorders, 2019-2030

        10.8.14. In Vitro ADME Testing Services Market for Other Disorders, 2019-2030

        10.8.15. In Vitro ADME Testing Services Market: Market Attractiveness Analysis by Therapeutic Areas, 2019-2030

         

        10.9.     In Vitro ADME Testing Services Market: Distribution by Type of Sponsors, 2019-2030

        10.9.1.  In Vitro ADME Testing Services Market for Industry Players, 2019-2030

        10.9.2.  In Vitro ADME Testing Services Market for Non-Industry Players, 2019-2030

         

        1. CONCLUSION

        11.1.     Conducting In Vitro ADME Studies During the Early Stages of Drug Development has Demonstrated the Potential to Improve the Probability of Clinical Success

        11.2.     The Contract Services Landscape Features Several Capable CROs Offering Services for In Vitro ADME Testing; Most of these Companies are based in North America and Europe

        11.3.     Current Market Leaders Have Vast In Vitro ADME Testing Service Portfolios, Drug Metabolism-related Assays Represent the Major Fraction

        11.4.     Stakeholders are Actively Expanding their Existing Capabilities to Cater to the Increasing Demand; this is Evident in the Number of Acquisitions Reported over the Past Decade

        11.5.     Driven by the Need to Optimize the Drug Discovery and Development Process, the In Vitro ADME Testing Services Market is Expected to Grow at a Healthy Pace in the Foreseen Future

         

        1. EXECUTIVE INSIGHTS

        12.1.     Chapter Overview

        12.2.     490 BioTech

        12.2.1.  Company Snapshot

        12.2.2.  Interview Transcript: Dan Close, Chief Scientific Officer

         

        12.3.     JRF Global

        12.3.1.  Company Snapshot

        12.3.2.  Interview Transcript: Sridhar Iyer, Director and Global Head, Business Development and Sarang Gorte, Assistant Manager, Business Development

         

        1. APPENDIX I: TABULATED DATA

         

        1. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

         

        Contact Details

        Gaurav Chaudhary

        +1 (415) 800 3415

        gaurav.chaudhary@rootsanalysis.com

        In vitro ADME testing services market is likely to be worth USD 2.2 billion by 2030, growing at an annualized rate of ~9.8%, predicts Roots Analysis

        www.rootsanalysis.com
        Submitted 1 day(s) ago by Alberto Brando

         

        With increasing cases of drug failure, due to problems associated with pharmacokinetic profiles of candidate therapies, absorption, distribution, metabolism and excretion (ADME) properties and inherent toxicity, industry players are actively looking for more advanced solutions.

         

        Roots Analysis is pleased to announce the publication of its recent study, titled, “In Vitro ADME Testing Services Market, 2019-2030

         

        The  report features an extensive study on the current landscape and the likely future potential of the companies offering in vitro ADME services. The study features an in-depth analysis, highlighting the capabilities of various industry stakeholders. In addition to other elements, the report includes:

        • A detailed assessment of the current market landscape, of companies offering in vitro ADEM testing services.
        • A schematic logo landscape of in vitroADME service providers, highlighting their geographical distribution (on the basis of location of headquarters) and company size.
        • A discussion on the various outsourcing business models used in this domain, along with a list of key considerations that need to be taken into account by industry stakeholders while selecting a CRO partner.
        • Elaborate profiles of popular players that offer a wide range of in vitro ADME testing services (shortlisted on the basis of the company size).
        • A detailed peer group-based benchmarking analysis, comparing the involved players based on several relevant parameters related to company and services.
        • A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2005-2018
        • A discussion on the various regulatory guidelines related to in vitro ADME testing, which have been laid down by major international / regional regulatory bodies.
        • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

         

        • Type of Molecule
        • Small Molecules
        • Biologics

         

        • Type of Service
        • Absorption Testing
        • Distribution Testing
        • Metabolism and Elimination Testing

         

        • Type of Assay
        • Caco-2 Permeability Assay
        • PAMPA Permeability Assay
        • MDCK Permeability Assay
        • Protein Binding Assay
        • Blood Brain Barrier Assay
        • Blood to Plasma Ratio
        • Stability / Clearance Assay
        • Enzyme Induction Assay
        • Enzyme Inhibition Assay
        • Metabolite Profiling and Screening / Identification Assay
        • Metabolite Production Assay
        • Reaction Phenotyping Assay
        • Transporter Interactions Assay

         

        • Target Therapeutic Area
        • Blood Disorders
        • Cardiovascular Disorders
        • Gastrointestinal and Digestive Disorders
        • Hormonal Disorders
        • Infectious Diseases
        • Immunological Disorders
        • Metabolic Disorders
        • Mental Disorders
        • Neurological Disorders
        • Oncological Disorders
        • Respiratory Disorders
        • Skin Disorders
        • Urogenital Disorders
        • Others

         

        • Type of Sponsor
        • Industry Players
        • Non-Industry Players

         

        • Key Geographical Regions
        • North America
        • Europe
        • Asia-Pacific and Rest of the World

         

        Key companies covered in the report

        • Albany Molecular Research (AMRI)
        • Charles River Laboratories
        • Pharmaceutical Product Development (PPD)
        • RTI International
        • Eurofins Scientific
        • Evotec
        • Galapagos
        • Tecan Group
        • GVK Biosciences
        • Pharmaron
        • Sai Life Sciences
        • Shanghai Medicilon
        • WuXi AppTec

         

        For more information please click on the following link:

        https://www.rootsanalysis.com/reports/view_document/in-vitro-adme-testing-services-market-2019-2030/239.html  

         

        Other Recent Offerings

        1. In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules, 2020-2030
        2. AR / VR based Healthcare Digital Marketing Service Providers Market, 2020-2030
        3. Bioavailability Enhancement Technologies and Services Market, 2020-2030

         

        About Roots Analysis

        Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

         

        Contact Information

        Roots Analysis Private Limited

        Gaurav Chaudhary

        +1 (415) 800 3415

        gaurav.chaudhary@rootsanalysis.com

        In vitro ADME testing services market is likely to be worth USD 2.2 billion by 2030, growing at an annualized rate of ~9.8%, predicts Roots Analysis

        www.rootsanalysis.com
        Submitted 1 day(s) ago by Alberto Brando

         

        With increasing cases of drug failure, due to problems associated with pharmacokinetic profiles of candidate therapies, absorption, distribution, metabolism and excretion (ADME) properties and inherent toxicity, industry players are actively looking for more advanced solutions.

         

        Roots Analysis has announced the addition of “In Vitro ADME Testing Services Market, 2019-2030” report to its list of offerings.

         

        According to the US Food and Drug Administration (USFDA), less than 10% of investigational new drug (IND) candidates progress beyond the submission of a new drug application (NDA); this implies that majority of the drug / therapy candidates fail to reach the market owing to unacceptable safety and efficacy profiles and the problems associated with their pharmacokinetic profiles, ADME properties and inherent toxicity. ADME studies are considered to be critical in establishing the safety and efficacy of drug candidates.

         

        To order this 280+ page report, which features 135+ figures and 120+ tables, please visit this  link

         

        Key Market Insights

         

        Nearly 100 players currently claim to provide in vitro ADME testing services

        Nearly 60% of these companies are small and mid-sized firms. Further, close to 35% of the CROs engaged in this domain, claim to provide services to both pharmaceutical companies and academic institutes.

         

        Nearly 80% of in vitro ADME testing service providers are based in the developed geographies

        Within North America, the US has the maximum number of players, whereas, in Europe, most of the service providers are distributed across France, Germany, the UK, and Spain. On the other hand, there are companies that are using this approach for drug discovery operations, in emerging regions, such as Australia, India and China, as well.

         

        Over 85% companies claim to offer assays for drug metabolism and elimination testing

        Further, nearly 70% companies claim to have capabilities to conduct absorption and distribution related studies, respectively. It is worth mentioning that about 35% of players presently offer end-to-end drug discovery services.

         

        Nearly 95% CROs have received operational approval and certification from the USFDA

        In addition, companies have received necessary certifications from the EMA (50%), MHLW / PMDA (15%), ICH (13%), WHO (11%), MHRA (11%), followed by CFDA / MFDS / SFDA (9%) and TGA (4%).

         

        Over 35 acquisitions have taken place amongst various stakeholders, between 2005-2018

        The addition of capabilities (primarily related to drug metabolism and pharmacokinetics testing) emerged as the most important value drivers across all the acquisitions. Other key value drivers include geographical consolidation and geographical expansion.

         

        North America and Europe are anticipated to capture over 70% of the market share by 2030

        Within North America, US is anticipated to hold the 90% of the market share. It is worth mentioning that the market in Asia-Pacific region is anticipated to grow at a relatively faster rate (~11%).

         

        To request a sample copy / brochure of this report, please visit this  link

         

        Key Questions Answered

        • Who are the leading CROs offering in vitro ADME testing services?
        • What are the key services being offered by in vitro ADME testing service providers?
        • What is the trend of mergers and acquisitions in this domain?
        • How is the current and future market opportunity likely to be distributed across key market segments?
        • What are the anticipated future trends related to in vitro ADME testing services market?

         

        The USD 2.2 billion (by 2030) financial opportunity within the vitro ADME testing services market has been analyzed across the following segments:

         

        • Type of Molecule
        • Small Molecules
        • Biologics

         

        • Type of Service
        • Absorption Testing
        • Distribution Testing
        • Metabolism and Elimination Testing

         

        • Type of Assay
        • Caco-2 Permeability Assay
        • PAMPA Permeability Assay
        • MDCK Permeability Assay
        • Protein Binding Assay
        • Blood Brain Barrier Assay
        • Blood to Plasma Ratio
        • Stability / Clearance Assay
        • Enzyme Induction Assay
        • Enzyme Inhibition Assay
        • Metabolite Profiling and Screening / Identification Assay
        • Metabolite Production Assay
        • Reaction Phenotyping Assay
        • Transporter Interactions Assay

         

        • Target Therapeutic Area
        • Blood Disorders
        • Cardiovascular Disorders
        • Gastrointestinal and Digestive Disorders
        • Hormonal Disorders
        • Infectious Diseases
        • Immunological Disorders
        • Metabolic Disorders
        • Mental Disorders
        • Neurological Disorders
        • Oncological Disorders
        • Respiratory Disorders
        • Skin Disorders
        • Urogenital Disorders
        • Others

         

        • Type of Sponsor
        • Industry Players
        • Non-Industry Players

         

        • Key Geographical Regions
        • North America
        • Europe
        • Asia-Pacific and Rest of the World

         

        The report also features inputs from a number of eminent industry stakeholders. In fact, one of the experts interviewed concurred on the opinion that the drug developers today, prefer to opt for contract service providers that offer a range of capabilities, such as design, synthesis, initial scale-up, in vitro ADME testing, safety pharmacology, under one roof; this guarantees a certain degree of ease of operation, and enables sponsors to shortlist and rely on a capable partner for their outsourcing requirements.” The report features detailed transcripts of discussions held with the following individuals:

        • Dan Close (Chief Scientific Officer, 490 Bio Tech)
        • Sridhar Iyer (Director and Global Head, Business Development, JRF Global) and Sarang Gorte (Assistant Manager, Business Development, JRF Global)

         

        The research covers detailed profiles and assesses product portfolios of several companies, including (illustrative list, no selection criteria):

        • Albany Molecular Research (AMRI)
        • Charles River Laboratories
        • Pharmaceutical Product Development (PPD)
        • RTI International
        • Eurofins Scientific
        • Evotec
        • Galapagos
        • Tecan Group
        • GVK Biosciences
        • Pharmaron
        • Sai Life Sciences
        • Shanghai Medicilon
        • WuXi AppTec

         

        For additional details, please visit 

        https://www.rootsanalysis.com/reports/view_document/in-vitro-adme-testing-services-market-2019-2030/239.html  or email sales@rootsanalysis.com

         

        You may also be interested in the following titles:

        1. In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules, 2020-2030
        2. AR / VR based Healthcare Digital Marketing Service Providers Market, 2020-2030
        3. Bioavailability Enhancement Technologies and Services Market, 2020-2030

         

        Contact:

        Gaurav Chaudhary

        +1 (415) 800 3415

        Gaurav.Chaudhary@rootsanalysis.com

         

        How To Use & Safe Magnum XT - Is It Scam Or Legit?

        apnews.com
        Submitted 2 day(s) ago by bodytrimaus

        If you are truly wanting to grow your erection size and presentations, you may have to endeavor these tips near to the Magnum XT Male Enhancement Pills:Eat Better – You are what you eat. Thusly, if you eat a huge load of heartbreaking food, you will have unwanted erections and a s3xual conjunction to organize. Eat more profitable and see how it changes. Exercise – Exercising regularly underpins testosterone and urges you to stay at a sound weight. Being at a sound weight can improve your s3x drive and endurance. Stop Bad Habits – Along with the poor sustenance, you should in like manner endeavor to quit drinking and noticing such a lot of s3xual entertainment. Both can unfavorably influence your s3xual concurrence. Visit here to get Magnum XT from its real or official website: https://apnews.com/press-release/newmediawire/ceb0476c868ecb2836afb52dd3f000ed

        Keto Body Trim Nature Slim Reviews Canada [Updated 2021]: Is It Safe?

        apnews.com
        Submitted 2 day(s) ago by bodytrimaus

        There are a particularly huge number of preferences that you can see using Keto Body Trim Burn Pills ! With this awesome fat eliminator, you can all the more probable screen your weight, enter ketosis faster, increment colossal extra vitality, in conclusion achieve your weight decline goals. Such a great deal of using the ketogenic diet and these reformist pills. Regardless, best of all, THE KETO DIET WORKS. Assessment shows that using the keto diet can help uphold handling and control hunger. Visit on Its official website: https://apnews.com/press-release/newmediawire/north-america-canada-united-states-dd68a6dd05616ed80fb9cc9ce92df1cc

        ‘Human Microbiome Market: Focus on Therapeutics (including gut-brain axis targeting drugs), Diagnostics and Fecal Microbiota Therapies (FMTs) (3rd Edition), 2019-2030’ report features an extensive study of the current market landscape, offering an informe

        www.rootsanalysis.com
        Submitted 2 day(s) ago by Alberto Brando

         

        To order this detailed 640+ page report, please visit this link

         

        Key Inclusions

        • A detailed assessment of the current market landscape of microbiome therapeutics, providing information on drug / therapy developer(s) (such as year of establishment, location of headquarters and company size), clinical study sponsor(s) or collaborators, phase of development (clinical, preclinical, and discovery stage) of product candidates, type of molecule (small molecule and biologic), type of therapy (prebiotic, probiotic, and prescription drug), target indication(s), key therapeutic area(s), molecular / biological target (if available), mechanism of action (if available), route of administration, type of drug formulation (tablet, capsule, gel, lotion, cream, ointment, nasal spray and 4+ categories), dosing frequency (reported for clinical candidates only), and information on special drug designations (if any). In addition, the chapter highlights the various technology platforms that are being actively used for the development of microbiome therapeutics.

         

        • Elaborate profiles of key players (established after 2005) that are engaged in the development of microbiome therapeutics (which are presently in both preclinical and clinical stages of development); each profile features a brief overview of the company, its financial information (if available), microbiome-based product portfolio, information on advanced stage (phase II and above) pipeline candidates (featuring a drug overview, current status of development, clinical trial information, and clinical trial end-point analysis) and an informed future outlook.

         

        • A discussion on the various types of diagnostic tests, specifically highlighting the importance of next-generation sequencing within this field of research, along with [A] a detailed review of the current market landscape of microbiome diagnostic tests, including the information on the developer(s) (such as year of establishment, location of headquarters and company size), stage of development (commercialized and under development), type of sample used (blood, feces, saliva and vaginal swab), target indication(s), key therapeutic area(s), result turnaround time, and purpose of diagnosis, [B] brief profiles of popular diagnostic developers, and [C] an indicative list of screening and profiling test kits, including information on the developer(s) (such as year of establishment, location of headquarters and company size), type of sample used (blood, feces, saliva and vaginal swab), key therapeutic area(s), and result turnaround time.

         

        • A review of the historical evolution and other relevant aspects of FMT therapies, including details on the process of donor selection, therapy procedure, route of administration, important clinical guidelines, regulatory guidelines and insurance coverage, along with [A] a detailed assessment of the current market landscape of FMT therapies, providing information on FMT developer(s) (such as year of establishment, location of headquarters and company size), status of development (commercialized, clinical, and preclinical stage), target indication(s), key therapeutic area(s), and route of administration, [B] a geographical clinical trial analysis of ongoing / planned / completed studies of FMTs sponsored by non-industry players, featuring details related to specific FMT therapies and analysis based on relevant parameters, such as the number of registered trials, year of registration, current status, phase of development, study design, type of sponsor(s), target indication(s), key therapeutic area(s), key focus areas, number of patients enrolled and leading non-industry player(s), and [C] information on various stool banks (including year of establishment and location of headquarters), along with brief profiles of the most prominent stool banks located across the globe.

         

        • A detailed business portfolio analysis based on an attractiveness and competitiveness (AC) framework, highlighting the current market attractiveness and existing competition across the most popular disease indication(s) for which microbiome therapeutics are under investigation.

         

        • An analysis of the varied microbiome-focused initiatives of big pharma players (out of top 20 established pharmaceutical players), featuring a [A] heat map representation that highlights microbiome therapeutics under development (in partnership with core microbiome product developers), along with information on funding, partnership activity, and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), and [B] a spider web representation of the individual competitiveness of the initiatives of big pharma players based on multiple relevant parameters.

         

        • An analysis of the start-ups / small-sized players (established in the last seven years, with less than 50 employees) engaged in the development of microbiome therapeutics and diagnostics, featuring heat map representation based on parameters, such as number of microbiome therapeutics under development, diversity of product portfolio, funding information (including funding amount, number of investors and evolution of investment activity), partnership activity, disease indication(s) being treated and focus therapeutic area(s), and strength of intellectual property portfolio.

         

        • An assessment of the most commonly targeted therapeutic indications and details of microbiome-based drugs that are being developed against them, highlighting key epidemiological facts about specific diseases, available methods of diagnosis, and currently available treatment options and their side effects.

         

        • An analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in start-ups / small-sized companies (established in last seven years, with less than 50 employees) that are focused on developing microbiome therapeutics and diagnostics.

         

        • An elaborate discussion on the various steps involved in the development and manufacturing of microbiome therapeutics, along with [A] an indicative list of contract manufacturers, along with details on year of establishment, location of headquarters, company size, scale of operation, facility location and microbiome production capacity, [B] an indicative list of companies with in-house manufacturing facilities for microbiome therapeutics, along with details on year of establishment, location of headquarters, and company size, [C] an indicative list of CROs that currently claim to have the necessary capabilities to offer various research services (such as screening, sequencing, characterization, analytical), along with details on year of establishment, location of headquarters, company size, and service portfolio details, and [D] an insightful Harvey ball analysis of key considerations that need to be taken into account by industry stakeholders while selecting a suitable CMO / CRO partner.

         

        • An assessment of the emerging role of big data, highlighting efforts focused on the development and implementation of various algorithms / tools to analyze data generated from microbiome research along with [A] an insightful google trends analysis to demonstrate the rising interest of stakeholders in using big data tools to support microbiome research over the past decade, [B] a list of companies offering big data-related services / tools to support microbiome research, and [C] brief profiles of some of the popular companies that are engaged in this field of research.

         

        • An informative case study on the various other applications of microbiome products, such as agriculture, animal health, plant health, food products, featuring a list of nearly 80 products, including probiotic supplements, cosmetics, and over-the-counter (OTC) products that are being used as dietary supplements.

         

        The USD 4 billion (by 2030) financial opportunity within the microbiome therapeutics (Tx) market and diagnostics (Dx) markets, has been analyzed across the following segments:

        • Type of Therapy (Tx)
        • Prescription Drug
        • Prebiotics
        • Probiotics

         

        • Type of Molecule (Tx)
        • Small Molecules
        • Biologics

         

        • Target Indication (Tx+Dx)
        • Acne Vulgaris
        • Atopic Dermatitis
        • Clostridium difficile Infection
        • Colorectal Cancer
        • Crohn’s Disease
        • Diabetes
        • Irritable Bowel Syndrome
        • Lactose Intolerance
        • Lung Cancer
        • Nonalcoholic steatohepatitis (NASH)
        • Obesity
        • Ulcerative colitis

         

        • Therapeutic Area (Tx+Dx)
        • Autoimmune Disorders
        • Dental Disorders
        • Digestive and Gastrointestinal Disorders
        • Dermatological Disorders
        • Infectious Disease
        • Metabolic Disorders
        • Oncology
        • Others

         

        • Key Geographical Regions (Tx+Dx)
        • North America
        • Europe
        • Asia-Pacific and Rest of the World

         

        To request sample pages, please visit this link

         

        Key Questions Answered

        • Who are the leading developers of microbiome therapeutics and diagnostic tests?
        • What are the key technology platforms (available / under development) for microbiome-related therapies and diagnostics?
        • What are the disease indications against which microbiome-based therapeutics are being evaluated?
        • Which companies are targeting gut-brain axis for the development of microbiome therapies?
        • Who are the leading (industry and non-industry) players involved in the development of FMT products?
        • Who are the key contract research / manufacturing service providers in this domain?
        • What is the trend in capital investments in microbiome-related R&D?
        • What are the contributions of big pharma players in this domain?
        • Which are the popular players offering big data-related services / tools to support microbiome research?
        • How is the current and future market opportunity for microbiome-based therapeutics and diagnostics is likely to be distributed across key market segments?

         

        You may also be interested in the following titles:

        1. Antibody Drug Conjugates Market (5th Edition), 2019-2030
        2. Gene Therapy Market (3rd Edition), 2019 - 2030
        3. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030
        4. Synthetic Lethality-based Drugs and Targets Market, 2019-2030

         

        Contact:

        Gaurav Chaudhary

        +1 (415) 800 3415

        Gaurav.Chaudhary@rootsanalysis.com

        Presently, 260 drug candidates are being evaluated in clinical / preclinical stages for the treatment of a wide variety of disease indications; the US has emerged as the major hub for microbiome-based research

        www.rootsanalysis.com
        Submitted 2 day(s) ago by Alberto Brando

         

        The concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, defining a new frontier in the field of medicine. Despite having captured the interest of several venture capital firms and big pharma players, no microbiome-based therapeutic has been officially approved by an authorized medical product regulator. However, the current development pipeline of microbiome therapeutics has several promising candidates that are likely to result in commercial success stories soon.

         

        To order this 640+ page report, which features 235+ figures and 275+ tables, please visit this link

         

        The USD 4 billion (by 2030) financial opportunity within the microbiome therapeutics (Tx) market and diagnostics (Dx) markets, has been analyzed across the following segments:

        • Type of Therapy (Tx)
        • Prescription Drug
        • Prebiotics
        • Probiotics

         

        • Type of Molecule (Tx)
        • Small Molecules
        • Biologics

         

        • Target Indication (Tx+Dx)
        • Acne Vulgaris
        • Atopic Dermatitis
        • Clostridium difficile Infection
        • Colorectal Cancer
        • Crohn’s Disease
        • Diabetes
        • Irritable Bowel Syndrome
        • Lactose Intolerance
        • Lung Cancer
        • Nonalcoholic steatohepatitis (NASH)
        • Obesity
        • Ulcerative colitis

         

        • Therapeutic Area (Tx+Dx)
        • Autoimmune Disorders
        • Dental Disorders
        • Digestive and Gastrointestinal Disorders
        • Dermatological Disorders
        • Infectious Disease
        • Metabolic Disorders
        • Oncology
        • Others

         

        • Key Geographical Regions (Tx+Dx)
        • North America
        • Europe
        • Asia-Pacific and Rest of the World

         

         

        The Human Microbiome Market, 2019-2030 report features the following companies, which we identified to be key players in this domain:

        • 4D Pharma
        • Armata Pharmaceuticals
        • Evelo Biosciences
        • Rebiotix (Acquired by Ferring Pharmaceuticals)
        • Seres Therapeutics
        • Vedanta Biosciences

         

        Table of Contents

        1. Preface

         

        1. Executive Summary

         

        1. Introduction

         

        1. Microbiome Therapeutics: Market Landscape

         

        1. Company and Drug Profiles

         

        1. Microbiome Diagnostics: Market Landscape

         

        1. Fecal Microbiota Therapy (FMT)

         

        1. Attractiveness Competitiveness (AC) Matrix

         

        1. Microbiome Related Initiatives of Big Pharmaceutical Players

         

        1. Start-up Health Indexing

         

        1. Key Therapeutics Areas

         

        1. Funding and Investment Analysis

         

        1. Contract Services for Microbiome Therapeutics

         

        1. Big Data and Microbiome Therapeutics

         

        1. Microbiome Therapeutics: Market Forecast and Opportunity Analysis

         

        1. Microbiome Diagnostics: Market Forecast and Opportunity Analysis

         

        1. Fecal Microbiota Therapies: Market Forecast and Opportunity Analysis

         

        1. Case Study: Microbiome-based Products in Other Industries

         

        1. Concluding Remarks

         

        1. Executive Insights

         

        1. Appendix I: Tabulated Data

         

        1. Appendix II: List of Companies and Organizations

         

         

        To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html

         

        Contact Details

        Gaurav Chaudhary

        +1 (415) 800 3415

        gaurav.chaudhary@rootsanalysis.com 

         

        Human Microbiome-based Products Market is projected to be worth USD 4 Billion by 2030, growing at an annualized rate of over 40%, claims Roots Analysis

        www.rootsanalysis.com
        Submitted 2 day(s) ago by Alberto Brando

         

        Roots Analysis has announced the addition of “Human Microbiome Market, 2019-2030” report to its list of offerings.

         

        To order this 640+ page report, which features 235+ figures and 275+ tables, please visit this link

         

        Key Market Insights

        • Presently, 260 drug candidates are being evaluated in clinical / preclinical stages for the treatment of a wide variety of disease indications; the US has emerged as the major hub for microbiome-based research
        • The pipeline features both prebiotic and probiotic drugs, being evaluated across different stages of development; majority of these products are designed for administration via non-invasive routes, such as oral and topical
        • Microbiome therapeutics have demonstrated the potential to target a range of therapeutic areas; digestive and GI disorders, oncology, infectious diseases, and metabolic disorders are amongst the prime focus areas
        • Over 10 microbiome-focused disease diagnosis tests are already available in the market; several companies claim to have initiatives in this domain based on different sample types and therapeutic areas
        • Presently, FMTs are the only commercially available microbiome products for the treatment of recurrent CDIs; in fact, several trials evaluating FMTs, sponsored by non-industry players, have been registered in the past decade
        • Over time, well funded start-ups have initiated product development programs, having invested significant time and effort to explore the applicability of microbiome therapeutics across various indications
        • Several big pharmaceutical players have partnered with smaller and dedicated microbiome-based therapy / diagnostic developers in order to expand their respective capabilities in this upcoming field of pharmacology
        • Contract service providers have become an integral part of microbiome supply chain owing to their technical expertise and ability to overcome existing challenges related to both R&D and production
        • Prevalent trends indicate that microbiome drugs and diagnostics market is poised to grow significantly; the forecasted opportunity is anticipated to be distributed across different target indications and regions
        • Microbiome therapeutic developers are expected to witness significant momentum, in terms of revenues generation, as multiple late stage molecules for the treatment of different clinical conditions get commercialized

         

        For more information please visit: 

        https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html

         

        Table of Contents

        1. PREFACE

        1.1.       Scope of the Report

        1.2.       Research Methodology

        1.3.       Chapter Outlines

         

        1. EXECUTIVE SUMMARY

         

        1. INTRODUCTION

        3.1.       Chapter Overview

        3.2.       Concept of Microbiota and Microbiome

        3.2.1.    Discovery of the Human Microbiome

        3.2.2.    Functions of the Human Microbiome

         

        3.3.       Overview of Gut Flora

        3.3.1.    Role of Gut Flora in Healthy Individuals

        3.3.2.    Factors Affecting Gut Flora

        3.3.2.1. Antibiotic Consumption

        3.3.2.2. Age and Pregnancy

        3.3.2.2.1. Mode of Childbirth

        3.3.2.2.2. Type of Feeding

        3.3.2.2.3. Antibiotic Consumption by Mother

        3.3.2.3. Stress-related Factors

        3.3.2.4. Dietary Factors

        3.3.2.5. Impact of Lifestyle

         

        3.4.       The Microbiome and Disease

        3.4.1.    Cancer

        3.4.2.    Inflammatory Bowel Disease (IBD)

        3.4.3.    Obesity

        3.4.4.    Parkinson’s Disease

        3.4.5.    Type-II Diabetes

        3.4.6.    Other Disease Indications

        3.5.       Impact of Microbiota on Drug Pharmacokinetics

        3.6.       Impact of Microbiota on Therapeutic Outcomes

         

        3.7.       Microbiome Therapeutics

        3.7.1.    Probiotics

        3.7.1.1. Beneficial Bacterial Strains

        3.7.1.1.1. Lactobacilli

        3.7.1.1.2. Bifidobacteria

        3.7.1.1.3. Others

         

        3.7.1.2. Key Therapeutic Areas

        3.7.1.2.1. Antibiotic-Associated Diarrhea (AAD)

        3.7.1.2.2. Bacterial Vaginosis

        3.7.1.2.3. High Blood Pressure

        3.7.1.2.4. Hypercholesterolemia

        3.7.1.2.5. Infectious Childhood Diarrhea (ICD)

        3.7.1.2.6. Inflammatory Bowel Disease (IBD)

        3.7.1.2.7. Lactose Intolerance

        3.7.1.2.8. Vitamin Production

        3.7.1.2.9. Weight Management

         

        3.7.1.3. Side Effects of Probiotics

         

        3.7.2.    Prebiotics

        3.7.2.1. Sources of Prebiotics

        3.7.2.2. Types of Prebiotics

        3.7.2.2.1. Fructo-Oligosaccharides (FOS)

        3.7.2.2.2. Galacto-Oligosaccharides (GOS)

        3.7.2.2.3. Inulin

         

        3.7.2.3. Key Therapeutic Areas

        3.7.2.3.1. Antibiotic Associated Diarrhea (AAD)

        3.7.2.3.2. Constipation

        3.7.2.3.3. Gastrointestinal Disorders

        3.7.2.3.4. Dysbiosis

        3.7.2.4. Side Effects of Prebiotics

         

        3.8.       The Human Microbiome Project (HMP)

        3.8.1.    Project Approach

        3.8.2.    Project Initiatives

        3.8.3.    Project Achievements

                               

        3.9.       Regulatory Guidelines for Live Biotherapeutic Products (LBPs)

        3.10.     Key Challenges in the Development of Microbiome Therapeutics

        3.11.     Future Perspectives

         

        1. MICROBIOME THERAPEUTICS: MARKET LANDSCAPE

        4.1.       Chapter Overview

        4.2.       Microbiome Therapeutics: Clinical Pipeline

        4.2.1.    Analysis by Phase of Development

        4.2.2.    Analysis by Type of Molecule

        4.2.3.    Analysis by Type of Therapy

        4.2.4.    Analysis by Target Indication

        4.2.5.    Analysis by Therapeutic Area

        4.2.6.    Analysis by Dosing Frequency

        4.2.7.    Analysis by Route of Administration

        4.2.8.    Analysis by Drug Formulation

         

        4.3.       Microbiome Therapeutics: Early-Stage Pipeline

        4.3.1.    Analysis by Phase of Development

        4.3.2.    Analysis by Type of Molecule

        4.3.3.    Analysis by Type of Therapy

        4.3.4.    Analysis by Target Indication

        4.3.5.    Analysis by Therapeutic Area

         

        4.4.       Microbiome Therapeutics: List of Drug Developers

        4.4.1.    Analysis by Year of Establishment

        4.4.2.    Analysis by Location of Headquarters

        4.4.3.    Analysis by Company Size

        4.4.4.    Analysis by Company Size and Location of Headquarters

        4.4.5.    Leading Drug Developers: Analysis by Number of Microbiome Therapeutics

         

        4.5.       Grid Analysis: Microbiome and Key Therapeutic Areas

         

        4.6.       Microbiome Therapeutics: List of Discontinued Drugs

        4.7.       Emerging Role of Microbiome in Gut-Brain Axis

        4.8.       Microbiome Therapeutics: List of Technology Platforms

         

        1. COMPANY AND DRUG PROFILES

        5.1.       Chapter Overview

        5.2.       4D Pharma

        5.2.1.    Company Overview

        5.2.2.    Microbiome-based Product Portfolio

        5.2.2.1. Blautix®

        5.2.2.1.1. Drug Overview

        5.2.2.1.2. Current Status of Development

        5.2.2.1.3. Clinical Studies

        5.2.2.1.4. Clinical Trial End-Point Analysis

        5.2.3.    Recent Developments and Future Outlook

         

        5.3.       Armata Pharmaceuticals

        5.3.1.    Company Overview

        5.3.2.    Microbiome-Based Product Portfolio

        5.3.2.1. C16G2

        5.3.2.1.1. Drug Overview

        5.3.2.1.2. Current Status of Development

        5.3.2.1.3. Clinical Studies

        5.3.2.1.4. Clinical Trial End-Point Analysis

        5.3.3.    Recent Developments and Future Outlook

         

        5.4.       Evelo Biosciences

        5.4.1.    Company Overview

        5.4.2.    Microbiome-Based Product Portfolio

        5.4.2.1. EDP1503

        5.4.2.1.1. Drug Overview

        5.4.2.1.2. Current Status of Development

        5.4.2.1.3. Clinical Studies

        5.4.2.1.4. Clinical Trial End-Point Analysis

        5.4.3.    Recent Developments and Future Outlook

         

        5.5.       Rebiotix (Acquired by Ferring Pharmaceuticals)

        5.5.1.    Company Overview

        5.5.2.    Financial Information

        5.5.3.    Microbiome-Based Product Portfolio

        5.5.3.1. RBX2660

        5.5.3.1.1. Drug Overview

        5.5.3.1.2. Current Status of Development

        5.5.3.1.3. Clinical Studies

        5.5.3.1.4. Clinical Trial End-Point Analysis

        5.5.4.    Recent Developments and Future Outlook

         

        5.6.       Seres Therapeutics

        5.6.1.    Company Overview

        5.6.2.    Financial Information

        5.6.3.    Microbiome-Based Product Portfolio

        5.6.3.1. SER-109

        5.6.3.1.1. Drug Overview

        5.6.3.1.2. Current Status of Development

        5.6.3.1.3. Clinical Studies

        5.6.3.1.4. Clinical Trial End-Point Analysis

         

        5.6.3.2. SER-287

        5.6.3.2.1. Current Status of Development

        5.6.3.2.3. Clinical Studies

        5.6.3.2.4. Clinical Trial End-Point Analysis

        5.6.4.    Recent Developments and Future Outlook

         

        5.7.       Vedanta Biosciences

        5.7.1.    Company Overview

        5.7.2.    Microbiome-Based Product Portfolio

        5.7.2.1. VE303

        5.7.2.1.1. Drug Overview

        5.7.2.1.2. Current Status of Development

        5.7.2.1.3. Clinical Studies

        5.7.3.1.4. Clinical Trial End-Point Analysis

        5.7.3.    Recent Developments and Future Outlook

         

        1. MICROBIOME DIAGNOSTICS: MARKET LANDSCAPE

        6.1.       Chapter Overview

        6.2.       Overview of Microbiome Diagnostic Tests

        6.3.       Microbiome Diagnostic Tests: Marketed and Under Development Products

        6.3.1.    Analysis by Stage of Development

        6.3.2.    Analysis by Type of Sample Required

        6.3.3.    Analysis by Target Indication

        6.3.4.    Analysis by Therapeutic Area

        6.3.5.    Analysis by Purpose

         

        6.4.       Microbiome Diagnostic Tests: List of Diagnostic Developers

        6.4.1.    Analysis by Year of Establishment

        6.4.2.                Analysis by Location of Headquarters

        6.4.3.    Analysis by Company Size

        6.4.4.    Analysis by Company Size and Location of Headquarters

        6.4.5.    Leading Diagnostic Developers: Analysis by Number of Microbiome Diagnostics

         

        6.5.       Profiles of Prominent Diagnostic Developers

        6.5.1.    Enterome Bioscience

        6.5.1.1. Company Overview

        6.5.1.2. Service Portfolio

         

        6.5.2.    Vaiomer

        6.5.2.1. Company Overview

        6.5.2.2. Service Portfolio

        6.6.       Overview of Microbiome Screening / Profiling Tests

        6.6.1.    List of Microbiome Screening / Profiling Tests

        6.6.2.    List of Microbiome Screening / Profiling Test Developers

         

        1. FECAL MICROBIOTA THERAPY (FMT)

        7.1.       Chapter Overview

        7.2.       Introduction to FMT

        7.3.       Historical Overview

        7.4.       FMT: Procedure and Clinical Relevance

        7.4.1.    Donor Selection

        7.4.2.    Administration Procedure

        7.4.3.    Routes of Administration

        7.4.4.    Consequences and Adverse Events

        7.4.5.    Clinical Guidelines Associated with FMT

         

        7.5.       Regulatory Guidelines Related to FMT

        7.6.       Insurance Coverage for FMT

         

        7.7.       FMT: Competitive Landscape

        7.7.1.    Marketed / Development Pipeline (Industry Players)

        7.7.1.1. Analysis by Phase of Development

        7.7.1.2. Analysis by Therapeutic Area

        7.7.1.3. Analysis by Route of Administration

         

        7.7.2.    List of Developers (Industry Players)

        7.7.2.1. Analysis by Year of Establishment

        7.7.2.2. Analysis by Location of Headquarters

        7.7.2.3. Analysis by Company Size

         

        7.8.       Clinical Trial Analysis (Non-Industry Sponsored)

        7.8.1.    Scope and Methodology

        7.8.2.    List of Clinical Trials

        7.8.2.1. Analysis by Trial Registration Year

        7.8.2.2. Analysis by Trial Status

        7.8.2.3. Analysis by Phase of Development

        7.8.2.4. Analysis by Patients Enrolled

        7.8.2.5. Analysis of Number of Patients Enrolled by Trial Registration Year

        7.8.2.6. Analysis by Therapeutic Area

        7.8.2.7. Analysis by Popular Target Indications

        7.8.2.8. Analysis by Trial Registration Year and Recruitment Status

        7.8.2.9. Analysis by Study Design

        7.8.2.10.           Leading Non-Industry Players: Analysis by Number of Trials

        7.8.2.11.           Geographical Analysis by Number of Clinical Trials

        7.8.2.12.           Geographical Analysis by Enrolled Patient Population

        7.8.2.13.           Analysis by Type of Sponsor / Collaborator

        7.8.2.14.           Analysis by Trial Focus

        7.8.2.15.           Key Clinical Trials

         

        7.9.       Stool Banks

        7.9.1.    Introduction to Stool Banks

        7.9.2.    List of Stool Banks

         

        7.9.3.    Profiles of Prominent Stool Banks

        7.9.3.1. AdvancingBio

        7.9.3.1.1. Overview

        7.9.3.1.2. Fecal Microbiota Preparation

         

        7.9.3.2. Asia Microbiota bank

        7.9.3.2.1. Overview

        7.9.3.2.2. Fecal Microbiota Preparation

         

        7.9.3.3. Enterobiotix

        7.9.3.3.1. Overview

        7.9.3.3.2. Fecal Microbiota Preparation

         

        7.9.3.4. Flora Medicine

        7.9.3.4.1. Overview

        7.9.3.4.2. Fecal Microbiota Preparation

         

        7.9.3.5. OpenBiome

        7.9.3.5.1. Overview

        7.9.3.5.2. Fecal Microbiota Preparation

         

        1. ATTRACTIVENESS COMPETITIVENESS (AC) MATRIX

        8.1.       Chapter Overview

        8.2.       AC Matrix: An Overview

        8.2.1.    Strong Opportunity Areas

        8.2.2.    Average Opportunity Areas

        8.2.3.    Weak Opportunity Areas

         

        8.3.       AC Matrix: Analytical Methodology

        8.4.       AC Matrix: Plotting the Information

        8.5.       AC Matrix: Analyzing the Data

        8.5.1.    Strong Opportunity Areas

        8.5.2.    Average Opportunity Areas

        8.5.3.    Weak Opportunity Areas

         

        1. MICROBIOME RELATED INITIATIVES OF BIG PHARMACEUTICAL PLAYERS

        9.1.       Chapter Overview

        9.2.       Scope and Methodology

         

        9.3.       Initiatives of Big Pharmaceutical Players

        9.3.1.    Analysis by Portfolio Diversity

        9.3.2.    Analysis by Phase of Development

        9.3.3.    Analysis by Type of Molecule

        9.3.4.    Analysis by Type of Therapy

        9.3.5.    Analysis by Diversity of Therapeutic Areas

         

        9.4.       Benchmark Analysis of Big Pharmaceutical Players

        9.4.1.    Spider Web Analysis: Company A

        9.4.2.    Spider Web Analysis: Company B

        9.4.3.    Spider Web Analysis: Company C

        9.4.4.    Spider Web Analysis: Company D

        9.4.5.    Spider Web Analysis: Company E

        9.4.6.    Spider Web Analysis: Company F

        9.4.7.    Spider Web Analysis: Company G

        9.4.8.    Spider Web Analysis: Company H

        9.4.9.    Spider Web Analysis: Company I

        9.4.10.  Spider Web Analysis: Company J

        9.4.11.  Spider Web Analysis: Company K

         

        1. START-UP HEALTH INDEXING

        10.1.     Chapter Overview

        10.2.     Scope and Methodology

        10.3.     Benchmark Analysis of Start-ups

        10.3.1.  Benchmark Analysis by Portfolio Diversity

        10.3.2.  Benchmark Analysis by Phase of Development

        10.3.3.  Benchmark Analysis by Diversity in Therapeutic Areas

        10.3.4.  Benchmark Analysis by Funding Amount

        10.3.5.  Benchmark Analysis by Number of Investors

        10.3.6.  Benchmark Analysis by Progression in Funding

        10.3.7.  Benchmark Analysis by Partnership Activity

        10.3.8.  Benchmark Analysis by Patent Portfolio

        10.3.9.  Start-up Health Indexing: Roots Analysis Perspective

        10.3.9.1. Short Profiles of Top Five Players

        10.3.9.1.1. Evelo Biosciences

        10.3.9.1.2. AOBiome Therapuetics

        10.3.9.1.3. SFA Therapeutics

        10.3.9.1.4. Azitra

        10.3.9.1.5. Axial Biotherapeutics

         

        1. KEY THERAPEUTIC AREAS

        11.1.     Chapter Overview

        11.2.     Metabolic Disorders

        11.2.1.  Diabetes

        11.2.1.1. Disease Description

        11.2.1.2. Associated Health Risks / Complications

        11.2.1.3. Epidemiology

        11.2.1.4. Disease Diagnosis

        11.2.1.5. Current Treatment Options

        11.2.1.5.1. Insulin Therapies

        11.2.1.5.2. Non-Insulin Therapies

        11.2.1.6. Side Effects of Current Treatment Options

        11.2.1.7. Microbiome Therapeutics for Diabetes

         

        11.2.2.  Lactose Intolerance

        11.2.2.1. Disease Description

        1.2.2.2. Epidemiology

        11.2.2.3. Current Treatment Options

        11.2.2.4. Microbiome Therapeutics for Lactose Intolerance

         

        11.2.3.  Nonalcoholic Steatohepatitis (NASH)

        11.2.3.1. Disease Description

        11.2.3.2. Epidemiology

        11.2.3.3. Current Treatment Options

        11.2.3.4. Microbiome Therapeutics for NASH

         

        11.2.4.  Primary Hyperoxaluria

        11.2.4.1. Disease Description

        11.2.4.2. Epidemiology

        11.2.4.3. Current Treatment Options

        11.2.4.4. Microbiome Therapeutics for Primary Hyperoxaluria

         

        11.2.5.  Obesity

        11.2.5.1. Disease Description

        11.2.5.2. Epidemiology

        11.2.5.3. Current Treatment Options

        11.2.5.4. Side Effects of Current Treatment Options

        11.2.5.5. Microbiome Therapeutics for Obesity

         

        11.3.     Digestive and Gastrointestinal Disorders

        11.3.1.  Crohn’s Disease

        11.3.1.1. Disease Description

        11.3.1.2. Epidemiology

        11.3.1.3. Current Treatment Options

        11.3.1.4. Side Effects of Current Treatment Options

        11.3.1.5. Microbiome Therapeutics for Crohn’s Disease

         

        11.3.2.  Irritable Bowel Syndrome (IBS)

        11.3.2.1. Disease Description

        11.3.2.2. Epidemiology

        11.3.2.3. Current Treatment Options

        11.3.2.4. Microbiome Therapeutics for IBS

         

        11.3.3.  Ulcerative Colitis

        11.3.3.1. Disease Description

        11.3.3.2. Epidemiology

        11.3.3.3. Current Treatment Options

        11.3.3.4. Side Effects of Current Treatment Options

        11.3.3.5. Microbiome Therapeutics for Ulcerative Colitis

         

        11.4.     Oncological Indications

        11.4.1.  Colorectal Cancer

        11.4.1.1. Disease Description

        11.4.1.2. Epidemiology

        11.4.1.3. Current Treatment Options

        11.4.1.4. Side Effects of Current Treatments

        11.4.1.5. Microbiome Therapeutics for Colorectal Cancer

                               

        11.4.2.  Lung Cancer

        11.4.2.1. Disease Description

        11.4.2.2. Epidemiology

        11.4.2.3. Current Treatment Options

        11.4.2.4. Side Effects of Current Treatment Options

        11.4.2.5. Microbiome Therapeutics for Lung Cancer

         

        11.5.     Dermatological Disorders

        11.5.1.  Acne Vulgaris

        11.5.1.1. Disease Description

        11.5.1.2. Epidemiology

        11.5.1.3. Current Treatment Options

        11.5.1.4. Side Effects of Current Treatment Options

        11.5.1.5. Microbiome Therapeutics for Acne Vulgaris

         

        11.6.     Infectious Diseases

        11.6.1.  Clostridium Difficile Infections (CDIs)

        11.6.1.1. Description

        11.6.1.2. Epidemiology

        11.6.1.3. Disease Diagnosis

        11.6.1.4. Current Treatment Options

        11.6.1.5. Side Effects of Current Treatment Options

        11.6.1.6. Microbiome Therapeutics for CDI

         

        11.6.2.  Bacterial Vaginosis

        11.6.2.1. Disease Description

        11.6.2.2. Epidemiology

        11.6.2.3. Current Treatment Options

        11.6.2.4. Side Effects of Current Treatment Options

        11.6.2.5. Microbiome Therapeutics for Bacterial Vaginosis

         

        1. FUNDING AND INVESTMENT ANALYSIS

        12.1.     Chapter Overview

        12.2.     Types of Funding

         

        12.3.     Microbiome Therapeutics and Diagnostics: List of Funding and Investments

        12.3.1.  Analysis by Number of Instances

        12.3.2. Analysis by Amount Invested

        12.3.3. Analysis by Type of Funding

        12.3.4. Analysis by Type of Company

        12.3.5. Analysis by Purpose of Funding

        12.3.6. Analysis by Type of Molecule

        12.3.7. Analysis by Target Indication

        12.3.8. Analysis by Therapeutic Area

        12.3.9.  Analysis by Geography

        12.3.10. Most Active Players

        12.3.11. Most Active Investors

        12.3.12.  Analysis by Type of Investors

        12.3.13. Analysis by Location of Investors

        12.4.     Concluding Remarks

         

        1. CONTRACT SERVICES FOR MICROBIOME THERAPEUTICS

        13.1.     Chapter Overview

        13.2.     Manufacturing Microbiome Therapeutics

        13.2.1.  Key Steps Involved

        13.2.2.  Associated Challenges

        13.2.3.  Growing Demand for Contract Manufacturing Services

         

        13.2.4.  Contract Manufacturing Organizations (CMOs)

        13.2.4.1. Introduction to Contract Manufacturing

        13.2.4.2. List of Organizations Offering Services for Microbiome Therapeutics

         

        13.2.5.  In-House Manufacturers

        13.2.5.1. Introduction to In-House Manufacturing

        13.2.5.2. List of In-House Manufacturers

         

        13.3.     Microbiome Therapeutics-related R&D

        13.3.1.  Growing Demand for Contract Research Services

        13.3.2.  Contract Research Organizations (CROs)

        13.3.2.1. Introduction to Contract Research

        13.3.2.2. List of Organizations Offering Services for Microbiome Therapeutics

         

        13.4.     Key Considerations for Selecting a Suitable CMO / CRO Partner

         

        1. BIG DATA AND MICROBIOME THERAPEUTICS

        14.1.     Chapter Overview

        14.2.     Introduction to Big Data

        14.3.     Internet of Things

        14.4.     Growing Interest in Big Data: Google Trends Analysis

        14.5.     Key Application Areas

         

        14.6.     Big Data in Microbiome Research

        14.6.1.  Microbiome Data and Personalized Medicine

        14.6.2.  Microbiome-related Data Management Challenges

        14.6.3.  National Microbiome Data Center

         

        14.7.     Big Data Services for Microbiome Research: List of Companies

        14.8.     Big Data Services for Microbiome Research: Profiles of Key Players

        14.8.1.  Human Longevity

        14.8.1.1. Company Overview

        14.8.1.2. Technology and Service Portfolio

        14.8.1.3. Recent Developments

         

        14.8.2.  Resilient Biotics

        14.8.2.1. Company Overview

        14.8.2.2. Technology and Service Portfolio

        14.8.2.3. Recent Developments

         

        14.8.3.  Resphera Biosciences

        14.8.3.1. Company Overview

        14.8.3.2. Technology and Service Portfolio

         

        1. MICROBIOME THERAPEUTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS

        15.1.     Chapter Overview

        15.2.     Scope and Limitations

        15.3.     Forecast Methodology

         

        15.4.     Overall Microbiome Therapeutics Market, 2019-2030

        15.4.1.  Microbiome Therapeutics Market: Distribution by Type of Therapy, 2025 and 2030

        15.4.1.1. Microbiome Therapeutics Market for Prescription Drugs, 2019-2030

        15.4.1.2. Microbiome Therapeutics Market for Prebiotic Drugs, 2019-2030

        15.4.1.3. Microbiome Therapeutics Market for Probiotic Drugs, 2019-2030

         

        15.4.2.  Microbiome Therapeutics Market: Distribution by Type of Molecule, 2025 and 2030

        15.4.2.1. Microbiome Therapeutics Market for Small Molecules, 2019-2030

        15.4.2.2. Microbiome Therapeutics Market for Biologics, 2019-2030

         

        15.4.3.  Microbiome Therapeutics Market: Distribution by Target Indication, 2025 and 2030

        15.4.3.1. Microbiome Therapeutics Market for Acne Vulgaris, 2019-2030

        15.4.3.2. Microbiome Therapeutics Market for Atopic Dermatitis, 2019-2030

        15.4.3.3. Microbiome Therapeutics Market for CDI, 2019-2030

        15.4.3.4. Microbiome Therapeutics Market for Crohn’s Disease, 2019-2030

        15.4.3.5. Microbiome Therapeutics Market for Dental Caries, 2019-2030

        15.4.3.6. Microbiome Therapeutics Market for Diabetes, 2019-2030

        15.4.3.7. Microbiome Therapeutics Market for IBS, 2019-2030

        15.4.3.8. Microbiome Therapeutics Market for Lactose Intolerance, 2019-2030

        15.4.3.9. Microbiome Therapeutics Market for Lung Cancer, 2019-2030

        15.4.3.10. Microbiome Therapeutics Market for NASH, 2019-2030

        15.4.3.11. Microbiome Therapeutics Market for Primary Hyperoxaluria, 2019-2030

        15.4.3.12. Microbiome Therapeutics Market for Psoriasis, 2019-2030

        15.4.3.13. Microbiome Therapeutics Market for Ulcerative Colitis, 2019-2030

         

        15.4.4.  Microbiome Therapeutics Market: Distribution by Therapeutic Area, 2025 and 2030

        15.4.4.1. Microbiome Therapeutics Market for Autoimmune Disorders, 2019-2030

        15.4.4.2. Microbiome Therapeutics Market for Dental Disorders, 2019-2030

        15.4.4.3. Microbiome Therapeutics Market for Digestive and Gastrointestinal Disorders, 2019-2030

        15.4.4.4. Microbiome Therapeutics Market for Dermatological Disorders, 2019-2030

        15.4.4.5. Microbiome Therapeutics Market for Infectious Diseases, 2019-2030

        15.4.4.6. Microbiome Therapeutics Market for Metabolic Disorders, 2019-2030

        15.4.4.7. Microbiome Therapeutics Market for Oncology, 2019-2030

         

        15.4.5.  Microbiome Therapeutics Market: Distribution by Key Geographical Regions, 2025 and 2030

        15.4.5.1. Microbiome Therapeutics Market in North America, 2019-2030

        15.4.5.2. Microbiome Therapeutics Market in Europe, 2019-2030

        15.4.5.3. Microbiome Therapeutics Market in Asia-Pacific and Rest of the World, 2019-2030

        15.4.6.  Microbiome Therapeutics Market: Distribution by Leading Drug Developers, 2025 and 2030

        15.5.     Microbiome Therapeutics Market: Distribution by Leading Therapeutic Products, 2019-2030

        15.5.1.  Drug-wise Sales Forecast

        15.5.1.1. IBP-9414 (Infant Bacterial Therapeutics)

        15.5.1.2. Sales Forecast (USD Million)

        15.5.1.3. Net Present Value (USD Million)

        15.5.1.4. Value Creation Analysis

         

        15.5.2.1. Oxabact (OxThera)

        15.5.2.2. Sales Forecast (USD Million)

        15.5.2.3. Net Present Value (USD Million)

        15.5.2.4. Value Creation Analysis

         

        15.5.3.1. RBX2660 (Rebiotix)

        15.5.3.2. Sales Forecast (USD Million)

        15.5.3.3. Net Present Value (USD Million)

        15.5.3.4. Value Creation Analysis

         

        15.5.4.1. RP-G28 (Ritter Pharmaceuticals)

        15.5.4.2. Sales Forecast (USD Million)

        15.5.4.3. Net Present Value (USD Million)

        15.5.4.4. Value Creation Analysis

         

        15.5.5.1. SER-109 (Seres Therapeutics)

        15.5.5.2. Sales Forecast (USD Million)

        15.5.5.3. Net Present Value (USD Million)

        15.5.5.4. Value Creation Analysis

         

        1. MICROBIOME DIAGNOSTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS

        16.1.     Chapter Overview

        16.2.     Scope and Limitations

        16.3      Forecast Methodology

        16.4.     Overall Microbiome Diagnostics Market, 2019-2030

        16.4.1.  Overall Microbiome Diagnostics Market, 2019-2030 (By Value)

        16.4.2.  Overall Microbiome Diagnostics Market, 2019-2030 (By Volume)

         

        16.5.     Microbiome Diagnostics Market: Distribution by Target Indications, 2019, 2030

        16.5.1.  Microbiome Diagnostics Market: Distribution by Target Indications, 2019 and 2030 (By Value)

        16.5.1.1. Microbiome Diagnostics Market for Colorectal Cancer, 2019-2030 (By Value)

        16.5.1.2. Microbiome Diagnostics Market for Diabetes, 2019-2030 (By Value)

        16.5.1.3. Microbiome Diagnostics Market for IBD, 2019-2030 (By Value)

        16.5.1.4. Microbiome Diagnostics Market for IBS, 2019-2030 (By Value)

        16.5.1.5. Microbiome Diagnostics Market for NASH, 2019-2030 (By Value)

        16.5.1.6. Microbiome Diagnostics Market for Obesity, 2019-2030 (By Value)

        16.5.1.7. Microbiome Diagnostics Market for Others, 2019-2030 (By Value)

         

        16.5.2.  Microbiome Diagnostics Market: Distribution by Target Indications, 2019 and 2030 (By Volume)

        16.5.2.1. Microbiome Diagnostics Market for Colorectal Cancer, 2019-2030 (By Volume)

        16.5.2.2. Microbiome Diagnostics Market for Diabetes, 2019-2030 (By Volume)

        16.5.2.3. Microbiome Diagnostics Market for IBD, 2019-2030 (By Volume)

        16.5.2.4. Microbiome Diagnostics Market for IBS, 2019-2030 (By Volume)

        16.5.2.5. Microbiome Diagnostics Market for NASH, 2019-2030 (By Volume)

        16.5.2.6. Microbiome Diagnostics Market for Obesity, 2019-2030 (By Volume)

        16.5.2.7. Microbiome Diagnostics Market for Others, 2019-2030 (By Volume)

         

        16.6.     Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2019-2030

        16.6.1.  Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2019 and 2030 (By Value)

        16.6.1.2. Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, 2019-2030 (By Value)

        16.6.1.2. Microbiome Diagnostics Market for Metabolic Disorders, 2019-2030 (By Value)

        16.6.1.3. Microbiome Diagnostics Market for Oncology, 2019-2030 (By Value)

        16.6.1.4. Microbiome Diagnostics Market for Others, 2019-2030 (By Value)

         

        16.6.2.  Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2019 and 2030 (By Volume)

        16.6.2.1. Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, 2019-2030 (By Volume)

        16.6.2.2. Microbiome Diagnostics Market for Metabolic Disorders, 2019-2030 (By Volume)

        16.6.2.3. Microbiome Diagnostics Market for Oncology, 2019-2030 (By Volume)

        16.6.2.4. Microbiome Diagnostics Market for Others, 2019-2030 (By Volume)

         

        16.7.     Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2019-2030

        16.7.1.  Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2019 and 2030 (By Value)

        16.7.1.1. Microbiome Diagnostics Market in North America, 2019-2030 (By Value)

        16.7.1.2. Microbiome Diagnostics Market in Europe, 2019-2030 (By Value)

        16.7.1.3. Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, 2019-2030 (By Value)

         

        16.7.2.  Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2019 and 2030 (By Volume)

        16.7.2.1. Microbiome Diagnostics Market in North America, 2019-2030 (By Volume)

        16.7.2.2. Microbiome Diagnostics Market in Europe, 2019-2030 (By Volume)

        16.7.2.3. Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, 2019-2030 (By Volume)

         

        1. FECAL MICROBIOTA THERAPIES: MARKET FORECAST AND OPPORTUNITY ANALYSIS

        17.1.     Chapter Overview

        17.2.     Scope and Limitations

        17.3.     Forecast Methodology

        17.4.     Overall FMT Market, 2019-2030

        17.4.1.  Overall FMT Market, 2019-2030 (By Value)

        17.4.2.  Overall FMT Market, 2019-2030 (By Volume)

         

        17.5.     Overall Microbiome Market by Product Offerings, 2019-2030

         

        1. CASE STUDY: MICROBIOME-BASED PRODUCTS IN OTHER INDUSTRIES

        18.1.     Chapter Overview

        18.2.     List of Microbiome Products in Other Industries

        18.2.1.  Applications of Microbiome Based Products in Cosmetics and Food Industry

        18.3.     Applications of Microbiome Based Products in Agriculture Industry

        18.4.     Future Prospects

         

        1. CONCLUDING REMARKS

         

        1. EXECUTIVE INSIGHTS

        20.1      Chapter Overview

        20.2.     Floragraph

        20.2.1.  Company / Organization Snapshot

        20.2.2.  Interview Transcript: Alicia Scheffer, Chief Executive Officer

         

        20.3.     Rebiotix

        20.3.1.  Company / Organization Snapshot

        20.3.2.  Interview Transcript: Lee Jones, President and Chief Executive Officer

         

        20.4.     S-Biomedic

        20.4.1.  Company / Organization Snapshot

        20.4.2.  Interview Transcript: Veronika Oudova, Co-founder and Chief Executive Officer

         

        20.5.     Whole Biome

        20.5.1.  Company / Organization Snapshot

        20.5.2.  Interview Transcript: Colleen Cutcliffe, Co-founder and Chief Executive Officer

         

        20.6.     Siolta Therapeutics

        20.6.1.  Company / Organization Snapshot

        20.6.2.  Interview Transcript: Nikole E Kimes, Co-founder and Vice President

         

        20.7.     OpenBiome

        20.7.1.  Company / Organization Snapshot

        20.7.2.  Interview Transcript: James Burges, Executive Director

         

        20.8.     Assembly Biosciences

        20.8.1.  Company / Organization Snapshot

        20.8.2.  Interview Transcript: JP Benya, Vice President, Business Development

                               

        20.9.     List Biological Laboratories

        20.9.1.  Company / Organization Snapshot

        20.9.2.  Interview Transcript: Debbie Pinkston, Vice President, Sales and Business Development

         

        20.10.   Metabiomics

        20.10.1. Company / Organization Snapshot

        20.10.2. Interview Transcript: Gregory J Kuehn, Vice President, Business Development and Marketing

         

        20.11.   MicroBiome Therapeutics

        20.11.1. Company / Organization Snapshot

        20.11.2. Interview Transcript: Mark Heiman, Chief Scientific Officer and Vice President, Research

         

        20.12.   Universal Stabilization Technologies

        20.12.1. Company / Organization Snapshot

        20.12.2. Interview Transcript: Alexander Segal, Vice President, Business Development

         

        20.13.   BiomX

        20.13.1. Company / Organization Snapshot

        20.13.2. Interview Transcript: Assaf Oron, Chief Business Officer

         

        20.14.   Da Volterra

        20.14.1. Company / Organization Snapshot

        20.14.2. Interview Transcript: Pierre-Alain Bandinelli, Chief Business Officer

         

        20.15.   Chung Mei Pharmaceutical

        20.15.1. Company / Organization Snapshot

        20.15.2. Interview Transcript: Alexander Lin, Associate General Manager

         

        20.16.   Pacific Northwest National Laboratories

        20.16.1. Company / Organization Snapshot

        20.16.2. Interview Transcript: Aaron Wright, Senior Scientist

         

        1. APPENDIX I: TABULATED DATA

         

        1. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

         

        Contact Details

        Gaurav Chaudhary

        +1 (415) 800 3415

        gaurav.chaudhary@rootsanalysis.com

         

        What Are Benefits Ingredients Keto Wave

        apnews.com
        Submitted 2 day(s) ago by isfusdghlf

        Keto Wave

        https://apnews.com/press-release/newmediawire/lifestyle-nutrition-health-dietary-supplements-diet-and-exercise-dc2fa5071b456b90e51d3106d56cc291

        Human Microbiome-based Products Market is projected to be worth USD 4 Billion by 2030, growing at an annualized rate of over 40%, claims Roots Analysis

        www.rootsanalysis.com
        Submitted 2 day(s) ago by Alberto Brando

         

        Over the years, extensive R&D efforts have enabled microbiome-based therapy / diagnostic developers to make significant strides, in terms of progressing proprietary product candidates into the clinic

         

        Roots Analysis has announced the addition of “Human Microbiome Market, 2019-2030” report to its list of offerings

         

        The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:

        • A detailed assessment of the current market landscape of microbiome therapeutics, providing information on drug / therapy developer(s).
        • Elaborate profiles of key players (established after 2005) that are engaged in the development of microbiome therapeutics.
        • A detailed review of the current market landscape of microbiome diagnostic tests, brief profiles of popular diagnostic developers and indicative list of screening and profiling test kits.
        • A detailed assessment of the current market landscape of FMT therapies, a geographical clinical trial analysis and information on various stool banks.
        • A detailed business portfolio analysis based on an attractiveness and competitiveness (AC) framework.
        • An analysis of the varied microbiome-focused initiatives of big pharma players.
        • An analysis of the start-ups / small-sized players engaged in the development of microbiome therapeutics and diagnostics.
        • An assessment of the most commonly targeted therapeutic indications and details of microbiome-based drugs.
        • An analysis of the investments made at various stages of development in start-ups / small-sized companies.
        • An indicative list of contract manufacturers, in-house manufacturers and CROs that currently claim to have the necessary capabilities.
        • An assessment of the emerging role of big data highlighting efforts focused on the development and implementation of various algorithms / tools to analyze data generated from in the microbiome research.
        • An informative case study on the various other applications of microbiome products, such as agriculture, animal health, plant health, food products
        • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

        segments:

        • Type of Therapy (Tx)
        • Prescription Drug
        • Prebiotics
        • Probiotics

                           

        • Type of Molecule (Tx)
        • Small Molecules
        • Biologics

         

        • Target Indication (Tx+Dx)
        • Acne Vulgaris
        • Atopic Dermatitis
        • Clostridium difficile Infection
        • Colorectal Cancer
        • Crohn’s Disease
        • Diabetes
        • Irritable Bowel Syndrome
        • Lactose Intolerance
        • Lung Cancer
        • Nonalcoholic steatohepatitis (NASH)
        • Obesity
        • Ulcerative colitis

         

        • Therapeutic Area (Tx+Dx)
        • Autoimmune Disorders
        • Dental Disorders
        • Digestive and Gastrointestinal Disorders
        • Dermatological Disorders
        • Infectious Disease
        • Metabolic Disorders
        • Oncology
        • Others

         

        • Key Geographical Regions (Tx+Dx)
        • North America
        • Europe
        • Asia-Pacific and Rest of the World

         

        Key companies covered in the report

        • 4D Pharma
        • Armata Pharmaceuticals
        • Evelo Biosciences
        • Rebiotix (Acquired by Ferring Pharmaceuticals)
        • Seres Therapeutics
        • Vedanta Biosciences

         

        For more information please click on the following link: 

        https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html or email sales@rootsanalysis.com

         

        Other Recent Offerings:

        1. Antibody Drug Conjugates Market (5th Edition), 2019-2030
        2. Gene Therapy Market (3rd Edition), 2019 - 2030
        3. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030
        4. Synthetic Lethality-based Drugs and Targets Market, 2019-2030

         

         

        About Roots Analysis

        Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

         

        Contact Information

        Roots Analysis Private Limited

        Gaurav Chaudhary

        +1 (415) 800 3415

        gaurav.chaudhary@rootsanalysis.com

        Human Microbiome-based Products Market is projected to be worth USD 4 Billion by 2030, growing at an annualized rate of over 40%, claims Roots Analysis

        www.rootsanalysis.com
        Submitted 2 day(s) ago by Alberto Brando

         

        Over the years, extensive R&D efforts have established the basis for a wide range of microbiome-based therapeutic and diagnostic products, which may cause a paradigm shift in the way healthcare is delivered in the foreseen future

         

        Roots Analysis has announced the addition of “Human Microbiome Market, 2019-2030” report to its list of offerings.

         

        The concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, defining a new frontier in the field of medicine. Despite having captured the interest of several venture capital firms and big pharma players, no microbiome-based therapeutic has been officially approved by an authorized medical product regulator. However, the current development pipeline of microbiome therapeutics has several promising candidates that are likely to result in commercial success stories soon.

         

        To order this 640+ page report, which features 235+ figures and 275+ tables, please visit this link

         

        Key Market Insights

         

        260 therapy candidates are currently in different phases of development

        Nearly 25% of pipeline drugs are in the clinical phase of development, while the rest are in the preclinical / discovery stage. Interestingly, most of these drugs target digestive and gastrointestinal disorders (20%); this is followed by product candidates intended for treatment of oncological disorders (17%) and infectious diseases (13%).

         

        Over 30 microbiome diagnostic tests are currently available / under development

        Around 30% of the abovementioned tests have been commercialized, while the rest are under development. Of the total tests, notable examples of companies that launched a microbiome-based diagnostic solution include (in alphabetical order) ARTPred, Genetic Analysis, Goodgut, Invivo Healthcare, IS-diagnostics, Luxia Scientific and Varinos.

         

        FMTs are the only commercially available microbiome therapy

        This therapeutic product is presently indicated for the treatment of recurrent Clostridium difficile infections (rCDIs). Further, non-industry players (such as University of Alberta, The Second Hospital of Nanjing Medical University, University of California and Chinese University of Hong Kong) are making notable contributions in this arena, having been involved in ~200 clinical trials till August 2019.

         

        51% growth in capital investments has been observed since 2015; around 70% investment has come from Venture Capital investors

        It is worth noting that more than 80 investors have supported the R&D programs initiated by start-ups focused on microbiome-related products.  Well-funded start-ups have initiated product development programs, having invested significant time and effort to explore the applicability of microbiome therapeutics across various indications.

         

        Several big pharma players have microbiome-related initiatives

        Leading pharmaceutical companies have actively partnered with smaller business entities to develop capabilities related to microbiome-based therapies / diagnostics. Examples of small ventures that have received support from big pharma players include Assembly Biosciences, Enterome Bioscience, Finch Therapeutics and NuBiyota.

         

        Contract service providers have become an integral part of the microbiome supply chain

        Presently, certain firms claim to offer a wide array of contract research / manufacturing services for microbiome therapeutics. Examples of such players include Adare Pharmaceuticals, Biose, Cobra Biologics, CoreBiome, List Biological Laboratories, NIZO, ProDigest, Quay Pharma and Wacker Chemie.

         

        North America and Europe are anticipated to capture over 85% of the market share by 2030

        As late stage products are commercialized, the microbiome therapeutics market is likely to grow at an annualized growth rate of over 30%, during the next decade. In addition to North America and Europe, the market in China / broader Asia Pacific region is also anticipated to grow at a relatively faster rate.

         

        To request a sample copy / brochure of this report, please visit this link       

         

        Key Questions Answered

        • Who are the leading developers of microbiome therapeutics and diagnostic tests?
        • What are the key technology platforms (available / under development) for microbiome-related therapies and diagnostics?
        • What are the disease indications against which microbiome-based therapeutics are being evaluated?
        • Which companies are targeting gut-brain axis for the development of microbiome therapies?
        • Who are the leading (industry and non-industry) players involved in the development of FMT products?
        • Who are the key contract research / manufacturing service providers in this domain?
        • What is the trend in capital investments in microbiome-related R&D?
        • What are the contributions of big pharma players in this domain?
        • Which are the popular players offering big data-related services / tools to support microbiome research?
        • How is the current and future market opportunity for microbiome-based therapeutics and diagnostics is likely to be distributed across key market segments?

         

         

        The USD 4 billion (by 2030) financial opportunity within the microbiome therapeutics (Tx) market and diagnostics (Dx) markets, has been analyzed across the following segments:

        • Type of Therapy (Tx)
        • Prescription Drug
        • Prebiotics
        • Probiotics

         

        • Type of Molecule (Tx)
        • Small Molecules
        • Biologics

         

        • Target Indication (Tx+Dx)
        • Acne Vulgaris
        • Atopic Dermatitis
        • Clostridium difficile Infection
        • Colorectal Cancer
        • Crohn’s Disease
        • Diabetes
        • Irritable Bowel Syndrome
        • Lactose Intolerance
        • Lung Cancer
        • Nonalcoholic steatohepatitis (NASH)
        • Obesity
        • Ulcerative colitis

         

        • Therapeutic Area (Tx+Dx)
        • Autoimmune Disorders
        • Dental Disorders
        • Digestive and Gastrointestinal Disorders
        • Dermatological Disorders
        • Infectious Disease
        • Metabolic Disorders
        • Oncology
        • Others

         

        • Key Geographical Regions (Tx+Dx)
        • North America
        • Europe
        • Asia-Pacific and Rest of the World

         

        The report features inputs from eminent industry stakeholders, according to whom innovation in microbiome-related research is mostly being driven by start-ups / small-sized companies. The report includes detailed transcripts of discussions held with the following experts:

        • Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic)
        • Colleen Cutcliffe (Co-founder and Chief Executive Officer, Whole Biome)
        • Lee Jones (President and Chief Executive Officer, Rebiotix)
        • Mark Heiman (Chief Scientific Officer and Vice President, Research, MicroBiome Therapeutics)
        • Assaf Oron (Chief Business Officer, BiomX)
        • Pierre-Alain Bandinelli (Chief Business Officer, Da Volterra)
        • Nikole E Kimes (Co-founder and Vice President, Siolta Therapeutics)
        • James Burges (Executive Director, OpenBiome)
        • JP Benya (Vice President, Business Development, Assembly Biosciences)
        • Debbie Pinkston (Vice President, Sales and Business Development, List Biological Laboratories)
        • Gregory J Kuehn (Vice President, Business Development and Marketing, Metabiomics)
        • Alexander Segal (Vice President, Business Development, Universal Stabilization Technologies)
        • Alexander Lin (Associate General Manager, Chung Mei Pharmaceutical)
        • Aaron Wright (Senior Scientist, Pacific Northwest National Laboratories)

         

        The research covers detailed profiles, featuring a brief company overview, its financial information (if available), product portfolio details (such as status of development of pipeline candidates, clinical trial information and analysis of key trial end-points), recent developments and an informed future outlook.

        • 4D Pharma
        • Armata Pharmaceuticals
        • Evelo Biosciences
        • Rebiotix (Acquired by Ferring Pharmaceuticals)
        • Seres Therapeutics
        • Vedanta Biosciences

         

        For additional details, please visit 

        https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html or email sales@rootsanalysis.com

         

        You may also be interested in the following titles:

        1. Antibody Drug Conjugates Market (5th Edition), 2019-2030
        2. Gene Therapy Market (3rd Edition), 2019 - 2030
        3. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030
        4. Synthetic Lethality-based Drugs and Targets Market, 2019-2030

         

        Contact:

        Gaurav Chaudhary

        +1 (415) 800 3415

        Gaurav.Chaudhary@rootsanalysis.com

         

        The “Digital Health Market: Focus on Digital Therapeutics (2nd Edition), 2020-2030 (Based on Type of Solution (Software Solution, Gaming Solution and Combination Solution), Type of Therapy (Curative and Preventive), and Purpose of Solution (Medication Rep

        www.rootsanalysis.com
        Submitted 2 day(s) ago by Alberto Brando

         

        To order this 500+ page report, please visit this link

         

        Key Inclusions

        • An overview of the current market landscape of digital therapeutic solutions, including information on status of development, type of solution (combination offering of software application + device or AI or personal coach, and standalone software application), type of therapy (curative and preventive), purpose of solution (medication replacement and medication augmentation), target disease indication(s), therapeutic area(s), and target population. In addition, it presents details of the companies developing digital therapeutic solution, highlighting year of establishment, company size, type of business model used (B2B and B2C) and location of headquarters.
        • An in depth analysis of the contemporary market trends, presented using four schematic representations, including [A] a bubble analysis comparing the leading players engaged in the development of digital therapeutic solutions based on the parameters, such as product portfolio strength, number of target disease indication(s) and company size, [B] a grid representation illustrating the distribution of the digital therapeutic solutions based on status of development, type of solution and therapeutic area, [C] an insightful tree map representation of the digital therapeutic solutions, distributed on the basis of therapeutic area and company size, and [D] a world map representation highlighting the regional distribution of developer companies.
        • A detailed product competitiveness analysis of digital therapeutic solutions developed / under development for the most popular therapeutic areas taking into consideration the strength of product portfolio (based on the total number of digital therapeutic solutions being developed in that disease area) and key product specific parameters, such as status of development, type of solution, type of therapy, and purpose of solution.
        • Elaborate profiles of prominent small-sized and mid-sized players that are either engaged in the development or have developed digital therapeutic solutions. Each company profile features a brief overview of the company (with information on year of establishment, number of employees, location of headquarters and key members of the executive team), details of their respective product portfolio, recent developments and an informed future outlook.
        • A detailed analysis of more than 220 completed, ongoing and planned clinical studies of various digital therapeutic solutions, based on the various relevant parameters, such as trial registration year, trial phase, number of patients enrolled, study design, trial recruitment status and trial focus, highlighting leading sponsors and leading digital therapeutic solutions (in terms of number of trials conducted), type of organization, popular therapeutic areas and regional distribution of trials. In addition, it features an insightful clinical end-points analysis (for trials initiated since 2018 for popular therapeutic areas).
        • An analysis of the investments made in the period between 2009 and 2020 (till June), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are engaged in this field.
        • An analysis of the partnerships that have been inked by stakeholders in this domain, in the period between 2008 and 2020 (till May), covering clinical trial agreements, pilot product offerings, product integration agreements, product launch agreements, product / technology licensing agreements, marketing and distribution agreements, mergers / acquisitions, and research and development agreements.
        • A detailed analysis of the various business models and go-to-market strategies adopted by companies involved in this space, providing details on various channels adopted / being adopted by stakeholders in the industry to raise awareness and offer access to their proprietary products.
        • A Bowman’s Strategy Clock framework in order to analyze the competitive position of various companies in the marketplace, taking into consideration the prices and different features of their products.
        • An insightful discussion on the impact of COVID-19 pandemic on the overall digital therapeutic solutions market, and the key initiatives undertaken by big pharma players.
        • A review of the key aspects related to the remote digital monitoring and diagnostics solutions, including [A] a brief introduction to remote digital monitoring and diagnostics solutions, highlighting the key benefits and roadblocks [B] an assessment of the market landscape of remote digital monitoring and diagnostics solutions, based on various parameters, such as status of development, type of solution, target disease indication(s) and therapeutic area, along with details on the companies that develop these solutions, highlighting year of establishment, company size and location of headquarters [C] detailed profiles of some of the key players that presently offer digital monitoring / diagnostic solutions for chronic disease management; each profile features a brief overview of the company (with information on year of establishment, number of employees, location of headquarters, lead investors, key partners and members of the executive team), details of their product portfolio, recent developments and an informed future outlook, and [D] an insightful analysis on various capital investments that have been made into the digital monitoring / diagnostics domain.
        • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall digital therapeutic solutions industry.
        • An informative analysis of contemporary Google Trends in the time period between 2015 and 2020 (till July) and insights from the recent news articles related digital therapeutic solutions, indicating the increasing popularity of this domain. Furthermore, it highlights the potential future opportunities for players engaged in development of such solutions.

         

         

        The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

         

        • Type of Solution
        • Standalone Software Application
        • Software Application + Device + Personal Coach
        • Software Application + Device + AI Support
        • Software Application + Device
        • Software Application + AI Support
        • Software Application + Personal Coach
        • Other Types of Solutions

         

        • Purpose of Solution
        • Medication Replacement
        • Medication Augmentation

         

        • Type of Therapy
        • Curative
        • Preventive

         

        • Business Model
        • Business to Consumer (Patients and Caregivers)
        • Business to Business (Healthcare Providers, Payers, Employers and Pharmaceutical Companies)

         

        • Therapeutic Areas
        • Cardiovascular Disorders
        • Chronic Pain
        • Mental Health Problems
        • Metabolic Disorders
        • Neurological Disorders
        • Respiratory Disorders
        • Sleep Disorders
        • Substance Use Disorders
        • Others

         

        • Key Geographical Regions 
        • North America
        • Europe
        • Asia-Pacific
        • Rest of the world 

         

        The report includes detailed transcripts of discussions held with the following experts:

        • Eran Ofir (Co-Founder and Chief Executive Officer, Somatix)
        • Edouard Gasser (Co-Founder and Chief Executive Officer, Tilak Healthcare)
        • Stephanie Tilenius (Co-Founder and Chief Executive Officer, Vida Health)
        • Adam Kaufman (Chief Executive Officer, Canary Health)
        • Vijay Ravindran (Chief Executive Officer, Floreo)
        • Palakh R Sarogi (Vice President, Marketing, Wellthy Therapeutics), Arani Sarkra (Senior Manager, Consumer Marketing, Wellthy Therapeutics) and Yolande D’Mello (Marketing and Public Relations, Wellthy Therapeutics)
        • Amelie Janson (Communication Manager, Voluntis)
        • Anonymous (Founder and Chief Executive Officer, UK based Small-sized Company)

         

        To request sample pages, please visit this link

         

        Key Questions Answered

        • Who are the leading developers offering digital therapeutic solutions?
        • What are the most popular therapeutic areas for digital therapeutic solutions?
        • Which companies are actively involved in conducting clinical trials for their solutions?
        • What are the key factors influencing the price of digital therapeutic solutions?
        • What is the trend in capital investments in the digital therapeutics market?
        • Which partnership models are commonly adopted by stakeholders in this industry?
        • What type of marketing strategies are being adopted by developers in this domain?
        • What is the impact of COVID-19 outbreak on digital therapeutic solutions market?
        • What are the opportunities for digital therapeutic solutions in emerging markets?
        • How is the current and future opportunity likely to be distributed across key market segments?
        • What are the anticipated future trends related to digital therapeutic solutions market?

         

        You may also be interested in the following titles:

        1. AR / VR Based Healthcare Digital Marketing Service Providers Market, 2020-2030
        2. AI-Based Clinical Trial Solution Providers Market, 2020-2030
        3. Global Handheld Ultrasound Imaging Devices Market, 2020-2030

         

        Contact Us

        Gaurav Chaudhary

        +1 (415) 800 3415

        gaurav.chaudhary@rootsanalysis.com

        Over 100 industry players are engaged in evaluating the potential of several prescription (validated through clinical research) digital therapeutic solutions to prevent / treat various chronic diseases

        www.rootsanalysis.com
        Submitted 2 day(s) ago by Alberto Brando

         

         

        Recent advances in information technology and biomedical science have enabled the development of a number of versatile digital solutions that are capable of either mimicking or augmenting, the fundamental qualities of pharmacological interventions.

         

        To order this 500+ page report, which features 160+ figures and 200+ tables, please visit this link

        The USD 8.86 billion (by 2030) financial opportunity within the digital therapeutics market has been analyzed across the following segments:

        • Type of Solution
        • Standalone Software Application
        • Software Application + Device + Personal Coach
        • Software Application + Device + AI Support
        • Software Application + Device
        • Software Application + AI Support
        • Software Application + Personal Coach
        • Other Types of Solutions

         

        • Purpose of Solution
        • Medication Replacement
        • Medication Augmentation

         

        • Type of Therapy
        • Curative
        • Preventive

         

        • Business Model
        • Business to Consumer (Patients and Caregivers)
        • Business to Business (Healthcare Providers, Payers, Employers and Pharmaceutical Companies)

         

        • Therapeutic Areas
        • Cardiovascular Disorders
        • Chronic Pain
        • Mental Health Problems
        • Metabolic Disorders
        • Neurological Disorders
        • Respiratory Disorders
        • Sleep Disorders
        • Substance Use Disorders
        • Others

         

        • Key Geographical Regions 
        • North America
        • Europe
        • Asia-Pacific
        • Rest of the world 

         

        The Digital Health Market: Focus on Digital Therapeutics (2nd Edition), 2020-2030 (Based on Type of Solution (Software Solution, Gaming Solution and Combination Solution), Type of Therapy (Curative and Preventive), and Purpose of Solution (Medication Replacement and Medication Augmentation, report features the following companies, which we identified to be key players in this domain:

        • Akili Interactive
        • Beats Medical
        • Big Health
        • Bold Health
        • Click Therapeutics
        • CureApp
        • dreem
        • Ehave
        • Ginger
        • Happify Health
        • inMotion VR
        • Kaia Health
        • Lark Health
        • Mahana Therapeutics
        • MindMaze
        • Noom
        • NOVOSI
        • Omada Health
        • Palo Alto Health Sciences
        • Pear Therapeutics
        • Vida Health
        • Welldoc
        • ZOLL Medical

         

        Table of Contents

         

        1. Preface

          2. Executive Summary

        2. Introduction

        3. Current Market Landscape

        4. Product Competitiveness Analysis

         

        1. Company Profiles

        2. Clinical Trial Analysis

        3. Funding and Investment Analysis

         

        1. Partnerships and Collaborations

        2. Go-To-Market Strategy

        3. Bowman Clock Pricing Strategy Analysis

        4. Market Forecast

        5. Case Study: Impact of Coronavirus Outbreak

        6. Remote Digital Monitoring / Diagnostic Solutions

         

        1. Swot Analysis

         

        1. Digital Solutions: Recent Trends and Future Opportunities

        2. Executive Insights

         

        1. Appendix 1: Tabulated Data

         

        1. Appendix 2: List of Companies and Organizations

         

         

        To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/digital-health-market-focus-on-digital-therapeutic-monitoring-and-diag/208.html

         

        Contact Details

        Gaurav Chaudhary

        +1 (415) 800 3415

        gaurav.chaudhary@rootsanalysis.com

         

        The global digital therapeutics market is projected to be worth over USD 8.86 billion by 2030, growing at a CAGR of 19.7%, claims Roots Analysis

        www.rootsanalysis.com
        Submitted 2 day(s) ago by Alberto Brando

         

        Roots Analysis has done a detailed study on “Digital Health Market: Focus on Digital Therapeutics (2nd Edition), 2020-2030 (Based on Type of Solution (Software Solution, Gaming Solution and Combination Solution), Type of Therapy (Curative and Preventive), and Purpose of Solution (Medication Replacement and Medication Augmentation” covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

         

        To order this 500+ page report, which features 160+ figures and 200+ tables, please visit this link

         

        Key Market Insights

        • Eminent representatives from companies across the world attest to the fact that there is growing interest in the digital therapeutics market, highlighting the prevalent and anticipated trends in R&D and adoption
        • Over 100 industry players are engaged in evaluating the potential of several prescription (validated through clinical research) digital therapeutic solutions to prevent / treat various chronic diseases
        • The pipeline features a variety of digital health applications and therapy solutions that are in different stages of development, being investigated for diverse purposes, across a wide-range of clinical conditions
        • These solutions have demonstrated applicability across more than 20 therapeutic areas; several products have been marketed / approved for the treatment or prevention of mental health problems and metabolic disorders
        • In pursuit of a competitive edge, digital therapeutic solution developers are focusing on the integration of advanced features into their respective products and affiliated offerings
        • In the last few years, over 220 clinical trials evaluating the potential benefits of digital therapeutics in close to 80,000 patients, have been registered; most of these were / are being conducted at various centers in the US
        • Apart from the clinical benefit, cost is another key determinant of the acceptance and adoption of such novel interventions; pricing strategy matrix is likely to assist players to evaluate competitive market prices for solutions
        • To support the ongoing innovation in this field, several private and public investors have made substantial capital investments, amounting to approximately USD 1.7 billion, in various initiatives of stakeholders
        • The growing interest in this field is reflected by the increase in partnership activity, involving both international and indigenous stakeholders, across different geographical marketplaces
        • In order to promote the adoption of proprietary digital health solutions, developers are actively exploring various marketing strategies in order to highlight key features of their products across a number of platforms
        • Several digital monitoring / diagnostic solutions are also available to manage / diagnose patients for various chronic diseases; specifically, these remote monitoring solutions have gained interest during COVID-19
        • Given the rising incidence of chronic clinical conditions and a growing pipeline of modern medicines to treat such diseases, the market for evidence-based digital therapeutics is poised to grow at a CAGR of ~20% till 2030
        • The projected market opportunity is anticipated to be well-distributed across different therapeutic areas, distribution channels and key geographical regions

         

        For more information, please visit https://www.rootsanalysis.com/reports/view_document/digital-health-market-focus-on-digital-therapeutic-monitoring-and-diag/208.html

         

        Table of Contents

         

        1. PREFACE

        1.1.       Scope of the Report

        1.2.       Research Methodology

        1.3.       Chapter Outlines

         

        1. EXECUTIVE SUMMARY

         

        1. INTRODUCTION

        3.1        Chapter Overview

        3.2.       Digitization in the Healthcare Sector

        3.3.       Next-Generation Healthcare Solutions

         

        3.4.       Key Concepts Associated with Digital Health Solutions

        3.4.1.    Cognitive Behavioral Therapy (CBT)

        3.4.2.    Internet of Things (IoT)

        3.4.3.    Big Data

        3.4.4.    Artificial Intelligence (AI)

        3.4.5.    Gamification

         

        3.5.       Overview of Digital Therapeutics

        3.5.1.    Key Strategic Initiatives

        3.5.1.1. Digital Therapeutics Alliance (DTA)

        3.5.1.2. Personal Connected Health (PCH) Alliance

        3.5.1.3. Programs Initiated by The Centers for Disease Control and Prevention (CDC)

        3.5.1.4. Health Insurance Portability and Accountability Act (HIPAA)

        3.5.1.5. National Health Service (NHS) Guidelines

        3.5.1.6. United States Food and Drug Administration (USFDA) Regulations for Digital Therapeutics

         

        3.5.2.    Product Development and Commercialization Path for Digital Therapeutics

        3.5.2.1. Discovery and Preclinical Phase

        3.5.2.2. Clinical Trials and Validation

        3.5.2.3. Involving Insurance Providers / Payers

        3.5.2.4. Distribution and Marketing

         

        1. CURRENT MARKET LANDSCAPE

        4.1.       Chapter Overview

        4.2.       Digital Therapeutics: Overall Market Landscape

        4.2.1.    Analysis by Status of Development

        4.2.2.    Analysis by Type of Solution

        4.2.3.    Analysis by Type of Therapy     

        4.2.4.    Analysis by Purpose of Solution

        4.2.5.    Analysis by Target Disease Indication(s)

        4.2.6.    Analysis by Therapeutic Area

        4.2.7.    Analysis by Target Population

         

        4.3.       Digital Therapeutics: Additional Information

        4.3.1.    Analysis by Prescription Requirement

        4.3.2.    Analysis by Duration of Course

        4.3.3.    Analysis by Cost of Solution

         

        4.4.       Digital Therapeutics: List of Developers

        4.4.1.    Analysis by Year of Establishment

        4.4.2.    Analysis by Company Size

        4.4.3.    Analysis by Type of Business Model

        4.4.4.    Analysis by Location of Headquarters

         

        4.5.       Leading Developers: Analysis by Number of Digital Therapeutics Solutions

        4.6.       Leading Developers: 4D Bubble Analysis based on Portfolio Strength, Target Indication and Company Size

        4.7.       Grid Representation: Analysis by Status of Development, Type of Solution and Therapeutic Area

        4.8.       Tree Map Representation: Analysis by Therapeutic Area and Company Size

        4.9.       World Map Representation: Analysis of Regional Activity

        4.10.     Digital Therapeutics: Information on Additional Companies

         

        1. PRODUCT COMPETITIVENESS ANALYSIS

        5.1.       Chapter Overview

        5.2.       Methodology

        5.3.       Assumptions / Key Parameters

        5.4.       Key Therapeutic Areas

        5.4.1.    Cardiovascular Disorders

        5.4.1.1. Product Competitiveness Analysis

         

        5.4.2.    Mental Health Problems

        5.4.2.1. Product Competitiveness Analysis

         

        5.4.3.    Metabolic Disorders     

        5.4.3.1. Product Competitiveness Analysis

         

        5.4.4.    Neurological Disorders

        5.4.4.1. Product Competitiveness Analysis

         

        5.4.5.    Substance Use Disorders

        5.4.5.1. Product Competitiveness Analysis

         

        5.4.6.    Other Therapeutic Areas

        5.4.6.1. Product Competitiveness Analysis

         

        1. COMPANY PROFILES

        6.1.       Chapter Overview

        6.2.       Akili Interactive

        6.2.1     Company Overview

        6.2.2.    Product Portfolio

        6.2.3.    Recent Developments and Future Outlook

         

        6.3.       Big Health

        6.3.1.    Company Overview

        6.3.2.    Product Portfolio

        6.3.3.    Recent Developments and Future Outlook

         

        6.4.       dreem

        6.4.1.    Company Overview

        6.4.2.    Product Portfolio

        6.4.3.    Recent Developments and Future Outlook

         

        6.5        Kaia Health

        6.5.1.    Company Overview

        6.5.2.    Product Portfolio

        6.5.3.    Recent Developments and Future Outlook         

         

        6.6.       Mindmaze

        6.6.1.    Company Overview

        6.6.2.    Product Portfolio

        6.6.3.    Recent Developments and Future Outlook

         

        6.7.       Omada Health

        6.7.1.    Company Overview

        6.7.2.    Product Portfolio

        6.7.3.    Recent Developments and Future Outlook         

         

        6.8.       Pear Therapeutics

        6.8.1.    Company Overview

        6.8.2.    Product Portfolio

        6.8.3     Recent Developments and Future Outlook         

         

        6.9.       Vida Health

        6.9.1.    Company Overview

        6.9.2.    Product Portfolio

        6.9.3.    Recent Developments and Future Outlook

         

        6.10.     Voluntis

        6.10.1.  Company Overview

        6.10.2.  Product Portfolio

        6.10.3.  Recent Developments and Future Outlook

         

        6.11.     WellDoc

        6.11.1.  Company Overview

        6.11.2.  Product Portfolio

        6.11.3.  Recent Developments and Future Outlook

         

        6.12.     Wellthy Therapeutics

        6.12.1.  Company Overview

        6.12.2.  Product Portfolio

        6.12.3.  Recent Developments and Future Outlook         

         

        1. CLINICAL TRIAL ANALYSIS

        7.1.       Chapter Overview

        7.2.       Scope and Methodology

         

        7.3.       Digital Therapeutics: Clinical Trial Analysis

        7.3.1.    Analysis by Trial Registration Year

        7.3.2.    Analysis by Trial Phase

        7.3.3.    Analysis by Number of Patients Enrolled and Trial Registration Year

        7.3.4.    Analysis by Study Design

        7.3.5.    Analysis by Trial Recruitment Status

        7.3.6.    Analysis by Sponsor / Collaborator

        7.3.7.    Leading Industry Players: Analysis by Number of Registered Trials

        7.3.8     Leading Digital Therapeutic Solutions: Analysis by Number of Registered Trials

        7.3.9.    Analysis by Trial Focus

        7.3.10.  Analysis by Therapeutic Area

        7.3.11.  Geographical Analysis by Number of Clinical Trials

        7.3.12.  Geographical Analysis by Trial Recruitment Status

        7.3.13.  Geographical Analysis by Enrolled Patient Population

         

        7.4.       Clinical End-Points Analysis

         

        1. FUNDING AND INVESTMENT ANALYSIS

        8.1.       Chapter Overview

        8.2.       Types of Funding

         

        8.3.       Digital Therapeutics: Funding and Investment Analysis

        8.3.1.    Analysis by Number of Funding Instances

        8.3.2.    Analysis by Amount Invested

        8.3.3.    Analysis by Type of Funding

        8.3.4.    Analysis by Type of Therapy

        8.3.5.    Analysis by Therapeutic Area

        8.3.6.    Analysis by Geography 

        8.3.7.    Most Active Players: Analysis by Number of Funding Instances

        8.3.8.    Most Active Players: Analysis by Amount of Funding

        8.3.9.    Most Active Investors: Analysis by Number of Instances

                               

        8.4        Concluding Remarks

         

        1. PARTNERSHIPS AND COLLABORATIONS

        9.1.       Chapter Overview

        9.2.       Partnership Models

        9.3.       Digital Therapeutics: Recent Partnerships and Collaborations

        9.3.1.    Analysis by Year of Partnership

         

        9.3.2.    Analysis by Type of Partnership

        9.3.2.1. Analysis by Type of Partnership and Year of Partnership

        9.3.2.2. Analysis by Type of Partnership and Company Size

         

        9.3.3.    Analysis by Type of Partner

        9.3.3.1. Analysis by Type of Partner and Year of Partnership

        9.3.3.2. Analysis by Type of Partner and Type of Partnership

         

        9.3.4.    Analysis by Type of Therapy

        9.3.4.1. Analysis by Type of Therapy and Type of Partnership

        9.3.4.2. Analysis by Type of Therapy and Type of Partner

         

        9.3.5.    Analysis by Therapeutic Area

        9.3.5.1. Analysis by Therapeutic Area and Year of Partnership

        9.3.5.2  Analysis by Therapeutic Area and Type of Partner

         

        9.3.6.    Most Active Players: Analysis by Number of Partnerships

        9.3.7.    Regional Analysis

        9.3.8.    Intercontinental and Intracontinental Agreements

         

        1. GO-TO-MARKET STRATEGY

        10.1.     Chapter Overview

        10.2.     Marketing Strategies Adopted by Digital Therapeutic Developers

        10.2.1.  Participation in Global Events

        10.2.2.  Marketing on Social Media Platforms

        10.2.3.  Marketing on Online / Print Media Platforms

        10.2.4.  Undertaking Various Promotional Activities through Official Websites

        10.2.5.  Adoption of Different Business Models and Pricing Strategies

        10.2.5.1. B2C Business Model

        10.2.5.2. B2B Business Model

        10.2.5.2. B2B2C Business Model

         

        10.2.6.  Undertaking Various Promotional Activities through Product Add-ons

        10.3.     Concluding Remarks

         

        1. BOWMAN CLOCK PRICING STRATEGY ANALYSIS

        11.1.     Chapter Overview

        11.2.     Bowman Strategy Clock

        11.2.1.  Two Dimensions of Bowman Strategy Clock

        11.2.2.  Eight Positions on Bowman Strategic Clock

         

        11.3      Roots Analysis Framework

        11.3.1.  Methodology

        11.3.2.  Theoretical Framework and Price Evaluation Hypothesis

        11.3.3.  Results and Interpretation

        11.3.3.1. Product Price Evaluation Matrix: Based on Status of Development

        11.3.3.2. Product Price Evaluation Matrix: Based on Type of Solution

        11.3.3.3. Product Price Evaluation Matrix: Based on Purpose of Solution

        11.3.3.4. Product Price Evaluation Matrix: Based on Type of Therapy

        11.3.3.5. Product Price Evaluation Matrix: Based on Therapeutic Area

        11.3.3.6. Product Price Evaluation Matrix: Based on Prescription Requirement

        11.3.3.7. Product Price Evaluation Matrix: Based on Course Duration

        11.3.3.8. Product Price Evaluation Matrix: Based on Distribution Channel

        11.4.     Concluding Remarks

         

        1. MARKET FORECAST

        12.1.     Chapter Overview

        12.2.     Forecast Methodology and Key Assumptions

        12.3.     Global Digital Therapeutics Market, 2020-2030

         

        12.4.     Global Digital Therapeutics Market: Distribution by Type of Solution

        12.4.1.  Digital Therapeutics Market for Standalone Software Applications, 2020-2030

        12.4.2.  Digital Therapeutics Market for Combination Offerings (Software Application + Device + Personal Coach), 2020-2030

        12.4.3.  Digital Therapeutics Market for Combination Offerings (Software Application + Device + AI Support), 2020-2030

        12.4.4.  Digital Therapeutics Market for Combination Offerings (Software Application + Device), 2020-2030

        12.4.5.  Digital Therapeutics Market for Combination Offerings (Software Application +                 AI Support), 2020-2030

        12.4.6.  Digital Therapeutics Market for Combination Offerings (Software Application + Personal Coach), 2020-2030

        12.4.7.  Digital Therapeutics Market for Other Types of Solutions, 2020-2030

         

        12.5.     Global Digital Therapeutics Market: Distribution by Purpose of Solution

        12.5.1.  Digital Therapeutics Market for Medication Replacement Solutions, 2020-2030

        12.5.2.  Digital Therapeutics Market for Medication Augmentation Solutions, 2020-2030

         

        12.6.     Global Digital Therapeutics Market: Distribution by Type of Therapy

        12.6.1   Digital Therapeutics Market for Curative Therapy, 2020-2030

        12.6.2.  Digital Therapeutics Market for Preventive Therapy, 2020-2030

         

        12.7.     Global Digital Therapeutics Market: Distribution by Business Model

        12.7.1.  Digital Therapeutics Market for B2C Model (Patients and Caregivers), 2020-2030

        12.7.2.  Digital Therapeutics Market for B2B Model (Healthcare Providers, Payers,                                   Employers and Pharmaceutical Companies), 2020-2030

         

        12.8.     Global Digital Therapeutics Market: Distribution by Therapeutic Area

        12.8.1.  Digital Therapeutics Market for Cardiovascular Disorders, 2020-2030

        12.8.2.  Digital Therapeutics Market for Chronic Pain, 2020-2030

        12.8.3.  Digital Therapeutics Market for Mental Health Problems, 2020-2030

        12.8.4.  Digital Therapeutics Market for Metabolic Disorders, 2020-2030

        12.8.5.  Digital Therapeutics Market for Neurological Disorders, 2020-2030

        12.8.6.  Digital Therapeutics Market for Respiratory Disorders, 2020-2030

        12.8.7.  Digital Therapeutics Market for Sleep Disorders, 2020-2030

        12.8.8.  Digital Therapeutics Market for Substance Use Disorders, 2020-2030

        12.8.9.  Digital Therapeutics Market for Other Disorders, 2020-2030

         

        12.9.     Global Digital Therapeutics Market: Distribution by Geography

        12.9.1   Digital Therapeutics Market in North America, 2020-2030

        12.9.1.1 Digital Therapeutics Market in the US, 2020-2030

        12.9.1.2 Digital Therapeutics Market in Canada, 2020-2030

         

        12.9.2   Digital Therapeutics Market in Europe, 2020-2030

        12.9.2.1. Digital Therapeutics Market in France, 2020-2030

        12.9.2.2. Digital Therapeutics Market in Germany, 2020-2030

        12.9.2.3. Digital Therapeutics Market in Italy, 2020-2030

        12.9.2.4. Digital Therapeutics Market in Spain, 2020-2030

        12.9.2.5. Digital Therapeutics Market in the UK, 2020-2030

        12.9.2.6. Digital Therapeutics Market in Rest of Europe, 2020-2030

         

        12.9.3.  Digital Therapeutics Market in Asia-Pacific, 2020-2030

        12.9.3.1. Digital Therapeutics Market in Australia, 2020-2030

        12.9.3.2. Digital Therapeutics Market in China, 2020-2030

        12.9.3.3. Digital Therapeutics Market in India, 2020-2030

        12.9.3.4. Digital Therapeutics Market in Japan, 2020-2030

        12.9.3.5. Digital Therapeutics Market in South Korea, 2020-2030

        12.9.3.6. Digital Therapeutics Market in Rest of Asia-Pacific, 2020-2030

         

        12.9.4.  Digital Therapeutics Market in Rest of the World, 2020-2030

         

        1. CASE STUDY: IMPACT OF CORONAVIRUS OUTBREAK

        13.1.     Chapter Overview

        13.2.     Impact of Coronavirus Pandemic on Digital Therapeutics

        13.2.1.  Impact on Future Market Opportunity for Digital Therapeutic Solutions Market

         

        13.3.     Recuperative Strategies for Developer Businesses

        13.3.1.  Strategies for Implementation in the Short / Mid Term

        13.3.2.  Strategies for Implementation in the Long Term

         

        1. REMOTE DIGITAL MONITORING / DIAGNOSTIC SOLUTIONS

        14.1.     Chapter Overview

        14.2.     An Introduction to Remote Digital Monitoring / Diagnostic Solutions        

        14.3.     Remote Digital Monitoring / Diagnostic Solutions: Overall Market Landscape

        14.3.1.  Analysis by Status of Development

        14.3.2.  Analysis by Type of Solution

        14.3.3.  Analysis by Target Disease Indication(s)

        14.3.4.  Analysis by Therapeutic Area

        14.3.5.  Grid Representation: Analysis by Status of Development, Type of Solution, and                Therapeutic Area

         

        14.4.     Remote Digital Monitoring / Diagnostic Solutions: List of Developers       

        14.4.1.  Analysis by Year of Establishment

        14.4.2.  Analysis by Company Size

        14.4.3.  Analysis by Location of Headquarters

         

        14.5.     Remote Digital Monitoring / Diagnostic Solutions: Company Profiles

        14.5.1.  AliveCor

        14.5.1.1. Company Snapshot

        14.5.1.2. Product Portfolio

        14.5.1.3. Recent Developments and Future Outlook

         

        14.5.2.  Bioserenity

        14.5.2.1. Company Snapshot

        14.5.2.2. Product Portfolio

        14.5.2.3. Recent Developments and Future Outlook

         

        14.5.3.  Cue

        14.5.3.1. Company Snapshot

        14.5.2.2. Product Portfolio

        14.5.2.3. Recent Developments and Future Outlook

         

        14.5.4.  Kinsa

        14.5.4.1. Company Snapshot

        14.5.4.2. Product Portfolio

        14.5.4.3. Recent Developments and Future Outlook

         

        14.6.     Remote Digital Monitoring / Diagnostic Solutions: Funding and Investment Analysis

        14.6.1.  Types of Funding

        14.6.2.  Remote Digital Monitoring / Diagnostic Solutions: List of Funding and                               Investments

        14.6.2.1. Analysis by Number of Funding Instances

        14.6.2.2. Analysis by Amount Invested

        14.6.2.3. Analysis by Type of Funding

        14.6.2.4. Most Active Players: Analysis by Number of Funding Instances

        14.6.2.5. Most Active Players: Analysis by Amount Invested

        14.6.2.6. Most Active Investors: Analysis by Number of Funding Instances          

         

        14.7.     Concluding Remarks

         

        1. SWOT ANALYSIS

        15.1.     Chapter Overview

        15.2.     Comparison of SWOT Factors

        15.2.1.  Strengths

        15.2.2.  Weaknesses

        15.2.3.  Opportunities

        15.2.4.  Threats

         

        1. DIGITAL SOLUTIONS: RECENT TRENDS AND FUTURE OPPORTUNITIES

        16.1.     Chapter Overview

        16.2.     Prevalent Trends Related to Digital Therapeutics

        16.2.1.  Emerging Focus Areas

        16.2.2.  Key Historical Trends

        16.2.3.  Geographical Distribution of Activity

         

        16.3.     Trends Shaping the Future of Digital Therapeutics

        16.3.1.  Digital Solutions Closing the Digital Gap

        16.3.2.  Increasing Focus on Patient Centric Models

        16.3.3.  Applicability across a Variety of Disease Indications

        16.3.4.  Increasing Emphasis on Real-World Evidence in Research and Development

        16.3.5.  Advances in IT and Computing Power to Foster Future Innovation

        16.4.     Improving the Future Health: Opportunities Beyond Digital Therapeutics

         

        1. EXECUTIVE INSIGHTS

        17.1.     Chapter Overview

        17.2.     Vida Health

        17.2.1.  Company Snapshot

        17.2.2.  Interview Transcript: Stephanie Tilenius, Co-Founder and Chief Executive Officer

         

        17.3.     Canary Health

        17.3.1.  Company Snapshot

        17.3.2.  Interview Transcript: Adam Kaufman, Chief Executive Officer

         

        17.4.     Floreo

        17.4.1.  Company Snapshot

        17.4.2.  Interview Transcript: Vijay Ravidran, Chief Executive Officer

                   

        17.5.     Somatix

        17.5.1.  Company Snapshot

        17.5.2.  Interview Transcript: Eran Ofir, Chief Executive Officer   

         

        17.6.     Tilak Healthcare

        17.6.1.  Company Snapshot

        17.6.2.  Interview Transcript: Edouard Gasser, Chief Executive Officer    

         

        17.7.     Wellthy Therapeutics

        17.7.1.  Company Snapshot

        17.7.2.  Interview Transcript: Palakh R Saraogi, Vice President Marketing, Arani Sarkra,               Senior Manager Consumer Marketing, and Yolande D’Mello, Marketing and                                  Public Relations

         

        17.8.     Voluntis

        17.8.1.  Company Snapshot

        17.8.2.  Interview Transcript: Amelie Janson, Communications Manager

         

        17.9.     Anonymous

        17.9.1.  Interview Transcript: Anonymous, Founder and Chief Executive Officer

         

        1. APPENDIX 1: TABULATED DATA

         

        1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

         

        Contact Details

        Gaurav Chaudhary

        +1 (415) 800 3415

        gaurav.chaudhary@rootsanalysis.com

         

        The global digital therapeutics market is projected to be worth over USD 8.8 billion by 2030, predicts Roots Analysis

        www.rootsanalysis.com
        Submitted 2 day(s) ago by Alberto Brando

         

        Recent advances in information technology and biomedical science have enabled the development of a number of versatile digital solutions that are capable of either mimicking or augmenting, the fundamental qualities of pharmacological interventions.

         

        Roots Analysis is pleased to announce the publication of its recent study titled, “Digital Health Market: Focus on Digital Therapeutics (2nd Edition), 2020-2030 (Based on Type of Solution (Software Solution, Gaming Solution and Combination Solution), Type of Therapy (Curative and Preventive), and Purpose of Solution (Medication Replacement and Medication Augmentation”.

         

        The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these solutions over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report includes:

         

        • A detailed assessment of the current market landscape of companies engaged in the development of digital therapeutic solutions.
        • A detailed product competitiveness analysis of key industry players for the most popular therapeutic areas taking into consideration the strength of product portfolio and key product specific parameters.
        • Elaborate profiles of key industry players that offer a several digital therapeutic solutions (shortlisted on the basis of the product portfolio).
        • An insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain.
        • A detailed analysis of more than 220 completed, ongoing and planned clinical studies of various digital therapeutic solutions, based on the several relevant parameters.
        • An analysis of the investments made in the period between 2009 and 2020 at various stages of development in companies that are engaged in this field.
        • An analysis of the partnerships that have been inked by stakeholders in this domain, in the period between 2008 and 2020.
        • A detailed analysis of the various business models and go-to-market strategies adopted by companies involved in this space.
        • A Bowman’s Strategy Clock framework in order to analyze the competitive position of various companies in the marketplace, taking into consideration the prices and features of their products.
        • An insightful discussion on the impact of COVID-19 pandemic on the overall digital therapeutic solutions market, and the key initiatives undertaken by big pharma players.
        • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution.
        • An informative analysis of contemporary Google Trends in the time period between 2015 and 2020 (till July) and insights from the recent news articles related digital therapeutic solutions.
        • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

         

        • Type of Solution
        • Standalone Software Application
        • Software Application + Device + Personal Coach
        • Software Application + Device + AI Support
        • Software Application + Device
        • Software Application + AI Support
        • Software Application + Personal Coach
        • Other Types of Solutions

         

        • Purpose of Solution
        • Medication Replacement
        • Medication Augmentation

         

        • Type of Therapy
        • Curative
        • Preventive

         

        • Business Model
        • Business to Consumer (Patients and Caregivers)
        • Business to Business (Healthcare Providers, Payers, Employers and Pharmaceutical Companies)

         

        • Therapeutic Areas
        • Cardiovascular Disorders
        • Chronic Pain
        • Mental Health Problems
        • Metabolic Disorders
        • Neurological Disorders
        • Respiratory Disorders
        • Sleep Disorders
        • Substance Use Disorders
        • Others

         

        • Key Geographical Regions 
        • North America
        • Europe
        • Asia-Pacific
        • Rest of the world 

         

        Transcripts of interviews held with the following senior level representatives of stakeholder companies

        • Eran Ofir (Co-Founder and Chief Executive Officer, Somatix)
        • Edouard Gasser (Co-Founder and Chief Executive Officer, Tilak Healthcare)
        • Stephanie Tilenius (Co-Founder and Chief Executive Officer, Vida Health)
        • Adam Kaufman (Chief Executive Officer, Canary Health)
        • Vijay Ravindran (Chief Executive Officer, Floreo)
        • Palakh R Sarogi (Vice President, Marketing, Wellthy Therapeutics), Arani Sarkra (Senior Manager, Consumer Marketing, Wellthy Therapeutics) and Yolande D’Mello (Marketing and Public Relations, Wellthy Therapeutics)
        • Amelie Janson (Communication Manager, Voluntis)
        • Anonymous (Founder and Chief Executive Officer, UK based Small-sized Company)

         

        Key companies covered in the report

        • Akili Interactive
        • Beats Medical
        • Big Health
        • Bold Health
        • Click Therapeutics
        • CureApp
        • dreem
        • Ehave
        • Ginger
        • Happify Health
        • inMotion VR
        • Kaia Health
        • Lark Health
        • Mahana Therapeutics
        • MindMaze
        • Noom
        • NOVOSI
        • Omada Health
        • Palo Alto Health Sciences
        • Pear Therapeutics
        • Vida Health
        • Welldoc
        • ZOLL Medical

         

        For more information please click on the following link:

        https://www.rootsanalysis.com/reports/view_document/digital-health-market-focus-on-digital-therapeutic-monitoring-and-diag/208.html

         

        Other Recent Offerings

        1. AR / VR Based Healthcare Digital Marketing Service Providers Market, 2020-2030
        2. AI-Based Clinical Trial Solution Providers Market, 2020-2030
        3. Global Handheld Ultrasound Imaging Devices Market, 2020-2030

         

        About Roots Analysis

        Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

         

        Contact Information

        Roots Analysis Private Limited

        Gaurav Chaudhary

        +1 (415) 800 3415

        gaurav.chaudhary@rootsanalysis.com

        The global digital therapeutics market is projected to be worth over USD 8.86 billion by 2030, growing at a CAGR of 19.7%, claims Roots Analysis

        www.rootsanalysis.com
        Submitted 2 day(s) ago by Alberto Brando

         

        Recent advances in information technology and biomedical science have enabled the development of a number of versatile digital solutions that are capable of either mimicking or augmenting, the fundamental qualities of pharmacological interventions

         

        Roots Analysis has announced the addition of “Digital Health Market: Focus on Digital Therapeutics (2nd Edition), 2020-2030 (Based on Type of Solution (Software Solution, Gaming Solution and Combination Solution), Type of Therapy (Curative and Preventive), and Purpose of Solution (Medication Replacement and Medication Augmentation” report to its list of offerings.

         

        According to experts, digital therapeutic solutions are primarily based on behavior modification and are designed to address a variety of therapeutic needs across a wide range of disease indications. On the other hand, several digital solutions have been developed to enable remote doctor-patient consultations. Such solutions witnessed a surge in adoptions amidst the COVID-19 pandemic.

         

        To order this 500+ page report, which features 160+ figures and 200+ tables, please visit this link

         

        Key Market Insights

         

        Nearly 230 digital therapeutic solutions are currently available / under development

        Close to 45% of the aforementioned solutions are standalone software applications targeting more than 60 unique indications.

         

        Over 85% of digital therapeutic solutions are intended to replace medication

        Such solutions are currently available / being developed to treat neurological disorders (27%), mental health problems (24%), and certain metabolic disorders (24%). Alternatively, some digital health products are designed to augment the effect of conventional therapeutics and are currently being considered for treating substance use disorders and few mental health problems.

         

        220+ clinical trials, focused on digital therapeutics, have been registered since 2004

        Around 80,000 patients have been enrolled in clinical research initiatives aimed to validate the efficacy of digital therapeutics, and generate real world evidence concerning their efficacy and safety. Close to 50% of such trials have been / are being conducted in the US.

         

        Nearly USD 1.9 billion invested by both private and public investors in this domain

        ~85% of the total capital raised for digital therapeutics-related initiatives was from venture capital investors, featuring over 370 participants.

         

        Partnership activity in this field has grown at a CAGR of ~42%, between 2015 and 2019

        More than 70% of the reported deals were established after 2017, with the maximum activity being reported in 2019. Majority of the instances captured in the report were focused on pilot product offering (29%) and research and development agreements (21%).

         

        North America and Europe are anticipated to capture over 70% of the market share by 2030

        The market in Asia-Pacific regions is anticipated to grow at a relatively faster pace (23.2%). In 2030, digital solutions targeting metabolic disorders are likely to represent the largest market share, in terms of revenues from product sales (26%), followed by those intended for mental health problems (20%) and neurological disorders (19%).

         

        To request a sample copy / brochure of this report, please visit this link

         

        Key Questions Answered

        • Who are the leading players engaged in the development of digital therapeutic solutions?
        • What are the most popular therapeutic areas addressed by digital health solutions?
        • What are the key factors influencing the price of digital therapeutics?
        • What is the trend of capital investments in the digital therapeutics market?
        • Which partnership models are commonly adopted by stakeholders in this industry?
        • What type of marketing strategies are being adopted by developers in this domain?
        • How is the COVID-19 pandemic likely to impact the digital therapeutics market?
        • How is the current and future opportunity likely to be distributed across key market segments?
        • What are the anticipated future trends related to digital therapeutics?

         

        The USD 8.86 billion (by 2030) financial opportunity within the digital therapeutics market has been analyzed across the following segments:

        • Type of Solution
        • Standalone Software Application
        • Software Application + Device + Personal Coach
        • Software Application + Device + AI Support
        • Software Application + Device
        • Software Application + AI Support
        • Software Application + Personal Coach
        • Other Types of Solutions

         

        • Purpose of Solution
        • Medication Replacement
        • Medication Augmentation

         

        • Type of Therapy
        • Curative
        • Preventive

         

        • Business Model
        • Business to Consumer (Patients and Caregivers)
        • Business to Business (Healthcare Providers, Payers, Employers and Pharmaceutical Companies)

         

        • Therapeutic Areas
        • Cardiovascular Disorders
        • Chronic Pain
        • Mental Health Problems
        • Metabolic Disorders
        • Neurological Disorders
        • Respiratory Disorders
        • Sleep Disorders
        • Substance Use Disorders
        • Others

         

        • Key Geographical Regions 
        • North America
        • Europe
        • Asia-Pacific
        • Rest of the world 

         

        The report features inputs from eminent industry stakeholders, according to whom, digital therapeutic solutions are likely to witness enhanced adoption due to their broader applicability, remote guidance and other advanced features, thereby, offering lucrative opportunities to their developers. The report includes detailed transcripts of the discussions held with following industry experts:

        • Eran Ofir (Co-Founder and Chief Executive Officer, Somatix)
        • Edouard Gasser (Co-Founder and Chief Executive Officer, Tilak Healthcare)
        • Stephanie Tilenius (Co-Founder and Chief Executive Officer, Vida Health)
        • Adam Kaufman (Chief Executive Officer, Canary Health)
        • Vijay Ravindran (Chief Executive Officer, Floreo)
        • Palakh R Sarogi (Vice President, Marketing, Wellthy Therapeutics), Arani Sarkra (Senior Manager, Consumer Marketing, Wellthy Therapeutics) and Yolande D’Mello (Marketing and Public Relations, Wellthy Therapeutics)
        • Amelie Janson (Communication Manager, Voluntis)
        • Anonymous (Founder and Chief Executive Officer, UK based Small-sized Company)

         

        The research covers brief profiles of key players engaged in the development of digital therapeutic solutions; other popular industry players featured in the report include:

        • Akili Interactive
        • Beats Medical
        • Big Health
        • Bold Health
        • Click Therapeutics
        • CureApp
        • dreem
        • Ehave
        • Ginger
        • Happify Health
        • inMotion VR
        • Kaia Health
        • Lark Health
        • Mahana Therapeutics
        • MindMaze
        • Noom
        • NOVOSI
        • Omada Health
        • Palo Alto Health Sciences
        • Pear Therapeutics
        • Vida Health
        • Welldoc
        • ZOLL Medical

         

        For additional details, please visit

        https://www.rootsanalysis.com/reports/view_document/digital-health-market-focus-on-digital-therapeutic-monitoring-and-diag/208.html

         

        You may also be interested in the following titles:

        1. AR / VR Based Healthcare Digital Marketing Service Providers Market, 2020-2030
        2. AI-Based Clinical Trial Solution Providers Market, 2020-2030
        3. Global Handheld Ultrasound Imaging Devices Market, 2020-2030

         

        Contact:

        Gaurav Chaudhary

        +1 (415) 800 3415

        +44 (122) 391 1091

        Gaurav.Chaudhary@rootsanalysis.com 

        Submit your article?

        Submit your articles for more traffic to your website!

        Submit article
        © 2019 posts123.com. Imprint, All rights reserved.
        Friend sites: